{"PMC7267313": [], "PMC7312505": [], "e5c5839a04c9129980e75fa252b316cdb85c154b": [["IntroductionFirst described in Wuhan, China, in December 2019, coronavirus disease 2019 (COVID-19) is a viral illness caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (1, 2) .", [["coronavirus disease", "DISEASE", 63, 82], ["COVID-19", "CHEMICAL", 89, 97], ["viral illness", "DISEASE", 104, 117], ["acute respiratory syndrome coronavirus", "DISEASE", 145, 183], ["coronavirus disease 2019 (COVID-19", "SPECIES", 63, 97], ["severe acute respiratory syndrome coronavirus", "SPECIES", 138, 183], ["SARS-CoV2)", "SPECIES", 187, 197], ["coronavirus disease", "PROBLEM", 63, 82], ["COVID", "TEST", 89, 94], ["a viral illness", "PROBLEM", 102, 117], ["the novel severe acute respiratory syndrome coronavirus", "PROBLEM", 128, 183], ["viral illness", "OBSERVATION", 104, 117], ["severe", "OBSERVATION_MODIFIER", 138, 144], ["acute", "OBSERVATION_MODIFIER", 145, 150], ["respiratory syndrome", "OBSERVATION", 151, 171]]], ["According to the World Health Organization, over 5 488 825 cases and 349 095 deaths have been reported worldwide as of May 27, 2020 (3) .", [["deaths", "DISEASE", 77, 83]]], ["Clinically, the disease typically manifests as a pneumonia characterized by fever, cough, dyspnea, myalgia, and fatigue (1) .IntroductionTo date, most radiologic literature has focused on the distinctive chest CT abnormalities caused by COVID-19, including peripheral basal-predominant areas of ground-glass opacification or consolidation, often in a bilateral distribution (4) .", [["chest", "ANATOMY", 204, 209], ["pneumonia", "DISEASE", 49, 58], ["fever", "DISEASE", 76, 81], ["cough", "DISEASE", 83, 88], ["dyspnea", "DISEASE", 90, 97], ["myalgia", "DISEASE", 99, 106], ["fatigue", "DISEASE", 112, 119], ["chest", "ORGAN", 204, 209], ["COVID-19", "DNA", 237, 245], ["the disease", "PROBLEM", 12, 23], ["a pneumonia", "PROBLEM", 47, 58], ["fever", "PROBLEM", 76, 81], ["cough", "PROBLEM", 83, 88], ["dyspnea", "PROBLEM", 90, 97], ["myalgia", "PROBLEM", 99, 106], ["fatigue", "PROBLEM", 112, 119], ["the distinctive chest CT abnormalities", "TEST", 188, 226], ["COVID", "TEST", 237, 242], ["ground-glass opacification", "PROBLEM", 295, 321], ["consolidation", "PROBLEM", 325, 338], ["disease", "OBSERVATION", 16, 23], ["pneumonia", "OBSERVATION", 49, 58], ["fever", "OBSERVATION", 76, 81], ["cough", "OBSERVATION", 83, 88], ["myalgia", "OBSERVATION", 99, 106], ["chest", "ANATOMY", 204, 209], ["peripheral", "ANATOMY_MODIFIER", 257, 267], ["basal", "ANATOMY_MODIFIER", 268, 273], ["predominant", "OBSERVATION_MODIFIER", 274, 285], ["areas", "OBSERVATION_MODIFIER", 286, 291], ["ground-glass opacification", "OBSERVATION", 295, 321], ["consolidation", "OBSERVATION", 325, 338], ["bilateral", "ANATOMY_MODIFIER", 351, 360]]], ["However, emerging research has demonstrated that the inflammation and hypoxemia caused by COVID-19 can result in deranged coagulation parameters and a markedly increased risk of thromboembolic complications, which may be associated with significant morbidity and mortality (5, 6) .", [["inflammation", "DISEASE", 53, 65], ["hypoxemia", "DISEASE", 70, 79], ["COVID-19", "CHEMICAL", 90, 98], ["thromboembolic complications", "DISEASE", 178, 206], ["COVID-19", "CHEMICAL", 90, 98], ["the inflammation", "PROBLEM", 49, 65], ["hypoxemia", "PROBLEM", 70, 79], ["COVID", "TEST", 90, 95], ["deranged coagulation parameters", "PROBLEM", 113, 144], ["thromboembolic complications", "PROBLEM", 178, 206], ["significant morbidity", "PROBLEM", 237, 258], ["inflammation", "OBSERVATION", 53, 65], ["hypoxemia", "OBSERVATION", 70, 79], ["markedly", "OBSERVATION_MODIFIER", 151, 159], ["increased", "OBSERVATION_MODIFIER", 160, 169], ["thromboembolic complications", "OBSERVATION", 178, 206], ["may be associated with", "UNCERTAINTY", 214, 236], ["significant", "OBSERVATION_MODIFIER", 237, 248], ["morbidity", "OBSERVATION", 249, 258]]], ["It is thought that viral spreading beyond the respiratory system to other organ systems in the 2nd week of the disease course (correlating with clinical worsening) leads to increased immune-mediated injury and hypercoagulability (7) .", [["respiratory system", "ANATOMY", 46, 64], ["organ", "ANATOMY", 74, 79], ["hypercoagulability", "DISEASE", 210, 228], ["organ", "ORGAN", 74, 79], ["viral spreading", "PROBLEM", 19, 34], ["organ systems", "TEST", 74, 87], ["the disease course", "PROBLEM", 107, 125], ["increased immune-mediated injury", "PROBLEM", 173, 205], ["hypercoagulability", "PROBLEM", 210, 228], ["viral", "OBSERVATION", 19, 24], ["respiratory system", "ANATOMY", 46, 64], ["disease", "OBSERVATION", 111, 118], ["increased", "OBSERVATION_MODIFIER", 173, 182], ["injury", "OBSERVATION", 199, 205], ["hypercoagulability", "OBSERVATION", 210, 228]]], ["In this updated review, we expand on the information presented in our 2020 article (8) and focus on the development of thrombosis and thrombus-related complications in COVID-19.Thrombus and Thrombus-related Complications in COVID-19Several recent studies have explored the link between COVID-19 and hypercoagulability, with early investigations suggesting that the most common laboratory test result abnormalities include elevated d-dimer levels and mild thrombocytopenia (2) .", [["thrombus", "ANATOMY", 134, 142], ["Thrombus", "ANATOMY", 177, 185], ["thrombosis", "DISEASE", 119, 129], ["thrombus", "DISEASE", 134, 142], ["Thrombus", "DISEASE", 177, 185], ["Thrombus", "DISEASE", 190, 198], ["hypercoagulability", "DISEASE", 299, 317], ["thrombocytopenia", "DISEASE", 455, 471], ["thrombus", "PATHOLOGICAL_FORMATION", 134, 142], ["d-dimer", "GENE_OR_GENE_PRODUCT", 431, 438], ["thrombosis", "PROBLEM", 119, 129], ["thrombus", "PROBLEM", 134, 142], ["complications", "PROBLEM", 151, 164], ["COVID", "TEST", 168, 173], ["Thrombus", "PROBLEM", 177, 185], ["Thrombus", "PROBLEM", 190, 198], ["Complications in COVID", "PROBLEM", 207, 229], ["COVID", "TEST", 286, 291], ["hypercoagulability", "PROBLEM", 299, 317], ["early investigations", "TEST", 324, 344], ["the most common laboratory test result abnormalities", "PROBLEM", 361, 413], ["elevated d-dimer levels", "PROBLEM", 422, 445], ["mild thrombocytopenia", "PROBLEM", 450, 471], ["thrombosis", "OBSERVATION", 119, 129], ["thrombus", "OBSERVATION", 134, 142], ["Thrombus", "OBSERVATION", 190, 198], ["Complications", "OBSERVATION_MODIFIER", 207, 220], ["hypercoagulability", "OBSERVATION", 299, 317], ["elevated", "OBSERVATION_MODIFIER", 422, 430], ["d-dimer", "OBSERVATION_MODIFIER", 431, 438], ["mild", "OBSERVATION_MODIFIER", 450, 454], ["thrombocytopenia", "OBSERVATION", 455, 471]]], ["Less commonly, test results may indicate prolonged international normalized ratio (INR), thrombin time, and prothrombin time (PT) or a shortened activated partial thromboplastin time (aPTT) (2).", [["thrombin", "GENE_OR_GENE_PRODUCT", 89, 97], ["prothrombin", "GENE_OR_GENE_PRODUCT", 108, 119], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 163, 177], ["thrombin", "PROTEIN", 89, 97], ["prolonged international normalized ratio", "PROBLEM", 41, 81], ["INR", "TEST", 83, 86], ["thrombin time", "TEST", 89, 102], ["prothrombin time", "TEST", 108, 124], ["PT", "TEST", 126, 128], ["a shortened activated partial thromboplastin time", "TREATMENT", 133, 182], ["aPTT", "TEST", 184, 188]]], ["In contradistinction, some studies have shown prolonged aPTT in patients with confirmed COVID-19, often in conjunction with the presence of lupus anticoagulant antibodies.", [["lupus", "DISEASE", 140, 145], ["aPTT", "GENE_OR_GENE_PRODUCT", 56, 60], ["patients", "ORGANISM", 64, 72], ["lupus anticoagulant antibodies", "GENE_OR_GENE_PRODUCT", 140, 170], ["aPTT", "PROTEIN", 56, 60], ["lupus anticoagulant antibodies", "PROTEIN", 140, 170], ["patients", "SPECIES", 64, 72], ["some studies", "TEST", 22, 34], ["prolonged aPTT", "PROBLEM", 46, 60], ["COVID", "TEST", 88, 93], ["lupus anticoagulant antibodies", "PROBLEM", 140, 170], ["lupus anticoagulant antibodies", "OBSERVATION", 140, 170]]], ["Despite the prolonged aPTT, these patients do not exhibit symptoms of bleeding diathesis, and the use of anticoagulation therapy should not be discouraged (9) .", [["bleeding diathesis", "DISEASE", 70, 88], ["aPTT", "GENE_OR_GENE_PRODUCT", 22, 26], ["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["the prolonged aPTT", "TREATMENT", 8, 26], ["symptoms", "PROBLEM", 58, 66], ["bleeding diathesis", "PROBLEM", 70, 88], ["anticoagulation therapy", "TREATMENT", 105, 128], ["bleeding", "OBSERVATION", 70, 78]]], ["Elevated levels of d-dimer and fibrin degradation products and PT prolongation have been significantly correlated with increased mortality (10) .", [["d-dimer", "GENE_OR_GENE_PRODUCT", 19, 26], ["fibrin", "GENE_OR_GENE_PRODUCT", 31, 37], ["PT", "GENE_OR_GENE_PRODUCT", 63, 65], ["fibrin", "PROTEIN", 31, 37], ["Elevated levels of d-dimer", "PROBLEM", 0, 26], ["fibrin degradation products", "TREATMENT", 31, 58], ["PT prolongation", "PROBLEM", 63, 78], ["d-dimer", "OBSERVATION", 19, 26], ["fibrin degradation", "OBSERVATION", 31, 49]]], ["Some investigators have also reported a significant association between COVID-19 and abdominopelvic organ dysfunction, includ- This copy is for personal use only.", [["abdominopelvic organ", "ANATOMY", 85, 105], ["abdominopelvic organ dysfunction", "DISEASE", 85, 117], ["COVID-19", "GENE_OR_GENE_PRODUCT", 72, 80], ["organ", "ORGAN", 100, 105], ["COVID", "TEST", 72, 77], ["abdominopelvic organ dysfunction", "PROBLEM", 85, 117], ["abdominopelvic organ", "ANATOMY", 85, 105], ["dysfunction", "OBSERVATION", 106, 117]]], ["To order printed copies, contact reprints@rsna.org ent at imaging, and areas of necrosis have demonstrated unique characteristics, including yellow discoloration at surgery and clear demarcation of the borders of ischemia without anatomic transition zones, varying between circumferential and patchy antimesenteric involvement (13, 16) .Thrombus and Thrombus-related Complications in COVID-19It has been suggested by some groups that this phenomenon may occur as a result of microvascular thrombosis and associated inflammation (13, 16) .", [["antimesenteric", "ANATOMY", 300, 314], ["Thrombus", "ANATOMY", 337, 345], ["microvascular", "ANATOMY", 475, 488], ["necrosis", "DISEASE", 80, 88], ["ischemia", "DISEASE", 213, 221], ["Thrombus", "DISEASE", 337, 345], ["Thrombus", "DISEASE", 350, 358], ["COVID-19It", "CHEMICAL", 384, 394], ["microvascular thrombosis", "DISEASE", 475, 499], ["inflammation", "DISEASE", 515, 527], ["COVID-19It", "CHEMICAL", 384, 394], ["COVID-19It", "SIMPLE_CHEMICAL", 384, 394], ["microvascular", "TISSUE", 475, 488], ["org ent at imaging", "TEST", 47, 65], ["necrosis", "PROBLEM", 80, 88], ["yellow discoloration", "PROBLEM", 141, 161], ["surgery", "TREATMENT", 165, 172], ["ischemia", "PROBLEM", 213, 221], ["anatomic transition zones", "PROBLEM", 230, 255], ["circumferential and patchy antimesenteric involvement", "PROBLEM", 273, 326], ["Thrombus", "PROBLEM", 337, 345], ["Thrombus", "PROBLEM", 350, 358], ["Complications in COVID", "PROBLEM", 367, 389], ["microvascular thrombosis", "PROBLEM", 475, 499], ["associated inflammation", "PROBLEM", 504, 527], ["areas", "OBSERVATION_MODIFIER", 71, 76], ["necrosis", "OBSERVATION", 80, 88], ["yellow discoloration", "OBSERVATION", 141, 161], ["clear", "OBSERVATION_MODIFIER", 177, 182], ["demarcation", "OBSERVATION_MODIFIER", 183, 194], ["borders", "OBSERVATION_MODIFIER", 202, 209], ["ischemia", "OBSERVATION", 213, 221], ["without", "UNCERTAINTY", 222, 229], ["anatomic transition", "OBSERVATION", 230, 249], ["zones", "OBSERVATION_MODIFIER", 250, 255], ["varying", "OBSERVATION_MODIFIER", 257, 264], ["circumferential", "OBSERVATION_MODIFIER", 273, 288], ["patchy", "OBSERVATION_MODIFIER", 293, 299], ["antimesenteric involvement", "OBSERVATION", 300, 326], ["Thrombus", "OBSERVATION", 350, 358], ["Complications", "OBSERVATION", 367, 380], ["microvascular", "ANATOMY", 475, 488], ["thrombosis", "OBSERVATION", 489, 499], ["inflammation", "OBSERVATION", 515, 527]]], ["In one study, several bowel pathologic specimens demonstrated fibrin thrombi in submucosal arterioles, as well as arteriole damage with perivascular neutrophils (16) .", [["bowel", "ANATOMY", 22, 27], ["specimens", "ANATOMY", 39, 48], ["fibrin thrombi", "ANATOMY", 62, 76], ["submucosal arterioles", "ANATOMY", 80, 101], ["arteriole", "ANATOMY", 114, 123], ["perivascular neutrophils", "ANATOMY", 136, 160], ["thrombi", "DISEASE", 69, 76], ["arteriole damage", "DISEASE", 114, 130], ["bowel", "ORGAN", 22, 27], ["fibrin", "GENE_OR_GENE_PRODUCT", 62, 68], ["submucosal arterioles", "MULTI-TISSUE_STRUCTURE", 80, 101], ["arteriole", "MULTI-TISSUE_STRUCTURE", 114, 123], ["perivascular neutrophils", "CELL", 136, 160], ["perivascular neutrophils", "CELL_TYPE", 136, 160], ["one study", "TEST", 3, 12], ["several bowel pathologic specimens", "TEST", 14, 48], ["fibrin thrombi in submucosal arterioles", "PROBLEM", 62, 101], ["arteriole damage", "PROBLEM", 114, 130], ["perivascular neutrophils", "TEST", 136, 160], ["bowel", "ANATOMY", 22, 27], ["pathologic", "OBSERVATION", 28, 38], ["fibrin thrombi", "OBSERVATION", 62, 76], ["submucosal arterioles", "ANATOMY", 80, 101], ["arteriole", "ANATOMY_MODIFIER", 114, 123], ["damage", "OBSERVATION", 124, 130], ["perivascular", "ANATOMY_MODIFIER", 136, 148], ["neutrophils", "OBSERVATION", 149, 160]]], ["At imaging, bowel wall abnormalities, including wall thickening and altered enhancement, can be visualized, and on 20% of CT images in patients in the intensive care unit, changes of late ischemia, including pneumatosis and portal venous gas, have been described (Figs 1, 2)Thrombus and Thrombus-related Complications in COVID-19ing abnormal liver function test results, pancreatic injury, and bowel necrosis (11) (12) (13) .", [["bowel wall", "ANATOMY", 12, 22], ["wall", "ANATOMY", 48, 52], ["portal venous", "ANATOMY", 224, 237], ["liver", "ANATOMY", 342, 347], ["pancreatic", "ANATOMY", 371, 381], ["bowel", "ANATOMY", 394, 399], ["ischemia", "DISEASE", 188, 196], ["pneumatosis", "DISEASE", 208, 219], ["Thrombus", "DISEASE", 274, 282], ["Thrombus", "DISEASE", 287, 295], ["abnormal liver function", "DISEASE", 333, 356], ["pancreatic injury", "DISEASE", 371, 388], ["necrosis", "DISEASE", 400, 408], ["bowel wall", "MULTI-TISSUE_STRUCTURE", 12, 22], ["wall", "TISSUE", 48, 52], ["patients", "ORGANISM", 135, 143], ["portal venous", "MULTI-TISSUE_STRUCTURE", 224, 237], ["Thrombus", "PATHOLOGICAL_FORMATION", 274, 282], ["liver", "ORGAN", 342, 347], ["pancreatic", "ORGAN", 371, 381], ["bowel", "ORGAN", 394, 399], ["patients", "SPECIES", 135, 143], ["At imaging", "TEST", 0, 10], ["bowel wall abnormalities", "PROBLEM", 12, 36], ["wall thickening", "PROBLEM", 48, 63], ["altered enhancement", "PROBLEM", 68, 87], ["CT images", "TEST", 122, 131], ["late ischemia", "PROBLEM", 183, 196], ["pneumatosis", "PROBLEM", 208, 219], ["portal venous gas", "PROBLEM", 224, 241], ["Thrombus", "PROBLEM", 274, 282], ["Thrombus", "PROBLEM", 287, 295], ["Complications", "PROBLEM", 304, 317], ["COVID", "TEST", 321, 326], ["abnormal liver function test", "PROBLEM", 333, 361], ["pancreatic injury", "PROBLEM", 371, 388], ["bowel necrosis", "PROBLEM", 394, 408], ["bowel", "ANATOMY", 12, 17], ["wall", "ANATOMY_MODIFIER", 18, 22], ["abnormalities", "OBSERVATION", 23, 36], ["wall", "ANATOMY_MODIFIER", 48, 52], ["thickening", "OBSERVATION", 53, 63], ["altered", "OBSERVATION_MODIFIER", 68, 75], ["enhancement", "OBSERVATION_MODIFIER", 76, 87], ["late", "OBSERVATION_MODIFIER", 183, 187], ["ischemia", "OBSERVATION", 188, 196], ["pneumatosis", "OBSERVATION", 208, 219], ["portal venous", "ANATOMY", 224, 237], ["gas", "OBSERVATION", 238, 241], ["Thrombus", "OBSERVATION", 274, 282], ["Thrombus", "OBSERVATION", 287, 295], ["liver", "ANATOMY", 342, 347], ["pancreatic", "ANATOMY", 371, 381], ["injury", "OBSERVATION", 382, 388], ["bowel", "ANATOMY", 394, 399], ["necrosis", "OBSERVATION", 400, 408]]], ["The pathogenic mechanisms by which COVID-19 incites thrombosis and generalized organ damage are still emerging, but it has been observed that SARS-CoV-2 enters alveolar epithelial cells in the lung by binding to the angiotensin-converting enzyme 2 (ACE2) receptor (14) .", [["organ", "ANATOMY", 79, 84], ["alveolar epithelial cells", "ANATOMY", 160, 185], ["lung", "ANATOMY", 193, 197], ["thrombosis", "DISEASE", 52, 62], ["organ damage", "DISEASE", 79, 91], ["angiotensin", "CHEMICAL", 216, 227], ["organ", "ORGAN", 79, 84], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 142, 152], ["alveolar epithelial cells", "CELL", 160, 185], ["lung", "ORGAN", 193, 197], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 216, 247], ["ACE2", "GENE_OR_GENE_PRODUCT", 249, 253], ["alveolar epithelial cells", "CELL_TYPE", 160, 185], ["angiotensin-converting enzyme 2 (ACE2) receptor", "PROTEIN", 216, 263], ["The pathogenic mechanisms", "PROBLEM", 0, 25], ["COVID", "TEST", 35, 40], ["incites thrombosis", "PROBLEM", 44, 62], ["generalized organ damage", "PROBLEM", 67, 91], ["SARS", "TEST", 142, 146], ["CoV", "TEST", 147, 150], ["alveolar epithelial cells in the lung", "PROBLEM", 160, 197], ["the angiotensin", "TEST", 212, 227], ["thrombosis", "OBSERVATION", 52, 62], ["generalized", "OBSERVATION_MODIFIER", 67, 78], ["organ", "ANATOMY", 79, 84], ["damage", "OBSERVATION", 85, 91], ["alveolar", "ANATOMY_MODIFIER", 160, 168], ["epithelial cells", "OBSERVATION", 169, 185], ["lung", "ANATOMY", 193, 197]]], ["These receptors are expressed at high levels in biliary epithelial cells (14) and pancreatic islet cells (12) and have been detected in gastrointestinal epithelial cells (15) , suggesting that receptor expression may enhance cytotoxic effects by facilitating local viral infection and replication.Thrombus and Thrombus-related Complications in COVID-19In cases demonstrating bowel ischemia or necrosis, the main mesenteric vasculature was pat- inflammatory markers.", [["biliary epithelial cells", "ANATOMY", 48, 72], ["pancreatic islet cells", "ANATOMY", 82, 104], ["gastrointestinal epithelial cells", "ANATOMY", 136, 169], ["Thrombus", "ANATOMY", 297, 305], ["Thrombus", "ANATOMY", 310, 318], ["bowel", "ANATOMY", 375, 380], ["mesenteric vasculature", "ANATOMY", 412, 434], ["viral infection", "DISEASE", 265, 280], ["Thrombus", "DISEASE", 297, 305], ["Thrombus", "DISEASE", 310, 318], ["bowel ischemia", "DISEASE", 375, 389], ["necrosis", "DISEASE", 393, 401], ["biliary epithelial cells", "CELL", 48, 72], ["pancreatic islet cells", "CELL", 82, 104], ["gastrointestinal epithelial cells", "CELL", 136, 169], ["Thrombus", "PATHOLOGICAL_FORMATION", 297, 305], ["bowel", "ORGAN", 375, 380], ["mesenteric vasculature", "MULTI-TISSUE_STRUCTURE", 412, 434], ["biliary epithelial cells", "CELL_TYPE", 48, 72], ["pancreatic islet cells", "CELL_TYPE", 82, 104], ["gastrointestinal epithelial cells", "CELL_TYPE", 136, 169], ["inflammatory markers", "PROTEIN", 444, 464], ["biliary epithelial cells", "TEST", 48, 72], ["pancreatic islet cells", "TEST", 82, 104], ["receptor expression", "PROBLEM", 193, 212], ["cytotoxic effects", "PROBLEM", 225, 242], ["local viral infection", "PROBLEM", 259, 280], ["Thrombus", "PROBLEM", 297, 305], ["Thrombus", "PROBLEM", 310, 318], ["Complications", "PROBLEM", 327, 340], ["COVID", "TEST", 344, 349], ["bowel ischemia", "PROBLEM", 375, 389], ["necrosis", "PROBLEM", 393, 401], ["high", "OBSERVATION_MODIFIER", 33, 37], ["biliary epithelial", "ANATOMY", 48, 66], ["cells", "OBSERVATION", 67, 72], ["pancreatic", "ANATOMY", 82, 92], ["islet cells", "OBSERVATION", 93, 104], ["gastrointestinal epithelial cells", "ANATOMY", 136, 169], ["viral infection", "OBSERVATION", 265, 280], ["Thrombus", "OBSERVATION", 310, 318], ["bowel", "ANATOMY", 375, 380], ["ischemia", "OBSERVATION", 381, 389], ["necrosis", "OBSERVATION", 393, 401], ["main", "ANATOMY_MODIFIER", 407, 411], ["mesenteric vasculature", "ANATOMY", 412, 434], ["inflammatory", "OBSERVATION_MODIFIER", 444, 456]]], ["This is among the proposed mechanisms of liver injury in patients with COVID-19 (14) .Thrombus and Thrombus-related Complications in COVID-19Furthermore, several authors have proposed that the abrupt onset of multisystem organ failure in some patients with COVID-19 may be attributable to severe systemic inflammation caused by the upregulation of both cellular and natural immunity (14, 19) .", [["liver", "ANATOMY", 41, 46], ["Thrombus", "ANATOMY", 86, 94], ["organ", "ANATOMY", 221, 226], ["cellular", "ANATOMY", 353, 361], ["liver injury", "DISEASE", 41, 53], ["COVID-19", "CHEMICAL", 71, 79], ["Thrombus", "DISEASE", 86, 94], ["Thrombus", "DISEASE", 99, 107], ["multisystem organ failure", "DISEASE", 209, 234], ["COVID-19", "CHEMICAL", 257, 265], ["inflammation", "DISEASE", 305, 317], ["COVID-19", "CHEMICAL", 71, 79], ["COVID-19", "CHEMICAL", 257, 265], ["liver", "ORGAN", 41, 46], ["patients", "ORGANISM", 57, 65], ["organ", "ORGAN", 221, 226], ["patients", "ORGANISM", 243, 251], ["cellular", "CELL", 353, 361], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 243, 251], ["liver injury", "PROBLEM", 41, 53], ["COVID", "TEST", 71, 76], ["Thrombus", "PROBLEM", 86, 94], ["Thrombus", "PROBLEM", 99, 107], ["Complications in COVID", "PROBLEM", 116, 138], ["multisystem organ failure", "PROBLEM", 209, 234], ["COVID", "TEST", 257, 262], ["severe systemic inflammation", "PROBLEM", 289, 317], ["liver", "ANATOMY", 41, 46], ["injury", "OBSERVATION", 47, 53], ["Thrombus", "OBSERVATION", 99, 107], ["abrupt", "OBSERVATION_MODIFIER", 193, 199], ["multisystem", "OBSERVATION_MODIFIER", 209, 220], ["organ", "ANATOMY", 221, 226], ["failure", "OBSERVATION", 227, 234], ["may be attributable to", "UNCERTAINTY", 266, 288], ["severe", "OBSERVATION_MODIFIER", 289, 295], ["systemic", "OBSERVATION_MODIFIER", 296, 304], ["inflammation", "OBSERVATION", 305, 317], ["upregulation", "OBSERVATION_MODIFIER", 332, 344], ["both", "OBSERVATION_MODIFIER", 348, 352], ["cellular", "OBSERVATION_MODIFIER", 353, 361], ["natural", "OBSERVATION_MODIFIER", 366, 373], ["immunity", "OBSERVATION_MODIFIER", 374, 382]]], ["SARS-CoV-2 infection triggers activation of T lymphocytes and inflammatory signaling pathways that ultimately result in the release of multiple proinflammatory markers, including granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-2, IL-6, IL-7, IL-10, and tumor necrosis factor-\u03b1 (TNF-a), among others.", [["T lymphocytes", "ANATOMY", 44, 57], ["SARS", "DISEASE", 0, 4], ["infection", "DISEASE", 11, 20], ["necrosis", "DISEASE", 287, 295], ["SARS-CoV-2", "ORGANISM", 0, 10], ["T lymphocytes", "CELL", 44, 57], ["granulocyte-macrophage colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 179, 227], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 229, 235], ["interleukin (IL)-2", "GENE_OR_GENE_PRODUCT", 238, 256], ["IL-6", "GENE_OR_GENE_PRODUCT", 258, 262], ["IL-7", "GENE_OR_GENE_PRODUCT", 264, 268], ["IL-10", "GENE_OR_GENE_PRODUCT", 270, 275], ["tumor necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 281, 304], ["TNF", "GENE_OR_GENE_PRODUCT", 306, 309], ["T lymphocytes", "CELL_TYPE", 44, 57], ["proinflammatory markers", "PROTEIN", 144, 167], ["granulocyte-macrophage colony-stimulating factor", "PROTEIN", 179, 227], ["CSF", "PROTEIN", 232, 235], ["IL-10", "PROTEIN", 270, 275], ["tumor necrosis factor-\u03b1", "PROTEIN", 281, 304], ["TNF", "PROTEIN", 306, 309], ["SARS", "PROBLEM", 0, 4], ["2 infection", "PROBLEM", 9, 20], ["T lymphocytes", "PROBLEM", 44, 57], ["inflammatory signaling pathways", "PROBLEM", 62, 93], ["multiple proinflammatory markers", "TEST", 135, 167], ["granulocyte", "TEST", 179, 190], ["macrophage colony", "TEST", 191, 208], ["stimulating factor", "TEST", 209, 227], ["GM-CSF", "TEST", 229, 235], ["interleukin (IL)", "TEST", 238, 254], ["IL", "TEST", 258, 260], ["IL", "TEST", 264, 266], ["IL", "TEST", 270, 272], ["tumor necrosis factor", "PROBLEM", 281, 302], ["TNF", "TEST", 306, 309], ["infection", "OBSERVATION", 11, 20], ["inflammatory", "OBSERVATION_MODIFIER", 62, 74], ["multiple", "OBSERVATION_MODIFIER", 135, 143], ["proinflammatory markers", "OBSERVATION", 144, 167], ["granulocyte", "ANATOMY", 179, 190], ["macrophage colony", "OBSERVATION", 191, 208], ["tumor", "ANATOMY", 281, 286], ["necrosis", "OBSERVATION", 287, 295]]], ["This cytokine cascade can ultimately yield extensive cell damage, necrosis, and injury to multiple organs (14, 19) and may partially explain the disparate multisystem symptoms in patients In a recent study, lungs obtained at autopsy in patients who died from COVID-19 demonstrated distinctive vascular features, including severe endothelial injury associated with intracellular virus and disrupted cell membranes, as well as extensive thrombosis, microangiopathy, alveolar capillary microthrombi, and more new vessel growth or angiogenesis compared with those lungs obtained at autopsy from patients who died from influenza (17) .Thrombus and Thrombus-related Complications in COVID-19Other authors have postulated that lung injury and impaired gas exchange may increase production of proinflammatory cytokines, and contributing viral infection may also result in direct damage to the vascular endothelium (18) .", [["cell", "ANATOMY", 53, 57], ["organs", "ANATOMY", 99, 105], ["lungs", "ANATOMY", 207, 212], ["vascular", "ANATOMY", 293, 301], ["endothelial", "ANATOMY", 329, 340], ["intracellular", "ANATOMY", 364, 377], ["cell membranes", "ANATOMY", 398, 412], ["alveolar capillary", "ANATOMY", 464, 482], ["vessel", "ANATOMY", 510, 516], ["lungs", "ANATOMY", 560, 565], ["Thrombus", "ANATOMY", 630, 638], ["lung", "ANATOMY", 720, 724], ["vascular endothelium", "ANATOMY", 885, 905], ["necrosis", "DISEASE", 66, 74], ["endothelial injury", "DISEASE", 329, 347], ["thrombosis", "DISEASE", 435, 445], ["microangiopathy", "DISEASE", 447, 462], ["influenza", "DISEASE", 614, 623], ["Thrombus", "DISEASE", 630, 638], ["lung injury", "DISEASE", 720, 731], ["viral infection", "DISEASE", 829, 844], ["COVID-19", "CHEMICAL", 259, 267], ["cell", "CELL", 53, 57], ["organs", "ORGAN", 99, 105], ["patients", "ORGANISM", 179, 187], ["lungs", "ORGAN", 207, 212], ["patients", "ORGANISM", 236, 244], ["vascular", "MULTI-TISSUE_STRUCTURE", 293, 301], ["endothelial", "TISSUE", 329, 340], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 364, 377], ["cell membranes", "CELLULAR_COMPONENT", 398, 412], ["alveolar capillary", "TISSUE", 464, 482], ["vessel", "MULTI-TISSUE_STRUCTURE", 510, 516], ["lungs", "ORGAN", 560, 565], ["patients", "ORGANISM", 591, 599], ["lung", "ORGAN", 720, 724], ["vascular endothelium", "TISSUE", 885, 905], ["cytokine", "PROTEIN", 5, 13], ["proinflammatory cytokines", "PROTEIN", 785, 810], ["patients", "SPECIES", 179, 187], ["patients", "SPECIES", 236, 244], ["patients", "SPECIES", 591, 599], ["This cytokine cascade", "PROBLEM", 0, 21], ["extensive cell damage", "PROBLEM", 43, 64], ["necrosis", "PROBLEM", 66, 74], ["injury to multiple organs", "PROBLEM", 80, 105], ["the disparate multisystem symptoms", "PROBLEM", 141, 175], ["a recent study", "TEST", 191, 205], ["COVID", "TEST", 259, 264], ["distinctive vascular features", "PROBLEM", 281, 310], ["severe endothelial injury", "PROBLEM", 322, 347], ["intracellular virus", "PROBLEM", 364, 383], ["disrupted cell membranes", "PROBLEM", 388, 412], ["extensive thrombosis", "PROBLEM", 425, 445], ["microangiopathy", "PROBLEM", 447, 462], ["alveolar capillary microthrombi", "PROBLEM", 464, 495], ["new vessel growth", "PROBLEM", 506, 523], ["angiogenesis", "PROBLEM", 527, 539], ["influenza", "PROBLEM", 614, 623], ["Thrombus", "PROBLEM", 630, 638], ["Thrombus", "PROBLEM", 643, 651], ["Complications in COVID", "PROBLEM", 660, 682], ["lung injury", "PROBLEM", 720, 731], ["impaired gas exchange", "PROBLEM", 736, 757], ["proinflammatory cytokines", "PROBLEM", 785, 810], ["viral infection", "PROBLEM", 829, 844], ["direct damage to the vascular endothelium", "PROBLEM", 864, 905], ["extensive", "OBSERVATION_MODIFIER", 43, 52], ["cell damage", "OBSERVATION", 53, 64], ["necrosis", "OBSERVATION", 66, 74], ["injury", "OBSERVATION", 80, 86], ["multiple", "OBSERVATION_MODIFIER", 90, 98], ["organs", "ANATOMY", 99, 105], ["may partially explain", "UNCERTAINTY", 119, 140], ["multisystem", "OBSERVATION_MODIFIER", 155, 166], ["symptoms", "OBSERVATION", 167, 175], ["lungs", "ANATOMY", 207, 212], ["vascular", "ANATOMY", 293, 301], ["severe", "OBSERVATION_MODIFIER", 322, 328], ["endothelial", "ANATOMY", 329, 340], ["injury", "OBSERVATION", 341, 347], ["intracellular virus", "OBSERVATION", 364, 383], ["disrupted cell membranes", "OBSERVATION", 388, 412], ["extensive", "OBSERVATION_MODIFIER", 425, 434], ["thrombosis", "OBSERVATION", 435, 445], ["microangiopathy", "OBSERVATION", 447, 462], ["alveolar", "ANATOMY_MODIFIER", 464, 472], ["capillary microthrombi", "OBSERVATION", 473, 495], ["more", "OBSERVATION_MODIFIER", 501, 505], ["new", "OBSERVATION_MODIFIER", 506, 509], ["vessel", "ANATOMY", 510, 516], ["growth", "OBSERVATION_MODIFIER", 517, 523], ["angiogenesis", "OBSERVATION", 527, 539], ["lungs", "ANATOMY", 560, 565], ["Thrombus", "OBSERVATION", 643, 651], ["lung", "ANATOMY", 720, 724], ["injury", "OBSERVATION", 725, 731], ["impaired", "OBSERVATION_MODIFIER", 736, 744], ["gas exchange", "OBSERVATION", 745, 757], ["proinflammatory cytokines", "OBSERVATION", 785, 810], ["viral infection", "OBSERVATION", 829, 844], ["vascular endothelium", "ANATOMY", 885, 905]]], ["Some data suggest that the hypoxia induced by COVID-19 pneumonia may result in hypoxia-reperfusion and resultant cell death.", [["cell", "ANATOMY", 113, 117], ["hypoxia", "DISEASE", 27, 34], ["COVID-19", "CHEMICAL", 46, 54], ["pneumonia", "DISEASE", 55, 64], ["death", "DISEASE", 118, 123], ["COVID-19", "CHEMICAL", 46, 54], ["COVID-19", "ORGANISM", 46, 54], ["cell", "CELL", 113, 117], ["the hypoxia", "PROBLEM", 23, 34], ["COVID", "TEST", 46, 51], ["pneumonia", "PROBLEM", 55, 64], ["hypoxia-reperfusion", "PROBLEM", 79, 98], ["resultant cell death", "PROBLEM", 103, 123], ["hypoxia", "OBSERVATION", 27, 34], ["pneumonia", "OBSERVATION", 55, 64], ["resultant cell death", "OBSERVATION", 103, 123]]], ["The concomitant rise in circulating reactive oxygen species and oxidation products can contribute to the further release of axial (b, c) contrast-enhanced CT images show multifocal small and large bowel wall thickening (arrows) creating a ribbonlike appearance, likely related to small vessel ischemia.", [["bowel wall", "ANATOMY", 197, 207], ["vessel", "ANATOMY", 286, 292], ["oxygen", "CHEMICAL", 45, 51], ["vessel ischemia", "DISEASE", 286, 301], ["oxygen", "CHEMICAL", 45, 51], ["reactive oxygen species", "SIMPLE_CHEMICAL", 36, 59], ["bowel wall", "PATHOLOGICAL_FORMATION", 197, 207], ["vessel", "MULTI-TISSUE_STRUCTURE", 286, 292], ["The concomitant rise", "PROBLEM", 0, 20], ["circulating reactive oxygen species", "TREATMENT", 24, 59], ["oxidation products", "TREATMENT", 64, 82], ["axial (b, c) contrast-enhanced CT images", "TEST", 124, 164], ["multifocal small and large bowel wall thickening", "PROBLEM", 170, 218], ["a ribbonlike appearance", "PROBLEM", 237, 260], ["small vessel ischemia", "PROBLEM", 280, 301], ["concomitant", "OBSERVATION_MODIFIER", 4, 15], ["rise", "OBSERVATION_MODIFIER", 16, 20], ["circulating", "OBSERVATION_MODIFIER", 24, 35], ["reactive", "OBSERVATION_MODIFIER", 36, 44], ["oxygen species", "OBSERVATION", 45, 59], ["multifocal", "OBSERVATION_MODIFIER", 170, 180], ["small", "OBSERVATION_MODIFIER", 181, 186], ["large", "OBSERVATION_MODIFIER", 191, 196], ["bowel", "ANATOMY", 197, 202], ["wall", "ANATOMY_MODIFIER", 203, 207], ["thickening", "OBSERVATION", 208, 218], ["likely related to", "UNCERTAINTY", 262, 279], ["small vessel ischemia", "OBSERVATION", 280, 301]]], ["Note the altered enhancement of the kidneys (arrowhead in c) in the setting of acute kidney injury and multifocal peripheral airspace opacities at the lung bases on the coronal CT image (d). bowel ischemia (Figs 1, 2) , pancreatitis (Fig 4) , portal vein thrombus, ischemic-type liver injury, or other visceral infarct (Figs 1, 3) .ConclusionThe results from the previously described studies indicate that in patients with suspected or confirmed COVID-19, radiologists should maintain a high index of suspicion for thromboembolic complications.", [["kidneys", "ANATOMY", 36, 43], ["kidney", "ANATOMY", 85, 91], ["peripheral airspace opacities", "ANATOMY", 114, 143], ["lung", "ANATOMY", 151, 155], ["bowel", "ANATOMY", 191, 196], ["portal vein thrombus", "ANATOMY", 243, 263], ["liver", "ANATOMY", 279, 284], ["visceral", "ANATOMY", 302, 310], ["acute kidney injury", "DISEASE", 79, 98], ["bowel ischemia", "DISEASE", 191, 205], ["pancreatitis", "DISEASE", 220, 232], ["portal vein thrombus", "DISEASE", 243, 263], ["ischemic-type liver injury", "DISEASE", 265, 291], ["visceral infarct", "DISEASE", 302, 318], ["thromboembolic", "DISEASE", 515, 529], ["kidneys", "ORGAN", 36, 43], ["kidney", "ORGAN", 85, 91], ["peripheral airspace", "PATHOLOGICAL_FORMATION", 114, 133], ["lung", "ORGAN", 151, 155], ["bowel", "ORGAN", 191, 196], ["portal vein", "MULTI-TISSUE_STRUCTURE", 243, 254], ["thrombus", "PATHOLOGICAL_FORMATION", 255, 263], ["liver", "ORGAN", 279, 284], ["visceral", "ORGANISM_SUBDIVISION", 302, 310], ["patients", "ORGANISM", 409, 417], ["patients", "SPECIES", 409, 417], ["the altered enhancement of the kidneys", "PROBLEM", 5, 43], ["acute kidney injury", "PROBLEM", 79, 98], ["multifocal peripheral airspace opacities at the lung bases", "PROBLEM", 103, 161], ["the coronal CT image", "TEST", 165, 185], ["bowel ischemia", "PROBLEM", 191, 205], ["pancreatitis", "PROBLEM", 220, 232], ["portal vein thrombus", "PROBLEM", 243, 263], ["ischemic-type liver injury", "PROBLEM", 265, 291], ["other visceral infarct", "PROBLEM", 296, 318], ["COVID", "TEST", 446, 451], ["thromboembolic complications", "PROBLEM", 515, 543], ["altered", "OBSERVATION_MODIFIER", 9, 16], ["enhancement", "OBSERVATION", 17, 28], ["kidneys", "ANATOMY", 36, 43], ["acute", "OBSERVATION_MODIFIER", 79, 84], ["kidney", "ANATOMY", 85, 91], ["injury", "OBSERVATION", 92, 98], ["multifocal", "OBSERVATION_MODIFIER", 103, 113], ["peripheral", "ANATOMY_MODIFIER", 114, 124], ["airspace", "ANATOMY_MODIFIER", 125, 133], ["opacities", "OBSERVATION", 134, 143], ["lung", "ANATOMY", 151, 155], ["bases", "ANATOMY_MODIFIER", 156, 161], ["ischemia", "OBSERVATION", 197, 205], ["pancreatitis", "OBSERVATION", 220, 232], ["portal vein", "ANATOMY", 243, 254], ["thrombus", "OBSERVATION", 255, 263], ["ischemic", "OBSERVATION", 265, 273], ["type", "OBSERVATION_MODIFIER", 274, 278], ["liver", "ANATOMY", 279, 284], ["injury", "OBSERVATION", 285, 291], ["visceral", "ANATOMY", 302, 310], ["infarct", "OBSERVATION", 311, 318], ["suspicion for", "UNCERTAINTY", 501, 514], ["thromboembolic complications", "OBSERVATION", 515, 543]]], ["Imaging features of thrombosis due to COVID-19 are nonspecific and similar in appearance to those seen in other pathologic conditions.", [["thrombosis", "DISEASE", 20, 30], ["COVID-19", "CHEMICAL", 38, 46], ["COVID-19", "DNA", 38, 46], ["Imaging features", "TEST", 0, 16], ["thrombosis", "PROBLEM", 20, 30], ["COVID", "TEST", 38, 43], ["thrombosis", "OBSERVATION", 20, 30], ["nonspecific", "OBSERVATION_MODIFIER", 51, 62], ["similar", "OBSERVATION_MODIFIER", 67, 74], ["pathologic", "OBSERVATION", 112, 122]]], ["However, radiologists' familiarity with its prevalence and pathogenesis in this subset of patients may lead to increased detection and more favorable outcomes.", [["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["increased detection", "PROBLEM", 111, 130]]], ["Further, given that fairly aggressive anticoagulation regimens are being adopted for these patients, bleeding complications can also be visualized at imaging.", [["bleeding", "DISEASE", 101, 109], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["fairly aggressive anticoagulation regimens", "TREATMENT", 20, 62], ["bleeding complications", "PROBLEM", 101, 123], ["imaging", "TEST", 150, 157]]], ["Finally, the presence of unexpected VTE at imaging performed for unrelated indications could herald the need for further workup for COVID-19, particularly in regions with high rates of endemic infection.Conclusionwith confirmed viral infection, including hepatic, pancreatic, and gastrointestinal ischemia.", [["hepatic", "ANATOMY", 255, 262], ["pancreatic", "ANATOMY", 264, 274], ["gastrointestinal", "ANATOMY", 280, 296], ["VTE", "DISEASE", 36, 39], ["infection", "DISEASE", 193, 202], ["viral infection", "DISEASE", 228, 243], ["hepatic, pancreatic, and gastrointestinal ischemia", "DISEASE", 255, 305], ["hepatic", "ORGAN", 255, 262], ["pancreatic", "MULTI-TISSUE_STRUCTURE", 264, 274], ["gastrointestinal", "ORGAN", 280, 296], ["unexpected VTE", "PROBLEM", 25, 39], ["imaging", "TEST", 43, 50], ["further workup", "TEST", 113, 127], ["COVID", "TEST", 132, 137], ["endemic infection", "PROBLEM", 185, 202], ["viral infection", "PROBLEM", 228, 243], ["hepatic, pancreatic, and gastrointestinal ischemia", "PROBLEM", 255, 305], ["high", "OBSERVATION_MODIFIER", 171, 175], ["endemic", "OBSERVATION_MODIFIER", 185, 192], ["infection", "OBSERVATION", 193, 202], ["viral", "OBSERVATION_MODIFIER", 228, 233], ["infection", "OBSERVATION", 234, 243], ["hepatic", "ANATOMY", 255, 262], ["pancreatic", "ANATOMY", 264, 274], ["gastrointestinal", "ANATOMY", 280, 296], ["ischemia", "OBSERVATION", 297, 305]]], ["Preliminary data suggest that in patients with COVID-19 with coagulopathy, treatment with low-molecular-weight heparin may decrease mortality (20) .ConclusionIn a recent study by Cui et al (21) , which encompassed 81 patients who were critically ill, the incidence of venous thromboembolism (VTE) was 25%, with a mortality rate of 40% in that subset of patients.", [["venous", "ANATOMY", 268, 274], ["coagulopathy", "DISEASE", 61, 73], ["heparin", "CHEMICAL", 111, 118], ["critically ill", "DISEASE", 235, 249], ["venous thromboembolism", "DISEASE", 268, 290], ["VTE", "DISEASE", 292, 295], ["patients", "ORGANISM", 33, 41], ["low-molecular-weight heparin", "SIMPLE_CHEMICAL", 90, 118], ["patients", "ORGANISM", 217, 225], ["venous", "MULTI-TISSUE_STRUCTURE", 268, 274], ["patients", "ORGANISM", 353, 361], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 217, 225], ["patients", "SPECIES", 353, 361], ["Preliminary data", "TEST", 0, 16], ["COVID", "TEST", 47, 52], ["coagulopathy", "PROBLEM", 61, 73], ["treatment", "TREATMENT", 75, 84], ["low-molecular-weight heparin", "TREATMENT", 90, 118], ["a recent study", "TEST", 161, 175], ["critically ill", "PROBLEM", 235, 249], ["venous thromboembolism", "PROBLEM", 268, 290], ["VTE", "TEST", 292, 295], ["a mortality rate", "TEST", 311, 327], ["coagulopathy", "OBSERVATION", 61, 73], ["venous", "ANATOMY", 268, 274], ["thromboembolism", "OBSERVATION", 275, 290]]], ["In a study by Klok et al (5) , 184 patients with confirmed COVID-19 pneumonia who were admitted to intensive care units across three hospitals in the Netherlands were evaluated, and thrombotic complications were found in 31% (VTE in 27%, arterial thrombotic events in 3.7%), the most common of which was pulmonary embolism (Fig 3) .", [["arterial", "ANATOMY", 238, 246], ["pulmonary", "ANATOMY", 304, 313], ["pneumonia", "DISEASE", 68, 77], ["thrombotic complications", "DISEASE", 182, 206], ["VTE", "DISEASE", 226, 229], ["arterial thrombotic", "DISEASE", 238, 257], ["pulmonary embolism", "DISEASE", 304, 322], ["patients", "ORGANISM", 35, 43], ["arterial", "MULTI-TISSUE_STRUCTURE", 238, 246], ["pulmonary", "ORGAN", 304, 313], ["patients", "SPECIES", 35, 43], ["a study", "TEST", 3, 10], ["COVID", "TEST", 59, 64], ["pneumonia", "PROBLEM", 68, 77], ["thrombotic complications", "PROBLEM", 182, 206], ["VTE", "TEST", 226, 229], ["arterial thrombotic events", "PROBLEM", 238, 264], ["pulmonary embolism", "PROBLEM", 304, 322], ["pneumonia", "OBSERVATION", 68, 77], ["thrombotic", "OBSERVATION_MODIFIER", 182, 192], ["complications", "OBSERVATION", 193, 206], ["arterial", "ANATOMY", 238, 246], ["thrombotic", "OBSERVATION", 247, 257], ["pulmonary", "ANATOMY", 304, 313], ["embolism", "OBSERVATION", 314, 322]]], ["Similar results were reported by Leonard-Lorant et al (22) , who demonstrated a positivity rate of 30% for thrombotic complications (32 of 106 patients) in patients with COVID-19 who underwent CT pulmonary angiography.", [["pulmonary", "ANATOMY", 196, 205], ["thrombotic complications", "DISEASE", 107, 131], ["patients", "ORGANISM", 143, 151], ["patients", "ORGANISM", 156, 164], ["pulmonary", "ORGAN", 196, 205], ["patients", "SPECIES", 143, 151], ["patients", "SPECIES", 156, 164], ["a positivity rate", "TEST", 78, 95], ["thrombotic complications", "PROBLEM", 107, 131], ["COVID", "TEST", 170, 175], ["CT pulmonary angiography", "TEST", 193, 217], ["pulmonary", "ANATOMY", 196, 205]]], ["As noted previously, other groups have described . (a, b) Axial (a) and coronal (b) contrast-enhanced CT images of the abdomen and pelvis show severe acute interstitial pancreatitis. (c) Axial CT image of the lung shows multifocal peripheral areas of ground-glass opacity and consolidation (arrow), findings concerning for organizing or viral pneumonia.", [["abdomen", "ANATOMY", 119, 126], ["pelvis", "ANATOMY", 131, 137], ["interstitial", "ANATOMY", 156, 168], ["lung", "ANATOMY", 209, 213], ["interstitial pancreatitis", "DISEASE", 156, 181], ["pneumonia", "DISEASE", 343, 352], ["abdomen", "ORGAN", 119, 126], ["pelvis", "ORGAN", 131, 137], ["interstitial pancreatitis", "PATHOLOGICAL_FORMATION", 156, 181], ["lung", "ORGAN", 209, 213], ["Axial (a) and coronal (b) contrast-enhanced CT images of the abdomen and pelvis", "TEST", 58, 137], ["severe acute interstitial pancreatitis", "PROBLEM", 143, 181], ["Axial CT image of the lung", "TEST", 187, 213], ["multifocal peripheral areas of ground-glass opacity", "PROBLEM", 220, 271], ["consolidation", "PROBLEM", 276, 289], ["viral pneumonia", "PROBLEM", 337, 352], ["abdomen", "ANATOMY", 119, 126], ["pelvis", "ANATOMY", 131, 137], ["severe", "OBSERVATION_MODIFIER", 143, 149], ["acute", "OBSERVATION_MODIFIER", 150, 155], ["interstitial", "ANATOMY_MODIFIER", 156, 168], ["pancreatitis", "OBSERVATION", 169, 181], ["lung", "ANATOMY", 209, 213], ["multifocal", "OBSERVATION_MODIFIER", 220, 230], ["peripheral", "OBSERVATION_MODIFIER", 231, 241], ["areas", "OBSERVATION_MODIFIER", 242, 247], ["ground-glass opacity", "OBSERVATION", 251, 271], ["consolidation", "OBSERVATION", 276, 289], ["concerning for", "UNCERTAINTY", 308, 322], ["viral", "OBSERVATION_MODIFIER", 337, 342], ["pneumonia", "OBSERVATION", 343, 352]]], ["Test results for COVID-19 were negative.", [["COVID-19", "DNA", 17, 25], ["COVID", "TEST", 17, 22]]], ["However, the patient was clinically still presumed to be a patient under investigation, as ischemic pancreatitis had been described, possibly related to microthrombi.", [["pancreatitis", "DISEASE", 100, 112], ["microthrombi", "DISEASE", 153, 165], ["patient", "ORGANISM", 13, 20], ["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 13, 20], ["patient", "SPECIES", 59, 66], ["ischemic pancreatitis", "PROBLEM", 91, 112], ["microthrombi", "PROBLEM", 153, 165], ["ischemic", "OBSERVATION_MODIFIER", 91, 99], ["pancreatitis", "OBSERVATION", 100, 112], ["possibly related to", "UNCERTAINTY", 133, 152], ["microthrombi", "OBSERVATION", 153, 165]]]], "40b2b0e3d2cf519723d858a138e77a26a70f460f": [["What are the new findings?", [["new", "OBSERVATION_MODIFIER", 13, 16]]]], "8fe981e02d39695a50a3f753f39dadf727768651": [["Highligths-COVID-19 asymptomatic patients could become an important cause of virus spread.Highligths-A high proportion (42%) of close contacts of COVID-19 patients were infected with SARS-CoV-2 -The average of contacts infected with SARS-CoV-2 by index COVID-19 case was 4.3.Highligths-The mean of time of SARS-CoV-2 positive test was 18.9 days.Highligths-82.4% of contacts infected with SARS-CoV-2 had less than two or had no respiratory symptoms.IntroductionThe coronavirus disease 19 (COVID 19) epidemic represents a health problem with the characteristics of contagiousness, quick transmission and general susceptibility.", [["respiratory", "ANATOMY", 427, 438], ["SARS", "DISEASE", 183, 187], ["SARS", "DISEASE", 233, 237], ["SARS", "DISEASE", 306, 310], ["SARS", "DISEASE", 388, 392], ["respiratory symptoms", "DISEASE", 427, 447], ["coronavirus disease", "DISEASE", 464, 483], ["contagiousness", "DISEASE", 563, 577], ["patients", "ORGANISM", 33, 41], ["patients", "ORGANISM", 155, 163], ["SARS-CoV-2", "ORGANISM", 183, 193], ["SARS-CoV-2", "ORGANISM", 233, 243], ["SARS-CoV-2", "ORGANISM", 388, 398], ["coronavirus", "ORGANISM", 464, 475], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 155, 163], ["CoV-", "SPECIES", 393, 397], ["SARS-CoV", "SPECIES", 183, 191], ["SARS-CoV", "SPECIES", 233, 241], ["SARS-CoV", "SPECIES", 306, 314], ["SARS-CoV", "SPECIES", 388, 396], ["Highligths", "TEST", 0, 10], ["COVID", "TEST", 11, 16], ["asymptomatic", "PROBLEM", 20, 32], ["virus spread", "PROBLEM", 77, 89], ["COVID", "TEST", 146, 151], ["SARS", "TEST", 183, 187], ["CoV", "TEST", 188, 191], ["SARS", "TEST", 233, 237], ["CoV", "TEST", 238, 241], ["index COVID", "TEST", 247, 258], ["SARS", "TEST", 306, 310], ["CoV", "TEST", 311, 314], ["Highligths", "TEST", 345, 355], ["SARS-CoV", "TEST", 388, 396], ["respiratory symptoms", "PROBLEM", 427, 447], ["The coronavirus disease", "PROBLEM", 460, 483], ["epidemic", "PROBLEM", 498, 506], ["a health problem", "PROBLEM", 518, 534], ["contagiousness", "PROBLEM", 563, 577], ["quick transmission and general susceptibility", "PROBLEM", 579, 624], ["virus", "OBSERVATION", 77, 82], ["no", "UNCERTAINTY", 424, 426], ["respiratory", "ANATOMY", 427, 438], ["symptoms", "OBSERVATION", 439, 447], ["coronavirus disease", "OBSERVATION", 464, 483], ["susceptibility", "OBSERVATION_MODIFIER", 610, 624]]], ["In Mexico up the end of 24 September 2020, the statistics showed 743,435 patients infected with SARS-CoV-2 and 76,647 deaths due to COVID-19 2 .IntroductionThe coronavirus 2 of severe acute respiratory syndrome (SARS-CoV-2) infection is directly linked with the recognition and binding of its spike protein to the human angiotensin-converting enzyme 2 receptor 3 .IntroductionThis receptor is mainly located in the lung alveolar epithelial cells, which are potentially target of this virus.", [["lung alveolar epithelial cells", "ANATOMY", 415, 445], ["SARS", "DISEASE", 96, 100], ["deaths", "DISEASE", 118, 124], ["acute respiratory syndrome", "DISEASE", 184, 210], ["SARS", "DISEASE", 212, 216], ["infection", "DISEASE", 224, 233], ["angiotensin", "CHEMICAL", 320, 331], ["patients", "ORGANISM", 73, 81], ["coronavirus 2", "ORGANISM", 160, 173], ["SARS-CoV-2", "ORGANISM", 212, 222], ["human", "ORGANISM", 314, 319], ["angiotensin-converting enzyme 2 receptor 3", "GENE_OR_GENE_PRODUCT", 320, 362], ["lung alveolar epithelial cells", "CELL", 415, 445], ["spike protein", "PROTEIN", 293, 306], ["human angiotensin-converting enzyme 2 receptor 3", "PROTEIN", 314, 362], ["lung alveolar epithelial cells", "CELL_TYPE", 415, 445], ["patients", "SPECIES", 73, 81], ["coronavirus", "SPECIES", 160, 171], ["human", "SPECIES", 314, 319], ["SARS-CoV", "SPECIES", 96, 104], ["severe acute respiratory syndrome (SARS-CoV-2", "SPECIES", 177, 222], ["human", "SPECIES", 314, 319], ["SARS", "TEST", 96, 100], ["CoV", "TEST", 101, 104], ["COVID", "TEST", 132, 137], ["severe acute respiratory syndrome", "PROBLEM", 177, 210], ["SARS", "PROBLEM", 212, 216], ["infection", "PROBLEM", 224, 233], ["its spike protein", "PROBLEM", 289, 306], ["the human angiotensin", "TREATMENT", 310, 331], ["enzyme 2 receptor", "TREATMENT", 343, 360], ["this virus", "PROBLEM", 479, 489], ["infected", "OBSERVATION", 82, 90], ["severe", "OBSERVATION_MODIFIER", 177, 183], ["acute", "OBSERVATION_MODIFIER", 184, 189], ["respiratory syndrome", "OBSERVATION", 190, 210], ["lung", "ANATOMY", 415, 419], ["alveolar", "ANATOMY_MODIFIER", 420, 428], ["epithelial cells", "OBSERVATION", 429, 445]]], ["As a result of a pro-inflammatory response, the SARS-CoV-2 may cause acute respiratory distress syndrome and in severe cases may result in fatal outcomes 4 .", [["respiratory", "ANATOMY", 75, 86], ["SARS", "DISEASE", 48, 52], ["respiratory distress syndrome", "DISEASE", 75, 104], ["SARS-CoV-2", "ORGANISM", 48, 58], ["SARS-CoV", "SPECIES", 48, 56], ["a pro-inflammatory response", "PROBLEM", 15, 42], ["the SARS", "TEST", 44, 52], ["acute respiratory distress syndrome", "PROBLEM", 69, 104], ["severe cases", "PROBLEM", 112, 124], ["fatal outcomes", "PROBLEM", 139, 153], ["pro-inflammatory response", "OBSERVATION", 17, 42], ["may cause", "UNCERTAINTY", 59, 68], ["acute", "OBSERVATION_MODIFIER", 69, 74], ["respiratory distress syndrome", "OBSERVATION", 75, 104], ["severe", "OBSERVATION_MODIFIER", 112, 118]]], ["SARS-CoV-2 has a high homology with coronavirus of severe acute respiratory syndrome (SARS-CoV) and like SARS-CoV its transmission mode is human-to-human.", [["SARS", "DISEASE", 0, 4], ["acute respiratory syndrome (SARS-CoV)", "DISEASE", 58, 95], ["SARS", "DISEASE", 105, 109], ["SARS-CoV-2", "ORGANISM", 0, 10], ["SARS-CoV", "ORGANISM", 86, 94], ["SARS-CoV", "ORGANISM", 105, 113], ["human", "ORGANISM", 139, 144], ["human", "ORGANISM", 148, 153], ["coronavirus", "SPECIES", 36, 47], ["human", "SPECIES", 139, 144], ["human", "SPECIES", 148, 153], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 86, 94], ["SARS-CoV", "SPECIES", 105, 113], ["human", "SPECIES", 139, 144], ["human", "SPECIES", 148, 153], ["severe acute respiratory syndrome", "PROBLEM", 51, 84], ["SARS", "PROBLEM", 86, 90], ["like SARS", "PROBLEM", 100, 109], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["acute", "OBSERVATION_MODIFIER", 58, 63], ["respiratory syndrome", "OBSERVATION", 64, 84]]], ["The number of secondary cases produced by a single infected person with SARS-CoV-2 in a susceptible population (R 0 ) has been estimated to be between two and three, which is higher than that previously reported for SARS-CoV 5, 6 .IntroductionThe fast capacity to spread of SARS-CoV-2 highlights the importance of having a sensitive and specific virus detection method.", [["SARS", "DISEASE", 72, 76], ["SARS", "DISEASE", 216, 220], ["SARS", "DISEASE", 274, 278], ["SARS-CoV-2", "ORGANISM", 72, 82], ["SARS-CoV 5", "ORGANISM", 216, 226], ["person", "SPECIES", 60, 66], ["SARS-CoV", "SPECIES", 72, 80], ["SARS-CoV", "SPECIES", 216, 224], ["SARS-CoV", "SPECIES", 274, 282], ["SARS", "PROBLEM", 72, 76], ["The fast capacity", "PROBLEM", 243, 260], ["SARS", "PROBLEM", 274, 278], ["a sensitive and specific virus detection method", "PROBLEM", 321, 368], ["higher", "OBSERVATION_MODIFIER", 175, 181]]], ["The gold standard for COVID-19 diagnosis is the molecular detection of the genome of SARS-CoV-2 in pharyngeal swab samples using a real-time reverse transcription-polymerase chain reaction (RT-PCR) assay.", [["pharyngeal swab samples", "ANATOMY", 99, 122], ["SARS", "DISEASE", 85, 89], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 85, 95], ["pharyngeal swab samples", "CANCER", 99, 122], ["SARS-CoV", "SPECIES", 85, 93], ["SARS", "PROBLEM", 85, 89], ["CoV", "TEST", 90, 93], ["pharyngeal swab samples", "TEST", 99, 122], ["polymerase chain reaction", "TEST", 163, 188], ["RT-PCR", "TEST", 190, 196], ["pharyngeal", "ANATOMY", 99, 109]]], ["The enzyme-linked immunoassay (ELISA) for specific immunoglobulin M (IgM) and G (IgG) has been suggested as an acceptable choice to reduce the false negatives rate that could occur with the RT-PCR method 7 .", [["immunoglobulin M", "GENE_OR_GENE_PRODUCT", 51, 67], ["IgM", "GENE_OR_GENE_PRODUCT", 69, 72], ["G", "GENE_OR_GENE_PRODUCT", 78, 79], ["IgG", "GENE_OR_GENE_PRODUCT", 81, 84], ["immunoglobulin M", "PROTEIN", 51, 67], ["IgM", "PROTEIN", 69, 72], ["IgG", "PROTEIN", 81, 84], ["The enzyme", "TEST", 0, 10], ["immunoassay", "TEST", 18, 29], ["ELISA", "TEST", 31, 36], ["specific immunoglobulin M", "TEST", 42, 67], ["IgM", "TEST", 69, 72], ["G (IgG", "TEST", 78, 84], ["the false negatives rate", "PROBLEM", 139, 163], ["the RT", "TEST", 186, 192], ["PCR method", "TEST", 193, 203]]], ["In addition to an accurate method of detection, a good screening strategy should allow to break the channels of viral transmission.", [["a good screening strategy", "TREATMENT", 48, 73], ["viral transmission", "OBSERVATION", 112, 130]]], ["At this point, the person-to-person contact in the spread of disease has an important role, especially when asymptomatic infected patients are involved, because the absence of symptoms may lead to them not being screened and, therefore, remain undetected.", [["patients", "ORGANISM", 130, 138], ["person", "SPECIES", 19, 25], ["patients", "SPECIES", 130, 138], ["symptoms", "PROBLEM", 176, 184]]], ["Asymptomatic individuals represent a substantial fraction of the SARS-CoV-2 infected population estimated at 17.9% 8 .", [["SARS-CoV-2 infected", "DISEASE", 65, 84], ["SARS-CoV-2", "ORGANISM", 65, 75], ["SARS-CoV", "SPECIES", 65, 73], ["Asymptomatic individuals", "PROBLEM", 0, 24], ["the SARS", "PROBLEM", 61, 69], ["CoV", "TEST", 70, 73], ["substantial", "OBSERVATION_MODIFIER", 37, 48], ["fraction", "OBSERVATION_MODIFIER", 49, 57], ["SARS", "OBSERVATION", 65, 69], ["infected", "OBSERVATION_MODIFIER", 76, 84]]], ["In a recent study Hu et al (2020), evaluated twenty-four asymptomatic COVID-19 infections from the screening of close contacts of COVID-19 patients in China.", [["infections", "DISEASE", 79, 89], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["19 infections", "PROBLEM", 76, 89], ["the screening", "TEST", 95, 108]]], ["Nineteen patients remained asymptomatic during hospitalization and the median communicable period (defined as the interval from the first day of positive nucleic acid tests to the first day of continuous negative tests), was 9.5 days (up to 21 days among the twenty-four asymptomatic cases).", [["nucleic acid", "CHEMICAL", 154, 166], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["asymptomatic", "PROBLEM", 27, 39], ["positive nucleic acid tests", "PROBLEM", 145, 172], ["asymptomatic", "OBSERVATION", 27, 39]]], ["These results suggest that infected asymptomatic close contacts, could become an important cause of virus transmission and, therefore, a strict monitoring of close contacts via multiple screening should be prioritized 7 .IntroductionMexico is in phase three of the COVID-19 pandemic and since the first reported case (February 28, 2020), the Mexican government increased measures to contain the spread of the virus.", [["infected asymptomatic close contacts", "PROBLEM", 27, 63], ["virus transmission", "PROBLEM", 100, 118], ["a strict monitoring", "TEST", 135, 154], ["multiple screening", "TEST", 177, 195], ["the virus", "PROBLEM", 405, 414], ["infected", "OBSERVATION_MODIFIER", 27, 35], ["virus", "OBSERVATION", 100, 105]]], ["These measures have included social distancing, closing schools, the obligatory use of mouth masks, and canceling massive events, among others 9, 10 .", [["mouth", "ANATOMY", 87, 92], ["mouth", "ORGANISM_SUBDIVISION", 87, 92], ["mouth masks", "TREATMENT", 87, 98], ["massive events", "PROBLEM", 114, 128]]], ["However, the SARS-CoV-2 screening tests in Mexico (until August 24, 2020), have been focused on people who met the operational criteria established by the Mexican Health Authority's consensus.", [["people", "ORGANISM", 96, 102], ["people", "SPECIES", 96, 102], ["the SARS", "TEST", 9, 17], ["screening tests", "TEST", 24, 39]]], ["These criteria included meeting two out of three of the following symptoms: fever \u226538\u00b0C, dry cough and/or headache, in addition to other COVID-19 related symptoms and the presence of a comorbidity 11, 12 .", [["fever", "DISEASE", 76, 81], ["dry cough", "DISEASE", 89, 98], ["headache", "DISEASE", 106, 114], ["fever", "PROBLEM", 76, 81], ["C", "PROBLEM", 86, 87], ["dry cough", "PROBLEM", 89, 98], ["headache", "PROBLEM", 106, 114], ["other COVID-19 related symptoms", "PROBLEM", 131, 162], ["a comorbidity", "PROBLEM", 183, 196]]], ["Considering the World Health Organization (WHO) recommendations regarding the need to increase the number of SARS-CoV-2 tests and the isolation and tracing of contacts, here, we conducted an investigation to evaluate the percentage of positive COVID-19 patients without diagnosis in Mexico because the total or partial absence of symptomatology in close contacts of COVID-19 patients 13 .IntroductionWe sought to depict the importance of asymptomatic infections in the patient-to-patient transmission of COVID-19 and the relevance of tracing and testing close contacts to contain potential outbreaks.Patients and study definitionsThe ethics committees of the Academic Unit of Human Medicine and Health Sciences from Universidad Autonoma de Zacatecas and the Alpha Medical Center approved this cross-sectional study carried out in Zacatecas, Mexico from June-July 2020 (Approval ID: AMCCI-FSARSC2-006 and 007).", [["SARS", "DISEASE", 109, 113], ["infections", "DISEASE", 451, 461], ["patients", "ORGANISM", 253, 261], ["patients", "ORGANISM", 375, 383], ["patient", "ORGANISM", 469, 476], ["patient", "ORGANISM", 480, 487], ["Patients", "ORGANISM", 600, 608], ["Human", "ORGANISM", 676, 681], ["patients", "SPECIES", 253, 261], ["patients", "SPECIES", 375, 383], ["patient", "SPECIES", 469, 476], ["patient", "SPECIES", 480, 487], ["Patients", "SPECIES", 600, 608], ["Human", "SPECIES", 676, 681], ["SARS-CoV", "SPECIES", 109, 117], ["CoV-2 tests", "TEST", 114, 125], ["the isolation", "TEST", 130, 143], ["an investigation", "TEST", 188, 204], ["symptomatology", "PROBLEM", 330, 344], ["COVID", "TEST", 366, 371], ["asymptomatic infections", "PROBLEM", 438, 461], ["COVID", "TEST", 504, 509], ["tracing and testing", "TEST", 534, 553], ["study definitions", "TEST", 613, 630], ["Human Medicine", "TREATMENT", 676, 690], ["this cross-sectional study", "TEST", 788, 814], ["asymptomatic", "OBSERVATION_MODIFIER", 438, 450], ["infections", "OBSERVATION", 451, 461]]], ["We retrospectively reviewed documents on epidemiological investigations of nineteen patients with laboratory test confirmation for COVID-19.Patients and study definitionsUsing patients' epidemiological records, we traced eighty-one close contacts for medical evaluation and sampling.", [["patients", "ORGANISM", 84, 92], ["Patients", "ORGANISM", 140, 148], ["patients", "ORGANISM", 176, 184], ["patients", "SPECIES", 84, 92], ["Patients", "SPECIES", 140, 148], ["patients", "SPECIES", 176, 184], ["epidemiological investigations", "TEST", 41, 71], ["laboratory test confirmation", "TEST", 98, 126], ["COVID", "TEST", 131, 136], ["study definitions", "TEST", 153, 170], ["medical evaluation", "TEST", 251, 269], ["sampling", "TEST", 274, 282]]], ["Indicated patients and their contacts (aged >18 years old) were contacted by telephone and invited to participate in the study.", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["the study", "TEST", 117, 126]]], ["The patient recruitment was carried out in the Centro de Salud \"Francisco Villa\" from Secretar\u00eda de Salud de Zacatecas and in the Molecular Medicine Laboratory from the Academic Unit of Human Medicine and Health Sciences from Universidad Aut\u00f3noma de Zacatecas.Patients and study definitionsA questionnaire consisting of demographic and clinical data and signs and symptoms related to COVID-19 was administered to the participants.", [["patient", "ORGANISM", 4, 11], ["Human", "ORGANISM", 186, 191], ["Patients", "ORGANISM", 260, 268], ["patient", "SPECIES", 4, 11], ["Human", "SPECIES", 186, 191], ["Patients", "SPECIES", 260, 268], ["participants", "SPECIES", 417, 429], ["Human Medicine", "TREATMENT", 186, 200], ["clinical data", "TEST", 336, 349], ["signs and symptoms", "PROBLEM", 354, 372], ["COVID", "TEST", 384, 389]]], ["There were no exclusion criteria for this study.", [["this study", "TEST", 37, 47], ["no exclusion", "UNCERTAINTY", 11, 23]]], ["A close contact was defined as an individual who has had closer than <6 feet for \u226515 min with people with a positive diagnosis for COVID-19, whether they were symptomatic or asymptomatic according to the Center for Disease Control and Prevention (CDC) definition 14 .Patients and study definitionsThroughout the protocol, the operational definition of suspicious case of COVID-19 was defined according to the Mexican Health Guidelines (august 24, 2020) as follows: a patient who met two out of three of the following symptoms: a fever \u2265 38\u00b0C, dry cough and/or headache, and have at least one other COVID-19 related symptoms (asthenia, odynophagia, myalgia, arthralgia, rhinorrhea, conjunctivitis, anosmia, dysgeusia, nausea, abdominal pain, and diarrhea) and underlying risk conditions (pregnancy, immunosuppression, previous lung disease, diabetes mellitus, systemic arterial hypertension, adults > 65 years old, or obesity) 11, 12 .Biological samples and SARS-CoV-2 screeningNasopharyngeal and oropharyngeal swab samples were obtained from each participant before beingData analysisGeneral characteristics of the study population were represented as the mean \u00b1 standard deviation (SD) and percentages.", [["abdominal", "ANATOMY", 725, 734], ["lung", "ANATOMY", 826, 830], ["arterial", "ANATOMY", 868, 876], ["samples", "ANATOMY", 945, 952], ["Nasopharyngeal", "ANATOMY", 977, 991], ["oropharyngeal swab samples", "ANATOMY", 996, 1022], ["fever", "DISEASE", 529, 534], ["38\u00b0C", "DISEASE", 537, 541], ["dry cough", "DISEASE", 543, 552], ["headache", "DISEASE", 560, 568], ["asthenia", "DISEASE", 625, 633], ["odynophagia", "DISEASE", 635, 646], ["myalgia", "DISEASE", 648, 655], ["arthralgia", "DISEASE", 657, 667], ["rhinorrhea", "DISEASE", 669, 679], ["conjunctivitis", "DISEASE", 681, 695], ["anosmia", "DISEASE", 697, 704], ["dysgeusia", "DISEASE", 706, 715], ["nausea", "DISEASE", 717, 723], ["abdominal pain", "DISEASE", 725, 739], ["diarrhea", "DISEASE", 745, 753], ["lung disease", "DISEASE", 826, 838], ["diabetes mellitus", "DISEASE", 840, 857], ["systemic arterial hypertension", "DISEASE", 859, 889], ["obesity", "DISEASE", 917, 924], ["people", "ORGANISM", 94, 100], ["Patients", "ORGANISM", 267, 275], ["patient", "ORGANISM", 467, 474], ["abdominal", "ORGANISM_SUBDIVISION", 725, 734], ["lung", "ORGAN", 826, 830], ["arterial", "MULTI-TISSUE_STRUCTURE", 868, 876], ["Nasopharyngeal", "CANCER", 977, 991], ["oropharyngeal swab samples", "CANCER", 996, 1022], ["people", "SPECIES", 94, 100], ["Patients", "SPECIES", 267, 275], ["patient", "SPECIES", 467, 474], ["participant", "SPECIES", 1047, 1058], ["SARS-CoV", "SPECIES", 957, 965], ["COVID", "TEST", 131, 136], ["symptomatic", "PROBLEM", 159, 170], ["asymptomatic", "PROBLEM", 174, 186], ["Disease Control", "TREATMENT", 215, 230], ["study definitions", "TEST", 280, 297], ["COVID", "TEST", 371, 376], ["a fever", "PROBLEM", 527, 534], ["dry cough", "PROBLEM", 543, 552], ["headache", "PROBLEM", 560, 568], ["related symptoms", "PROBLEM", 607, 623], ["asthenia", "PROBLEM", 625, 633], ["odynophagia", "PROBLEM", 635, 646], ["myalgia", "PROBLEM", 648, 655], ["arthralgia", "PROBLEM", 657, 667], ["rhinorrhea", "PROBLEM", 669, 679], ["conjunctivitis", "PROBLEM", 681, 695], ["anosmia", "PROBLEM", 697, 704], ["dysgeusia", "PROBLEM", 706, 715], ["nausea", "PROBLEM", 717, 723], ["abdominal pain", "PROBLEM", 725, 739], ["diarrhea", "PROBLEM", 745, 753], ["underlying risk conditions (pregnancy", "PROBLEM", 759, 796], ["immunosuppression", "TREATMENT", 798, 815], ["previous lung disease", "PROBLEM", 817, 838], ["diabetes mellitus", "PROBLEM", 840, 857], ["systemic arterial hypertension", "PROBLEM", 859, 889], ["obesity)", "PROBLEM", 917, 925], ["Biological samples", "TEST", 934, 952], ["SARS", "TEST", 957, 961], ["CoV", "TEST", 962, 965], ["2 screening", "TEST", 966, 977], ["Nasopharyngeal and oropharyngeal swab samples", "TEST", 977, 1022], ["Data analysis", "TEST", 1071, 1084], ["the study population", "TEST", 1111, 1131], ["conjunctivitis", "OBSERVATION", 681, 695], ["abdominal", "ANATOMY", 725, 734], ["diarrhea", "OBSERVATION", 745, 753], ["lung", "ANATOMY", 826, 830], ["disease", "OBSERVATION", 831, 838], ["arterial", "ANATOMY", 868, 876], ["hypertension", "OBSERVATION", 877, 889], ["Nasopharyngeal", "ANATOMY", 977, 991], ["oropharyngeal", "ANATOMY", 996, 1009]]], ["Comparisons of the risk factors and the clinical findings among the groups were performed using a Chi-squared or Fisher's exact test for categorical variables and a t-test or Mann-Whitney U test for continuous variables.", [["Fisher's exact test", "TEST", 113, 132], ["categorical variables", "TEST", 137, 158], ["a t-test", "TEST", 163, 171], ["Whitney U test", "TEST", 180, 194]]], ["The odds ratios (OR) with Yates continuity correction were calculated for significant comparisons.", [["The odds ratios", "TEST", 0, 15]]], ["Statistical analysis was carried out with the SigmaPlot v12.0 (Systat Software Inc., San Jose, CA, USA) software and a significance level of p <0.05 was considered significant.ResultsOne hundred patients were included in the study.", [["patients", "ORGANISM", 195, 203], ["patients", "SPECIES", 195, 203], ["Statistical analysis", "TEST", 0, 20], ["the SigmaPlot v", "TEST", 42, 57], ["the study", "TEST", 221, 230]]], ["Forty-seven were women.ResultsAmong the close contacts, 20.9% were nurses, 18.5% teachers, and 18.5% were students ( Table 1) .", [["women", "ORGANISM", 17, 22], ["women", "SPECIES", 17, 22]]], ["The most frequent comorbidity among the index patients was type 2 diabetes mellitus (T2DM) with two cases (10.5%), while arterial hypertension, dyslipidemia, and thyroid disease were present in only one indicated patient, respectively (5.2% each).", [["arterial", "ANATOMY", 121, 129], ["thyroid", "ANATOMY", 162, 169], ["type 2 diabetes mellitus", "DISEASE", 59, 83], ["T2DM", "DISEASE", 85, 89], ["arterial hypertension", "DISEASE", 121, 142], ["dyslipidemia", "DISEASE", 144, 156], ["thyroid disease", "DISEASE", 162, 177], ["patients", "ORGANISM", 46, 54], ["arterial", "MULTI-TISSUE_STRUCTURE", 121, 129], ["thyroid", "ORGAN", 162, 169], ["patient", "ORGANISM", 213, 220], ["patients", "SPECIES", 46, 54], ["patient", "SPECIES", 213, 220], ["The most frequent comorbidity", "PROBLEM", 0, 29], ["type 2 diabetes mellitus", "PROBLEM", 59, 83], ["T2DM", "PROBLEM", 85, 89], ["arterial hypertension", "PROBLEM", 121, 142], ["dyslipidemia", "PROBLEM", 144, 156], ["thyroid disease", "PROBLEM", 162, 177], ["arterial", "ANATOMY", 121, 129], ["hypertension", "OBSERVATION", 130, 142], ["dyslipidemia", "OBSERVATION", 144, 156], ["thyroid", "ANATOMY", 162, 169], ["disease", "OBSERVATION", 170, 177]]], ["Otherwise, the most frequent comorbidities amid the close contacts group were arterial hypertension with eight cases (9.8%), thyroid disease with six cases (7.4%), and T2DM with four cases (4.9%).", [["arterial", "ANATOMY", 78, 86], ["thyroid", "ANATOMY", 125, 132], ["arterial hypertension", "DISEASE", 78, 99], ["thyroid disease", "DISEASE", 125, 140], ["T2DM", "DISEASE", 168, 172], ["arterial", "MULTI-TISSUE_STRUCTURE", 78, 86], ["thyroid", "ORGAN", 125, 132], ["arterial hypertension", "PROBLEM", 78, 99], ["eight cases", "TEST", 105, 116], ["thyroid disease", "PROBLEM", 125, 140], ["six cases", "TEST", 146, 155], ["T2DM", "PROBLEM", 168, 172], ["arterial", "ANATOMY", 78, 86], ["hypertension", "OBSERVATION", 87, 99], ["thyroid", "ANATOMY", 125, 132]]], ["Considering both index patients and close contacts, four (21%) index patients and thirty-three (40.7%) close contacts usually smoked and five (26.3%) index cases and thirtysix (44.4%) close contacts affirmed alcohol consumption ( Table 2 ).", [["alcohol", "CHEMICAL", 208, 215], ["alcohol", "CHEMICAL", 208, 215], ["patients", "ORGANISM", 23, 31], ["patients", "ORGANISM", 69, 77], ["alcohol", "SIMPLE_CHEMICAL", 208, 215], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 69, 77], ["thirtysix", "TEST", 166, 175], ["index", "OBSERVATION_MODIFIER", 17, 22]]], ["There was no statistical significance between the general characteristics or risk factors for COVID-19 between the groups of index cases and close contacts (p > 0.05).SARS-CoV-2 screening testThe mean time of the index COVID-19 patients' diagnosis after onset of symptoms was 2.7 \u00b1 1.9 days.", [["patients", "ORGANISM", 228, 236], ["patients", "SPECIES", 228, 236], ["COVID", "TEST", 94, 99], ["screening test", "TEST", 178, 192], ["the index COVID", "TEST", 209, 224], ["symptoms", "PROBLEM", 263, 271], ["no", "UNCERTAINTY", 10, 12]]], ["Table 3 show a summary of the results of index COVID-19 cases and their contacts.SARS-CoV-2 IgM and IgG detectionOnly 67.1% of the study population had more than 2 weeks after their contact with a COVID-19 case.SARS-CoV-2 IgM and IgG detectionFrom the one hundred participants, eighty-seven of them had rapid test results available.", [["SARS-CoV-2 IgM", "GENE_OR_GENE_PRODUCT", 81, 95], ["IgG", "GENE_OR_GENE_PRODUCT", 100, 103], ["SARS-CoV-2 IgM", "GENE_OR_GENE_PRODUCT", 211, 225], ["IgG", "GENE_OR_GENE_PRODUCT", 230, 233], ["IgM", "PROTEIN", 92, 95], ["IgG", "PROTEIN", 100, 103], ["IgM", "PROTEIN", 222, 225], ["IgG", "PROTEIN", 230, 233], ["participants", "SPECIES", 264, 276], ["index COVID", "TEST", 41, 52], ["SARS", "TEST", 81, 85], ["CoV", "TEST", 86, 89], ["IgM", "TEST", 92, 95], ["IgG detectionOnly", "TEST", 100, 117], ["the study population", "TEST", 127, 147], ["SARS", "TEST", 211, 215], ["CoV", "TEST", 216, 219], ["rapid test results", "TEST", 303, 321]]], ["Regarding the close contacts of COVID-19 cases, thirteen (16%) showed positive results for IgM and/or IgG (23.1% for IgM, 7.7%, for IgG and 69.2% for IgG/IgM).SARS-CoV-2 IgM and IgG detectionC-S100 2 (2.5) 0 2 0 2 C-S110 3 (3.7) 0 3 0 3 C-S120 9 (11.1) 0 9 0 6 C-S130 4 (4.9) 0 4 0 4 C-S140 5 (6.2) 0 5 0 5 C-S150 5 (6.2) 2 3 4 1 C-S160 1 (1.2) 1 0 ND ND C-S170 2 (2.5) 0 2 ND ND C-S180 4 (4.9) 2 2 2 2 C-S190 3 (3.7) 3 0 3 0 \u2020 One contact linked to patient C-S110 was excluded because of insufficient data. \u2021 Three close contacts did not have an antibody count because of an insufficient sample.", [["IgM", "GENE_OR_GENE_PRODUCT", 91, 94], ["IgG", "GENE_OR_GENE_PRODUCT", 102, 105], ["IgM", "GENE_OR_GENE_PRODUCT", 117, 120], ["IgG", "GENE_OR_GENE_PRODUCT", 132, 135], ["IgG", "GENE_OR_GENE_PRODUCT", 150, 153], ["IgM", "GENE_OR_GENE_PRODUCT", 154, 157], ["SARS-CoV-2 IgM", "GENE_OR_GENE_PRODUCT", 159, 173], ["patient", "ORGANISM", 450, 457], ["C-S110", "CANCER", 458, 464], ["IgM", "PROTEIN", 91, 94], ["IgG", "PROTEIN", 102, 105], ["IgM", "PROTEIN", 117, 120], ["IgG", "PROTEIN", 132, 135], ["IgG", "PROTEIN", 150, 153], ["IgM", "PROTEIN", 154, 157], ["IgM", "PROTEIN", 170, 173], ["IgG", "PROTEIN", 178, 181], ["C-S110", "DNA", 458, 464], ["patient", "SPECIES", 450, 457], ["COVID", "TEST", 32, 37], ["IgM", "TEST", 91, 94], ["IgG", "TEST", 102, 105], ["IgM", "TEST", 117, 120], ["IgG", "TEST", 132, 135], ["IgG", "TEST", 150, 153], ["IgM", "TEST", 154, 157], ["SARS", "TEST", 159, 163], ["CoV", "TEST", 164, 167], ["IgM", "TEST", 170, 173], ["IgG detectionC", "TEST", 178, 192], ["C-S110", "TEST", 214, 220], ["C", "TEST", 237, 238], ["C", "TEST", 261, 262], ["S130", "TEST", 263, 267], ["C", "TEST", 284, 285], ["S140", "TEST", 286, 290], ["C", "TEST", 307, 308], ["S150", "TEST", 309, 313], ["C", "TEST", 330, 331], ["S160", "TEST", 332, 336], ["ND ND C", "TEST", 349, 356], ["S170", "TEST", 357, 361], ["ND ND C", "TEST", 374, 381], ["S180", "TEST", 382, 386], ["C", "TEST", 403, 404], ["S190", "TEST", 405, 409], ["patient C", "TEST", 450, 459], ["an antibody count", "TEST", 544, 561], ["an insufficient sample", "PROBLEM", 573, 595]]], ["They were associated with index COVID-19 patients C-S160 and C-S170.", [["patients", "ORGANISM", 41, 49], ["C-S170", "GENE_OR_GENE_PRODUCT", 61, 67], ["COVID-19 patients C-S160 and C-S170", "DNA", 32, 67], ["patients", "SPECIES", 41, 49], ["index COVID", "TEST", 26, 37], ["patients C", "TEST", 41, 51], ["C", "TEST", 61, 62]]], ["ND: no data.", [["no", "UNCERTAINTY", 4, 6]]], ["Table 2 There were twenty-nine symptomatic patients identified in the study and 24.1% had antibodies against SARS-CoV-2 (10.3% showed IgM, 3.4% IgG, and 17.2 % both IgG and IgM).", [["patients", "ORGANISM", 43, 51], ["SARS-CoV-2", "ORGANISM", 109, 119], ["IgM", "GENE_OR_GENE_PRODUCT", 134, 137], ["IgG", "GENE_OR_GENE_PRODUCT", 144, 147], ["IgG", "GENE_OR_GENE_PRODUCT", 165, 168], ["IgM", "GENE_OR_GENE_PRODUCT", 173, 176], ["antibodies", "PROTEIN", 90, 100], ["IgM", "PROTEIN", 134, 137], ["IgG", "PROTEIN", 144, 147], ["IgG", "PROTEIN", 165, 168], ["IgM", "PROTEIN", 173, 176], ["patients", "SPECIES", 43, 51], ["SARS-CoV", "SPECIES", 109, 117], ["the study", "TEST", 66, 75], ["antibodies", "TEST", 90, 100], ["SARS", "TEST", 109, 113], ["CoV", "TEST", 114, 117], ["IgM", "TEST", 134, 137], ["IgG", "TEST", 144, 147], ["IgG", "TEST", 165, 168], ["IgM", "TEST", 173, 176]]], ["From the five asymptomatic COVID-19 contacts, only two showed IgG/IgM antibodies ( Figure 1 ).DiscussionIn this study, we evaluated laboratory, clinical, and epidemiological information of one hundred subjects, 5, 15 .", [["IgG", "GENE_OR_GENE_PRODUCT", 62, 65], ["IgG", "PROTEIN", 62, 65], ["IgM antibodies", "PROTEIN", 66, 80], ["IgG/IgM antibodies", "TEST", 62, 80], ["this study", "TEST", 107, 117], ["IgM antibodies", "OBSERVATION", 66, 80]]], ["An example of this observation is the study reported by Hong-Jun Zhang et al. 19 .", [["Jun", "PROTEIN", 61, 64], ["this observation", "TEST", 14, 30], ["the study", "TEST", 34, 43]]], ["In their study, the authors evaluated two hundred eighty-four close contacts from asymptomatic COVID-19 patients and identified only 2.7% of the close contacts as positive for SARS-CoV-2 20 .", [["SARS", "DISEASE", 176, 180], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["their study", "TEST", 3, 14], ["SARS", "TEST", 176, 180], ["CoV", "TEST", 181, 184]]], ["Therefore, as the low percentage of asymptomatic close contacts were positive for COVID-19, the probability of infectivity from asymptomatic SARS-CoV-2 might be weak 15 .", [["SARS", "DISEASE", 141, 145], ["COVID", "TEST", 82, 87], ["infectivity", "PROBLEM", 111, 122], ["asymptomatic SARS", "PROBLEM", 128, 145], ["CoV", "TEST", 146, 149]]], ["However, even if the percentage of asymptomatic COVID-19 close contacts in our study was lower than the 17.9% reported on the \"Diamond Princess\" cruise, the non-evaluated SARS-CoV-2 asymptomatic patients may contribute to the rapid transmission and spread of the disease as the median duration of viral shedding is approximately 19 days, significantly longer than the 14 days in symptomatic patients 20 .DiscussionAn important finding in our study was that the most common symptoms observed (headache, myalgia, odynophagia, cough, and rhinorrhea) in the contacts group were mostly presented without fever, contrary to other related studies in which fever is considered as a common symptom 5, 7, 20, 21 .", [["SARS", "DISEASE", 171, 175], ["headache", "DISEASE", 492, 500], ["myalgia", "DISEASE", 502, 509], ["odynophagia", "DISEASE", 511, 522], ["cough", "DISEASE", 524, 529], ["rhinorrhea", "DISEASE", 535, 545], ["fever", "DISEASE", 599, 604], ["fever", "DISEASE", 649, 654], ["SARS-CoV-2", "ORGANISM", 171, 181], ["patients", "ORGANISM", 195, 203], ["patients", "ORGANISM", 391, 399], ["patients", "SPECIES", 195, 203], ["patients", "SPECIES", 391, 399], ["asymptomatic COVID", "PROBLEM", 35, 53], ["our study", "TEST", 75, 84], ["the non-evaluated SARS", "TEST", 153, 175], ["the rapid transmission", "PROBLEM", 222, 244], ["the disease", "PROBLEM", 259, 270], ["viral shedding", "PROBLEM", 297, 311], ["our study", "TEST", 438, 447], ["the most common symptoms", "PROBLEM", 457, 481], ["headache", "PROBLEM", 492, 500], ["myalgia", "PROBLEM", 502, 509], ["odynophagia", "PROBLEM", 511, 522], ["cough", "PROBLEM", 524, 529], ["rhinorrhea", "PROBLEM", 535, 545], ["fever", "PROBLEM", 599, 604], ["other related studies", "TEST", 618, 639], ["fever", "PROBLEM", 649, 654]]], ["Moreover, there was not a statistical difference in the presence of fever between the groups of contacts with or without SARS-CoV-2 infection (p = 0.078).", [["fever", "DISEASE", 68, 73], ["SARS", "DISEASE", 121, 125], ["infection", "DISEASE", 132, 141], ["fever", "PROBLEM", 68, 73], ["SARS", "PROBLEM", 121, 125], ["CoV-2 infection", "PROBLEM", 126, 141], ["fever", "OBSERVATION", 68, 73]]], ["It is important to note in our study that anosmia, conjunctivitis, chest pain, and irritability were symptoms exclusively presented by COVID-19 positive contacts (p < 0.05) but in the Mexican operational criteria they are grouped as the secondary symptoms group 11 .", [["chest", "ANATOMY", 67, 72], ["anosmia", "DISEASE", 42, 49], ["conjunctivitis", "DISEASE", 51, 65], ["chest pain", "DISEASE", 67, 77], ["irritability", "DISEASE", 83, 95], ["chest", "ORGANISM_SUBDIVISION", 67, 72], ["our study", "TEST", 27, 36], ["anosmia", "PROBLEM", 42, 49], ["conjunctivitis", "PROBLEM", 51, 65], ["chest pain", "PROBLEM", 67, 77], ["irritability", "PROBLEM", 83, 95], ["symptoms", "PROBLEM", 101, 109], ["COVID", "TEST", 135, 140], ["conjunctivitis", "OBSERVATION", 51, 65], ["chest", "ANATOMY", 67, 72]]], ["Considering our results and because the importance of these symptoms has been widely recognized, they should be considered as an essential criterion for the indication of SARS-CoV-2 testing by molecular diagnosis 22 .DiscussionHealth workers constituted an important proportion in our study as they formed 32% of the total sample and from these, two COVID-19 indicated patients had the most SARS-CoV-2 positive close contacts.DiscussionThis proportion was in agreement with the results of another study in which 25.3% of their close contacts were health care contacts 23 .", [["SARS", "DISEASE", 171, 175], ["SARS", "DISEASE", 391, 395], ["patients", "ORGANISM", 369, 377], ["patients", "SPECIES", 369, 377], ["these symptoms", "PROBLEM", 54, 68], ["SARS", "PROBLEM", 171, 175], ["CoV-2 testing", "TEST", 176, 189], ["our study", "TEST", 281, 290], ["two COVID", "TEST", 346, 355], ["another study", "TEST", 489, 502]]], ["Regarding only the close contacts with COVID-19, meet the Mexican operational definition for a COVID-19 suspected case did not significantly affect the rate of having a positive test for SARS-CoV-2 among the studied population, (OR: 3.1; 95% CI: 0.73 -13.6; p = 0.156).DiscussionAs only five (14.7%) of our COVID-19 positive contacts met the operational criteria, the importance of close vigilance and screening of contacts of COVID-19 confirmed patients, even if they do not meet with that definition should be an essential measure to avoid the disease spreading. it is important to emphasize that the sample size in this study was small and therefore variations in the proportions could be found if our results are compared with large-scale investigations.", [["SARS", "DISEASE", 187, 191], ["patients", "ORGANISM", 446, 454], ["patients", "SPECIES", 446, 454], ["SARS-CoV", "SPECIES", 187, 195], ["a COVID", "TEST", 93, 100], ["a positive test", "PROBLEM", 167, 182], ["SARS", "PROBLEM", 187, 191], ["CoV", "TEST", 192, 195], ["CI", "TEST", 242, 244], ["p", "TEST", 258, 259], ["our COVID", "TEST", 303, 312], ["COVID", "TEST", 427, 432], ["the disease spreading", "PROBLEM", 542, 563], ["the sample size", "TEST", 599, 614], ["this study", "TEST", 618, 628], ["large-scale investigations", "TEST", 731, 757], ["disease", "OBSERVATION", 546, 553], ["size", "OBSERVATION_MODIFIER", 610, 614], ["small", "OBSERVATION_MODIFIER", 633, 638]]], ["On the same sense, because the most of the participants had no severe COVID-19-related symptoms is important to identify the COVID-19 population in which the serology test will be useful and if the rapid test should be used to reduce the false negatives rate that could occur with the RT-PCR method and/or as an evolution follow-up factor of disease.ConclusionThere was a high proportion (42%) of close contacts of COVID-19 patients infected with SARS-CoV-2 and with less than two respiratory symptoms (67.6%).", [["respiratory", "ANATOMY", 481, 492], ["COVID", "DISEASE", 70, 75], ["SARS", "DISEASE", 447, 451], ["respiratory symptoms", "DISEASE", 481, 501], ["participants", "ORGANISM", 43, 55], ["patients", "ORGANISM", 424, 432], ["SARS-CoV-2", "ORGANISM", 447, 457], ["participants", "SPECIES", 43, 55], ["patients", "SPECIES", 424, 432], ["SARS-CoV", "SPECIES", 447, 455], ["severe COVID-19-related symptoms", "PROBLEM", 63, 95], ["the COVID", "TEST", 121, 130], ["the serology test", "TEST", 154, 171], ["the rapid test", "TEST", 194, 208], ["the false negatives rate", "PROBLEM", 234, 258], ["the RT-PCR method", "TEST", 281, 298], ["disease", "PROBLEM", 342, 349], ["COVID", "TEST", 415, 420], ["SARS-CoV", "TEST", 447, 455], ["two respiratory symptoms", "PROBLEM", 477, 501], ["high", "OBSERVATION_MODIFIER", 372, 376]]], ["There were notable differences in the presence of anosmia, conjunctivitis, chest pain, and irritability symptoms between close contacts of COVID-19 patients, with and without SARS-CoV-2 infection.", [["chest", "ANATOMY", 75, 80], ["anosmia", "DISEASE", 50, 57], ["conjunctivitis", "DISEASE", 59, 73], ["chest pain", "DISEASE", 75, 85], ["irritability", "DISEASE", 91, 103], ["SARS-CoV-2 infection", "DISEASE", 175, 195], ["chest", "ORGANISM_SUBDIVISION", 75, 80], ["patients", "ORGANISM", 148, 156], ["SARS-CoV-2", "ORGANISM", 175, 185], ["patients", "SPECIES", 148, 156], ["SARS-CoV-2", "SPECIES", 175, 185], ["anosmia", "PROBLEM", 50, 57], ["conjunctivitis", "PROBLEM", 59, 73], ["chest pain", "PROBLEM", 75, 85], ["irritability symptoms", "PROBLEM", 91, 112], ["SARS", "PROBLEM", 175, 179], ["CoV-2 infection", "PROBLEM", 180, 195], ["conjunctivitis", "OBSERVATION", 59, 73], ["chest", "ANATOMY", 75, 80], ["infection", "OBSERVATION", 186, 195]]], ["The average of SARS-CoV-2 infected close contacts by index COVID-19 case was 4.3 among the studied population, with the mean of time of positive test for SARS-CoV-2 being calculated as 18.9 days.", [["SARS", "DISEASE", 15, 19], ["SARS", "DISEASE", 154, 158], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 15, 25], ["SARS-CoV", "SPECIES", 15, 23], ["SARS-CoV", "SPECIES", 154, 162], ["SARS", "TEST", 15, 19], ["SARS", "TEST", 154, 158], ["CoV", "TEST", 159, 162]]], ["The screening for SARS-CoV-2 by RT-PCR in close contacts of positive COVID-19 patients should be encouraged to avoid a source of spreading the infection and expanding of the disease.", [["infection", "DISEASE", 143, 152], ["SARS-CoV-2", "ORGANISM", 18, 28], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["SARS-CoV", "SPECIES", 18, 26], ["The screening", "TEST", 0, 13], ["SARS", "TEST", 18, 22], ["CoV", "TEST", 23, 26], ["RT", "TEST", 32, 34], ["PCR", "TEST", 35, 38], ["positive COVID", "TREATMENT", 60, 74], ["spreading the infection", "PROBLEM", 129, 152], ["the disease", "PROBLEM", 170, 181], ["infection", "OBSERVATION", 143, 152], ["disease", "OBSERVATION", 174, 181]]]], "698ac94f38d2384c7fa63ef3b0439cf563aa4b97": [["A few weeks after the first Italian case of person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (Sars-CoV-2) 1 , Italian government promulgated a Decree-Law imposing a general lockdown, aimed at reducing the spread of coronavirus disease of 2019 .", [["acute respiratory syndrome coronavirus", "DISEASE", 84, 122], ["coronavirus disease", "DISEASE", 247, 266], ["coronavirus", "ORGANISM", 247, 258], ["person", "SPECIES", 44, 50], ["person", "SPECIES", 54, 60], ["severe acute respiratory syndrome coronavirus", "SPECIES", 77, 122], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 77, 122], ["coronavirus disease", "PROBLEM", 247, 266], ["severe", "OBSERVATION_MODIFIER", 77, 83], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["respiratory syndrome", "OBSERVATION", 90, 110]]], ["Among restrictions affecting healthcare system, outpatient clinics and day-services have been suspended, and in-ward access has been granted only for urgent procedures.", [["urgent procedures", "TREATMENT", 150, 167]]], ["If on the one hand this reduced the risk of in-hospital COVID-19 spread, on the other hand led to marked decrease in the clinic assistance of chronic diseases -i.e. heart failure (HF).", [["heart", "ANATOMY", 165, 170], ["chronic diseases", "DISEASE", 142, 158], ["heart failure", "DISEASE", 165, 178], ["HF", "DISEASE", 180, 182], ["heart", "ORGAN", 165, 170], ["chronic diseases", "PROBLEM", 142, 158], ["heart failure", "PROBLEM", 165, 178], ["HF", "PROBLEM", 180, 182], ["marked", "OBSERVATION_MODIFIER", 98, 104], ["decrease", "OBSERVATION_MODIFIER", 105, 113], ["chronic", "OBSERVATION_MODIFIER", 142, 149], ["diseases", "OBSERVATION", 150, 158], ["heart", "ANATOMY", 165, 170], ["failure", "OBSERVATION", 171, 178]]]], "PMC6267967": [["IntroductionSporotrichosis is a mycosis affecting humans and animals globally, caused by different members of the Sporothrix schenckii species complex, including S. brasiliensis, S. schenckii sensu stricto (s. str.), S. globosa, and S. luriei [1].", [["IntroductionSporotrichosis", "DISEASE", 0, 26], ["mycosis", "DISEASE", 32, 39], ["humans", "ORGANISM", 50, 56], ["Sporothrix schenckii species", "ORGANISM", 114, 142], ["S. brasiliensis", "ORGANISM", 162, 177], ["S. schenckii sensu stricto", "ORGANISM", 179, 205], ["s. str.", "ORGANISM", 207, 214], [")", "ORGANISM", 214, 215], ["S. globosa", "ORGANISM", 217, 227], ["S. luriei", "ORGANISM", 233, 242], ["humans", "SPECIES", 50, 56], ["Sporothrix schenckii", "SPECIES", 114, 134], ["S. brasiliensis", "SPECIES", 162, 177], ["S. schenckii", "SPECIES", 179, 191], ["sensu stricto", "SPECIES", 192, 205], ["S. globosa", "SPECIES", 217, 227], ["S. luriei", "SPECIES", 233, 242], ["humans", "SPECIES", 50, 56], ["Sporothrix schenckii", "SPECIES", 114, 134], ["S. brasiliensis", "SPECIES", 162, 177], ["S. schenckii sensu stricto (s. str.)", "SPECIES", 179, 215], ["S. globosa", "SPECIES", 217, 227], ["S. luriei", "SPECIES", 233, 242], ["IntroductionSporotrichosis", "PROBLEM", 0, 26], ["a mycosis affecting humans", "PROBLEM", 30, 56], ["the Sporothrix schenckii species complex", "PROBLEM", 110, 150], ["mycosis", "OBSERVATION", 32, 39], ["Sporothrix schenckii species", "OBSERVATION", 114, 142], ["globosa", "ANATOMY", 220, 227]]], ["Zoonotic transmission generally occurs through bites or scratches from infected cats [2\u20133].", [["cats", "ORGANISM", 80, 84], ["cats", "SPECIES", 80, 84], ["Zoonotic transmission", "TREATMENT", 0, 21], ["scratches", "PROBLEM", 56, 65]]], ["Increasing numbers of cases, including in immunocompromised humans, has led to increased interest in this emerging health problem [4\u20135].IntroductionSince 1998, an epidemic outbreak of sporotrichosis in Rio de Janeiro State, Brazil, with increasing number of cases in humans, dogs and cats [6\u20137] has been characterized by a high rate of transmission from infected cats to humans [8].", [["sporotrichosis", "DISEASE", 184, 198], ["humans", "ORGANISM", 60, 66], ["humans", "ORGANISM", 267, 273], ["dogs", "ORGANISM", 275, 279], ["cats", "ORGANISM", 284, 288], ["cats", "ORGANISM", 363, 367], ["humans", "ORGANISM", 371, 377], ["humans", "SPECIES", 60, 66], ["humans", "SPECIES", 267, 273], ["dogs", "SPECIES", 275, 279], ["cats", "SPECIES", 284, 288], ["cats", "SPECIES", 363, 367], ["humans", "SPECIES", 371, 377], ["humans", "SPECIES", 60, 66], ["humans", "SPECIES", 267, 273], ["humans", "SPECIES", 371, 377], ["sporotrichosis", "PROBLEM", 184, 198], ["numbers", "OBSERVATION_MODIFIER", 11, 18], ["sporotrichosis", "OBSERVATION", 184, 198]]], ["The metropolitan region of Rio de Janeiro is now a hyperendemic area for cat-associated sporotrichosis [9] that persists as a neglected zoonosis in this region [3].IntroductionClinically, lesions of feline sporotrichosis are characterized by subcutaneous nodules which ulcerate and are frequently widely disseminated.", [["lesions", "ANATOMY", 188, 195], ["subcutaneous nodules", "ANATOMY", 242, 262], ["sporotrichosis", "DISEASE", 88, 102], ["zoonosis", "DISEASE", 136, 144], ["feline sporotrichosis", "DISEASE", 199, 220], ["cat", "ORGANISM", 73, 76], ["lesions", "PATHOLOGICAL_FORMATION", 188, 195], ["feline", "ORGANISM", 199, 205], ["sporotrichosis", "CANCER", 206, 220], ["subcutaneous nodules", "CANCER", 242, 262], ["feline", "SPECIES", 199, 205], ["a hyperendemic area", "PROBLEM", 49, 68], ["associated sporotrichosis", "PROBLEM", 77, 102], ["lesions of feline sporotrichosis", "PROBLEM", 188, 220], ["subcutaneous nodules", "PROBLEM", 242, 262], ["sporotrichosis", "OBSERVATION", 88, 102], ["neglected", "OBSERVATION_MODIFIER", 126, 135], ["zoonosis", "OBSERVATION", 136, 144], ["lesions", "OBSERVATION", 188, 195], ["feline", "OBSERVATION_MODIFIER", 199, 205], ["sporotrichosis", "OBSERVATION", 206, 220], ["subcutaneous", "ANATOMY", 242, 254], ["nodules", "OBSERVATION", 255, 262], ["frequently", "OBSERVATION_MODIFIER", 286, 296], ["widely", "OBSERVATION_MODIFIER", 297, 303], ["disseminated", "OBSERVATION", 304, 316]]], ["The outcome of infection in cats ranges from subclinical disease, solitary lesions, to fatal disseminated disease [3, 10\u201311].IntroductionHuman sporotrichosis is generally characterized by localized skin lesions or lymphocutaneous lesions, although disseminated disease does occur, frequently associated with conditions of immunosuppression, such as HIV co-infection [5,8].", [["solitary lesions", "ANATOMY", 66, 82], ["skin lesions", "ANATOMY", 198, 210], ["lymphocutaneous lesions", "ANATOMY", 214, 237], ["infection", "DISEASE", 15, 24], ["disseminated disease", "DISEASE", 93, 113], ["sporotrichosis", "DISEASE", 143, 157], ["lymphocutaneous lesions", "DISEASE", 214, 237], ["disseminated disease", "DISEASE", 248, 268], ["HIV co-infection", "DISEASE", 349, 365], ["cats", "ORGANISM", 28, 32], ["solitary lesions", "CANCER", 66, 82], ["skin lesions", "PATHOLOGICAL_FORMATION", 198, 210], ["lymphocutaneous lesions", "PATHOLOGICAL_FORMATION", 214, 237], ["HIV", "ORGANISM", 349, 352], ["cats", "SPECIES", 28, 32], ["HIV", "SPECIES", 349, 352], ["infection", "PROBLEM", 15, 24], ["subclinical disease", "PROBLEM", 45, 64], ["solitary lesions", "PROBLEM", 66, 82], ["fatal disseminated disease", "PROBLEM", 87, 113], ["IntroductionHuman sporotrichosis", "PROBLEM", 125, 157], ["localized skin lesions", "PROBLEM", 188, 210], ["lymphocutaneous lesions", "PROBLEM", 214, 237], ["disseminated disease", "PROBLEM", 248, 268], ["immunosuppression", "TREATMENT", 322, 339], ["HIV co-infection", "PROBLEM", 349, 365], ["infection", "OBSERVATION", 15, 24], ["subclinical", "OBSERVATION_MODIFIER", 45, 56], ["disease", "OBSERVATION", 57, 64], ["solitary", "OBSERVATION_MODIFIER", 66, 74], ["lesions", "OBSERVATION", 75, 82], ["fatal", "OBSERVATION_MODIFIER", 87, 92], ["disseminated", "OBSERVATION_MODIFIER", 93, 105], ["disease", "OBSERVATION", 106, 113], ["sporotrichosis", "OBSERVATION", 143, 157], ["localized", "OBSERVATION_MODIFIER", 188, 197], ["skin", "ANATOMY", 198, 202], ["lesions", "OBSERVATION", 203, 210], ["lymphocutaneous", "OBSERVATION_MODIFIER", 214, 229], ["lesions", "OBSERVATION", 230, 237], ["disseminated", "OBSERVATION_MODIFIER", 248, 260], ["disease", "OBSERVATION", 261, 268]]], ["Feline disseminated sporotrichosis is frequently described in apparently immunocompetent animals [3,10,12].IntroductionThe most prevalent etiological agent and the primary pathogen of feline sporotrichosis in Brazil is S. brasiliensis [13].", [["sporotrichosis", "DISEASE", 20, 34], ["feline sporotrichosis", "DISEASE", 184, 205], ["Feline", "ORGANISM", 0, 6], ["feline", "ORGANISM", 184, 190], ["S. brasiliensis", "ORGANISM", 219, 234], ["feline", "SPECIES", 184, 190], ["S. brasiliensis", "SPECIES", 219, 234], ["S. brasiliensis", "SPECIES", 219, 234], ["Feline disseminated sporotrichosis", "PROBLEM", 0, 34], ["feline sporotrichosis", "PROBLEM", 184, 205], ["disseminated", "OBSERVATION_MODIFIER", 7, 19], ["sporotrichosis", "OBSERVATION", 20, 34], ["most prevalent", "OBSERVATION_MODIFIER", 123, 137], ["feline sporotrichosis", "OBSERVATION", 184, 205]]], ["Sporothrix brasiliensis has high virulence and is generally associated with disseminated cutaneous disease in humans.", [["cutaneous", "ANATOMY", 89, 98], ["cutaneous disease", "DISEASE", 89, 106], ["Sporothrix brasiliensis", "ORGANISM", 0, 23], ["cutaneous", "ORGANISM_SUBDIVISION", 89, 98], ["humans", "ORGANISM", 110, 116], ["Sporothrix brasiliensis", "SPECIES", 0, 23], ["humans", "SPECIES", 110, 116], ["Sporothrix brasiliensis", "SPECIES", 0, 23], ["humans", "SPECIES", 110, 116], ["Sporothrix brasiliensis", "PROBLEM", 0, 23], ["high virulence", "PROBLEM", 28, 42], ["disseminated cutaneous disease in humans", "PROBLEM", 76, 116], ["high virulence", "OBSERVATION_MODIFIER", 28, 42], ["generally associated with", "UNCERTAINTY", 50, 75], ["disseminated", "OBSERVATION_MODIFIER", 76, 88], ["cutaneous disease", "OBSERVATION", 89, 106]]], ["Patients infected with S. schenckii s. str. present with less severe sporotrichosis that can be highly localized [14].", [["sporotrichosis", "DISEASE", 69, 83], ["Patients", "ORGANISM", 0, 8], ["S. schenckii s. str", "ORGANISM", 23, 42], ["Patients", "SPECIES", 0, 8], ["S. schenckii", "SPECIES", 23, 35], ["S. schenckii s. str", "SPECIES", 23, 42], ["less severe sporotrichosis", "PROBLEM", 57, 83], ["infected", "OBSERVATION_MODIFIER", 9, 17], ["schenckii", "OBSERVATION_MODIFIER", 26, 35], ["less", "OBSERVATION_MODIFIER", 57, 61], ["severe", "OBSERVATION_MODIFIER", 62, 68], ["sporotrichosis", "OBSERVATION", 69, 83]]], ["It has been demonstrated that the genotype of Sporothrix from cats is identical to S. brasiliensis from human sources of the endemic area of Rio de Janeiro [13], therefore, the occurrence of cats with different clinical forms of sporotrichosis in this area suggests that other factors may be involved in the disease presentation of feline sporotrichosis.IntroductionFeline Immunodeficiency Virus (FIV) and Feline Leukemia Virus (FeLV) are associated with decreased counts of CD4+ T-cells in cats, which may lead to immunodeficiency and to the development of secondary infections [15\u201319].", [["CD4+ T-cells", "ANATOMY", 475, 487], ["sporotrichosis", "DISEASE", 229, 243], ["sporotrichosis", "DISEASE", 339, 353], ["IntroductionFeline Immunodeficiency Virus (FIV)", "DISEASE", 354, 401], ["Feline Leukemia Virus", "DISEASE", 406, 427], ["immunodeficiency", "DISEASE", 515, 531], ["infections", "DISEASE", 568, 578], ["cats", "ORGANISM", 62, 66], ["S. brasiliensis", "ORGANISM", 83, 98], ["human", "ORGANISM", 104, 109], ["cats", "ORGANISM", 191, 195], ["feline", "ORGANISM", 332, 338], ["IntroductionFeline Immunodeficiency Virus", "ORGANISM", 354, 395], ["FIV", "ORGANISM", 397, 400], ["Feline Leukemia Virus", "ORGANISM", 406, 427], ["FeLV", "ORGANISM", 429, 433], ["CD4", "GENE_OR_GENE_PRODUCT", 475, 478], ["cats", "ORGANISM", 491, 495], ["CD4", "PROTEIN", 475, 478], ["T-cells", "CELL_TYPE", 480, 487], ["cats", "SPECIES", 62, 66], ["S. brasiliensis", "SPECIES", 83, 98], ["human", "SPECIES", 104, 109], ["cats", "SPECIES", 191, 195], ["feline", "SPECIES", 332, 338], ["Feline Leukemia Virus", "SPECIES", 406, 427], ["cats", "SPECIES", 491, 495], ["S. brasiliensis", "SPECIES", 83, 98], ["human", "SPECIES", 104, 109], ["FIV", "SPECIES", 397, 400], ["Feline Leukemia Virus", "SPECIES", 406, 427], ["FeLV", "SPECIES", 429, 433], ["Sporothrix", "PROBLEM", 46, 56], ["sporotrichosis", "PROBLEM", 229, 243], ["feline sporotrichosis", "PROBLEM", 332, 353], ["IntroductionFeline Immunodeficiency Virus (FIV)", "PROBLEM", 354, 401], ["Feline Leukemia Virus (FeLV)", "PROBLEM", 406, 434], ["decreased counts", "PROBLEM", 455, 471], ["CD4", "TEST", 475, 478], ["T-cells in cats", "PROBLEM", 480, 495], ["immunodeficiency", "PROBLEM", 515, 531], ["secondary infections", "PROBLEM", 558, 578], ["Sporothrix", "OBSERVATION", 46, 56], ["endemic", "OBSERVATION_MODIFIER", 125, 132], ["sporotrichosis", "OBSERVATION", 229, 243], ["feline sporotrichosis", "OBSERVATION", 332, 353], ["Feline Leukemia Virus", "OBSERVATION", 406, 427], ["secondary", "OBSERVATION_MODIFIER", 558, 567], ["infections", "OBSERVATION", 568, 578]]], ["The diagnosis of FIV infection in cats is frequently based on the ELISA detection of antibodies against viral proteins such as p24 followed by Western-blot confirmation of inconclusive results [17].IntroductionFeLV infection is most commonly identified through ELISA detection of p27 antigen, a marker of infection [20,21].", [["FIV infection", "DISEASE", 17, 30], ["infection", "DISEASE", 215, 224], ["infection", "DISEASE", 305, 314], ["FIV", "ORGANISM", 17, 20], ["cats", "ORGANISM", 34, 38], ["p24", "GENE_OR_GENE_PRODUCT", 127, 130], ["p27 antigen", "GENE_OR_GENE_PRODUCT", 280, 291], ["antibodies", "PROTEIN", 85, 95], ["viral proteins", "PROTEIN", 104, 118], ["p24", "PROTEIN", 127, 130], ["p27 antigen", "PROTEIN", 280, 291], ["cats", "SPECIES", 34, 38], ["FIV", "SPECIES", 17, 20], ["FIV infection in cats", "PROBLEM", 17, 38], ["the ELISA detection", "TEST", 62, 81], ["antibodies", "PROBLEM", 85, 95], ["viral proteins", "PROBLEM", 104, 118], ["blot confirmation", "TEST", 151, 168], ["IntroductionFeLV infection", "PROBLEM", 198, 224], ["ELISA detection", "TEST", 261, 276], ["p27 antigen", "PROBLEM", 280, 291], ["infection", "PROBLEM", 305, 314], ["FIV", "OBSERVATION_MODIFIER", 17, 20], ["infection", "OBSERVATION", 21, 30], ["infection", "OBSERVATION", 215, 224], ["infection", "OBSERVATION", 305, 314]]], ["The development of quantitative real time PCR for the detection of FeLV provirus is crucial for the recognition of FeLV exposure.", [["FeLV", "DISEASE", 115, 119], ["FeLV", "ORGANISM", 67, 71], ["FeLV", "ORGANISM", 115, 119], ["FeLV", "SPECIES", 67, 71], ["FeLV", "SPECIES", 115, 119], ["quantitative real time PCR", "TEST", 19, 45], ["the detection", "TEST", 50, 63], ["FeLV provirus", "PROBLEM", 67, 80], ["FeLV exposure", "PROBLEM", 115, 128], ["FeLV provirus", "OBSERVATION", 67, 80], ["FeLV exposure", "OBSERVATION", 115, 128]]], ["FeLV provirus-positive/antigen-negative cats may be either at a very early stage of FeLV infection, when antigen is not yet detectable but provirus is, or they may have developed a protective immunity against FeLV and undergone regressive FeLV infection [22].", [["FeLV infection", "DISEASE", 84, 98], ["FeLV", "DISEASE", 209, 213], ["FeLV infection", "DISEASE", 239, 253], ["FeLV", "ORGANISM", 0, 4], ["antigen", "GENE_OR_GENE_PRODUCT", 23, 30], ["cats", "ORGANISM", 40, 44], ["FeLV", "ORGANISM", 84, 88], ["FeLV", "ORGANISM", 209, 213], ["FeLV", "ORGANISM", 239, 243], ["cats", "SPECIES", 40, 44], ["FeLV", "SPECIES", 84, 88], ["FeLV", "SPECIES", 209, 213], ["FeLV", "SPECIES", 239, 243], ["FeLV provirus", "TEST", 0, 13], ["antigen", "TEST", 23, 30], ["FeLV infection", "PROBLEM", 84, 98], ["FeLV", "PROBLEM", 209, 213], ["regressive FeLV infection", "PROBLEM", 228, 253], ["FeLV infection", "OBSERVATION", 84, 98], ["regressive", "OBSERVATION_MODIFIER", 228, 238], ["FeLV infection", "OBSERVATION", 239, 253]]], ["Cats that are antigen and provirus positive at the time of investigation are generally viremic and may subsequently undergo either regressive or progressive infection.", [["infection", "DISEASE", 157, 166], ["Cats", "ORGANISM", 0, 4], ["antigen and provirus positive", "PROBLEM", 14, 43], ["viremic", "PROBLEM", 87, 94], ["progressive infection", "PROBLEM", 145, 166], ["progressive", "OBSERVATION_MODIFIER", 145, 156], ["infection", "OBSERVATION", 157, 166]]], ["The latter is characterized by persistent antigenemia.", [["antigenemia", "DISEASE", 42, 53], ["persistent antigenemia", "PROBLEM", 31, 53], ["persistent", "OBSERVATION_MODIFIER", 31, 41], ["antigenemia", "OBSERVATION", 42, 53]]], ["Only by repeated determination of antigenemia can progressive and regressive infection outcomes be distinguished [23].IntroductionSevere forms of sporotrichosis in cats has not so far been associated with retrovirus co-infection [10\u201312,24].", [["antigenemia", "DISEASE", 34, 45], ["infection", "DISEASE", 77, 86], ["sporotrichosis", "DISEASE", 146, 160], ["retrovirus co-infection", "DISEASE", 205, 228], ["cats", "ORGANISM", 164, 168], ["retrovirus", "ORGANISM", 205, 215], ["cats", "SPECIES", 164, 168], ["antigenemia", "PROBLEM", 34, 45], ["regressive infection outcomes", "PROBLEM", 66, 95], ["sporotrichosis", "PROBLEM", 146, 160], ["retrovirus co-infection", "PROBLEM", 205, 228], ["antigenemia", "OBSERVATION", 34, 45], ["regressive", "OBSERVATION_MODIFIER", 66, 76], ["infection", "OBSERVATION", 77, 86], ["sporotrichosis", "OBSERVATION", 146, 160]]], ["However, in previous studies, the cats with sporotrichosis tested for retrovirus co-infection were mainly from Rio de Janeiro, where available resources do not allow confirmation of infection by Western blot or PCR.", [["sporotrichosis", "DISEASE", 44, 58], ["retrovirus co-infection", "DISEASE", 70, 93], ["infection", "DISEASE", 182, 191], ["cats", "ORGANISM", 34, 38], ["retrovirus", "ORGANISM", 70, 80], ["cats", "SPECIES", 34, 38], ["previous studies", "TEST", 12, 28], ["sporotrichosis", "PROBLEM", 44, 58], ["retrovirus co-infection", "PROBLEM", 70, 93], ["infection", "PROBLEM", 182, 191], ["PCR", "TEST", 211, 214], ["sporotrichosis", "OBSERVATION", 44, 58], ["infection", "OBSERVATION", 182, 191]]], ["Assessment of the immune status, as characterized by cytokine expression profiles, has also not been performed in previous cohorts of feline sporotrichosis.", [["sporotrichosis", "DISEASE", 141, 155], ["feline", "ORGANISM", 134, 140], ["cytokine", "PROTEIN", 53, 61], ["cytokine expression profiles", "TEST", 53, 81], ["feline sporotrichosis", "PROBLEM", 134, 155], ["feline sporotrichosis", "OBSERVATION", 134, 155]]], ["The aim of this study was to assess whether the co-infection with FIV or FeLV is related to changes in immunological parameters among cats with sporotrichosis.Serologic assays for the determination of Feline Leukemia Virus p27 antigenemia and the presence of anti-Feline Immunodeficiency Virus antibodies ::: Sampling ::: Material and methodsTo detect FeLV viremia, the presence of FeLV p27 antigen in the plasma was determined using a sandwich ELISA, as previously described [20].", [["plasma", "ANATOMY", 406, 412], ["co-infection", "DISEASE", 48, 60], ["sporotrichosis", "DISEASE", 144, 158], ["Feline Leukemia", "DISEASE", 201, 216], ["anti-Feline Immunodeficiency Virus", "DISEASE", 259, 293], ["FeLV viremia", "DISEASE", 352, 364], ["FIV", "ORGANISM", 66, 69], ["FeLV", "ORGANISM", 73, 77], ["cats", "ORGANISM", 134, 138], ["Feline Leukemia Virus", "ORGANISM", 201, 222], ["p27", "GENE_OR_GENE_PRODUCT", 223, 226], ["anti-Feline Immunodeficiency Virus", "ORGANISM", 259, 293], ["FeLV", "ORGANISM", 352, 356], ["FeLV", "ORGANISM", 382, 386], ["p27 antigen", "GENE_OR_GENE_PRODUCT", 387, 398], ["plasma", "ORGANISM_SUBSTANCE", 406, 412], ["anti-Feline Immunodeficiency Virus antibodies", "PROTEIN", 259, 304], ["FeLV p27 antigen", "PROTEIN", 382, 398], ["cats", "SPECIES", 134, 138], ["FIV", "SPECIES", 66, 69], ["FeLV", "SPECIES", 73, 77], ["Feline Leukemia Virus", "SPECIES", 201, 222], ["anti-Feline Immunodeficiency Virus", "SPECIES", 259, 293], ["FeLV", "SPECIES", 352, 356], ["FeLV", "SPECIES", 382, 386], ["this study", "TEST", 11, 21], ["the co-infection", "PROBLEM", 44, 60], ["FIV", "PROBLEM", 66, 69], ["FeLV", "PROBLEM", 73, 77], ["changes in immunological parameters", "PROBLEM", 92, 127], ["sporotrichosis", "PROBLEM", 144, 158], ["Serologic assays", "TEST", 159, 175], ["the determination", "TEST", 180, 197], ["Feline Leukemia Virus p27 antigenemia", "PROBLEM", 201, 238], ["anti-Feline Immunodeficiency Virus antibodies", "PROBLEM", 259, 304], ["FeLV viremia", "PROBLEM", 352, 364], ["FeLV p27 antigen", "TEST", 382, 398], ["a sandwich ELISA", "TEST", 434, 450], ["co-infection", "OBSERVATION", 48, 60], ["FeLV", "OBSERVATION", 73, 77], ["sporotrichosis", "OBSERVATION", 144, 158], ["Feline Leukemia", "OBSERVATION", 201, 216], ["Immunodeficiency Virus", "OBSERVATION", 271, 293], ["FeLV viremia", "OBSERVATION", 352, 364]]], ["Results were represented as percentages of a defined positive control (culture supernatant of FL-74 feline lymphoblastoid cell line permanently expressing FeLV), which was considered 100%.", [["supernatant", "ANATOMY", 79, 90], ["lymphoblastoid cell line", "ANATOMY", 107, 131], ["feline", "ORGANISM", 100, 106], ["lymphoblastoid cell line", "CELL", 107, 131], ["FeLV", "ORGANISM", 155, 159], ["FL-74 feline lymphoblastoid cell line", "CELL_LINE", 94, 131], ["feline", "SPECIES", 100, 106], ["culture", "TEST", 71, 78], ["FL", "TEST", 94, 96], ["feline lymphoblastoid cell line", "TREATMENT", 100, 131], ["lymphoblastoid cell line", "OBSERVATION", 107, 131]]], ["Samples determined to be > 5% of the positive control signal were considered positive [21].Serologic assays for the determination of Feline Leukemia Virus p27 antigenemia and the presence of anti-Feline Immunodeficiency Virus antibodies ::: Sampling ::: Material and methodsThe serum was tested by ELISA for FIV antibodies using recombinant FIV-Z2 transmembrane glycoprotein (TM- ELISA) as described elsewhere [25].", [["Samples", "ANATOMY", 0, 7], ["serum", "ANATOMY", 278, 283], ["Feline Leukemia", "DISEASE", 133, 148], ["anti-Feline Immunodeficiency Virus", "DISEASE", 191, 225], ["Feline Leukemia Virus", "ORGANISM", 133, 154], ["p27", "GENE_OR_GENE_PRODUCT", 155, 158], ["anti-Feline Immunodeficiency Virus", "ORGANISM", 191, 225], ["serum", "ORGANISM_SUBSTANCE", 278, 283], ["FIV", "ORGANISM", 308, 311], ["FIV-Z2 transmembrane glycoprotein", "GENE_OR_GENE_PRODUCT", 341, 374], ["anti-Feline Immunodeficiency Virus antibodies", "PROTEIN", 191, 236], ["FIV antibodies", "PROTEIN", 308, 322], ["recombinant FIV-Z2 transmembrane glycoprotein", "PROTEIN", 329, 374], ["TM", "PROTEIN", 376, 378], ["Feline Leukemia Virus", "SPECIES", 133, 154], ["anti-Feline Immunodeficiency Virus", "SPECIES", 191, 225], ["FIV", "SPECIES", 308, 311], ["FIV", "SPECIES", 341, 344], ["Samples", "TEST", 0, 7], ["the positive control signal", "PROBLEM", 33, 60], ["Serologic assays", "TEST", 91, 107], ["the determination", "TEST", 112, 129], ["Feline Leukemia Virus p27 antigenemia", "PROBLEM", 133, 170], ["anti-Feline Immunodeficiency Virus antibodies", "PROBLEM", 191, 236], ["The serum", "TEST", 274, 283], ["ELISA", "TEST", 298, 303], ["FIV antibodies", "TEST", 308, 322], ["recombinant FIV", "TREATMENT", 329, 344], ["Feline Leukemia", "OBSERVATION", 133, 148], ["Immunodeficiency Virus", "OBSERVATION", 203, 225]]], ["Samples that reached an OD value > 50% of the positive control were considered positive.Serologic assays for the determination of Feline Leukemia Virus p27 antigenemia and the presence of anti-Feline Immunodeficiency Virus antibodies ::: Sampling ::: Material and methodsPresence of antibodies to FIV was confirmed by the Western blot (reference standard method) technique as described previously [26].", [["Samples", "ANATOMY", 0, 7], ["Feline Leukemia", "DISEASE", 130, 145], ["anti-Feline Immunodeficiency Virus", "DISEASE", 188, 222], ["Feline Leukemia Virus", "ORGANISM", 130, 151], ["p27", "GENE_OR_GENE_PRODUCT", 152, 155], ["anti-Feline Immunodeficiency Virus", "ORGANISM", 188, 222], ["FIV", "ORGANISM", 297, 300], ["anti-Feline Immunodeficiency Virus antibodies", "PROTEIN", 188, 233], ["antibodies", "PROTEIN", 283, 293], ["Feline Leukemia Virus", "SPECIES", 130, 151], ["anti-Feline Immunodeficiency Virus", "SPECIES", 188, 222], ["FIV", "SPECIES", 297, 300], ["Samples", "TEST", 0, 7], ["an OD value", "TEST", 21, 32], ["Serologic assays", "TEST", 88, 104], ["the determination", "TEST", 109, 126], ["Feline Leukemia Virus p27 antigenemia", "PROBLEM", 130, 167], ["anti-Feline Immunodeficiency Virus antibodies", "PROBLEM", 188, 233], ["antibodies to FIV", "PROBLEM", 283, 300], ["Feline Leukemia", "OBSERVATION", 130, 145], ["Immunodeficiency Virus", "OBSERVATION", 200, 222]]], ["The presence of both the p24 band and p15 band was interpreted as a positive test result.TaqMan real-time qPCR assay for the detection of Feline Leukemia Virus provirus ::: Sampling ::: Material and methodsDNA was purified from EDTA blood samples using the MagNa Pure LC TNA isolation kit (Roche Diagnostics, Rotkreuz, Switzerland).", [["blood samples", "ANATOMY", 233, 246], ["Feline Leukemia", "DISEASE", 138, 153], ["EDTA", "CHEMICAL", 228, 232], ["p24", "GENE_OR_GENE_PRODUCT", 25, 28], ["p15", "GENE_OR_GENE_PRODUCT", 38, 41], ["Feline Leukemia Virus", "ORGANISM", 138, 159], ["methodsDNA", "SIMPLE_CHEMICAL", 199, 209], ["EDTA blood samples", "ORGANISM_SUBSTANCE", 228, 246], ["p24 band", "PROTEIN", 25, 33], ["p15 band", "PROTEIN", 38, 46], ["Feline Leukemia Virus provirus", "SPECIES", 138, 168], ["the p24 band and p15 band", "TREATMENT", 21, 46], ["a positive test result", "PROBLEM", 66, 88], ["TaqMan", "TEST", 89, 95], ["qPCR assay", "TEST", 106, 116], ["Feline Leukemia Virus provirus", "PROBLEM", 138, 168], ["EDTA blood samples", "TEST", 228, 246], ["the MagNa", "TEST", 253, 262], ["p24 band", "OBSERVATION", 25, 33], ["Feline Leukemia Virus provirus", "OBSERVATION", 138, 168]]], ["FeLV proviral DNA was tested by TaqMan real-time qPCR (reference standard method) as previously described [27].Assessment of cytokine profiles ::: Sampling ::: Material and methodsWithin one hour after collection, 2 aliquots of 100 \u03bcL of whole blood collected in EDTA tubes were admixed with 300 \u03bcL mRNA lysis buffer each (mRNA Isolation HS Kit, Roche Diagnostics), respectively and stored at -80\u00b0 C until subsequent analysis.Assessment of cytokine profiles ::: Sampling ::: Material and methodsThe mRNA was purified with mRNA Isolation Kit I and the Magna Pure LC Instrument (Roche Diagnostics) according to the manufacturer's recommendations.", [["blood", "ANATOMY", 244, 249], ["EDTA", "CHEMICAL", 263, 267], ["FeLV", "ORGANISM", 0, 4], ["DNA", "CELLULAR_COMPONENT", 14, 17], ["blood", "ORGANISM_SUBSTANCE", 244, 249], ["EDTA tubes", "ORGANISM_SUBSTANCE", 263, 273], ["FeLV proviral DNA", "DNA", 0, 17], ["cytokine", "PROTEIN", 125, 133], ["cytokine", "PROTEIN", 440, 448], ["mRNA", "RNA", 499, 503], ["FeLV", "SPECIES", 0, 4], ["FeLV proviral DNA", "PROBLEM", 0, 17], ["collection", "TEST", 202, 212], ["whole blood collected in EDTA tubes", "TREATMENT", 238, 273], ["300 \u03bcL mRNA lysis buffer", "TREATMENT", 292, 316], ["Roche Diagnostics", "TEST", 346, 363], ["subsequent analysis", "TEST", 406, 425], ["mRNA Isolation", "TREATMENT", 522, 536]]], ["For all extractions performed, 100 \u03bcL of phosphate Buffered Saline (PBS) was used as negative control, in order to monitor cross-contaminations.Assessment of cytokine profiles ::: Sampling ::: Material and methodsThe mRNA was eluted in 25 \u03bcL of elution buffer and the first-strand cDNA was synthesized using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to the manufacturer's instructions.", [["phosphate", "CHEMICAL", 41, 50], ["phosphate", "CHEMICAL", 41, 50], ["phosphate Buffered Saline", "SIMPLE_CHEMICAL", 41, 66], ["cytokine", "PROTEIN", 158, 166], ["mRNA", "RNA", 217, 221], ["first-strand cDNA", "DNA", 268, 285], ["all extractions", "TREATMENT", 4, 19], ["phosphate Buffered Saline (PBS)", "TREATMENT", 41, 72], ["elution buffer", "TREATMENT", 245, 259], ["the first-strand cDNA", "TREATMENT", 264, 285], ["the High Capacity cDNA", "TREATMENT", 308, 330]]], ["For each sample of mRNA, the cDNA was synthetized in duplicate and pooled.Assessment of cytokine profiles ::: Sampling ::: Material and methodsThe TaqMan real-time RT-qPCR assay was used for relative quantification of the following cytokines: interferon-\u03b3 (IFN-\u03b3), interleukin (IL) 4, 5, 6, 10 and 12 and tumor necrosis factor-\u03b1 (TNF-\u03b1) as previously described [28\u201330].", [["necrosis", "DISEASE", 311, 319], ["cDNA", "CELLULAR_COMPONENT", 29, 33], ["interferon-\u03b3", "GENE_OR_GENE_PRODUCT", 243, 255], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 257, 262], ["interleukin (IL) 4", "GENE_OR_GENE_PRODUCT", 265, 283], ["5", "GENE_OR_GENE_PRODUCT", 285, 286], ["6", "GENE_OR_GENE_PRODUCT", 288, 289], ["10", "GENE_OR_GENE_PRODUCT", 291, 293], ["12", "GENE_OR_GENE_PRODUCT", 298, 300], ["tumor necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 305, 328], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 330, 335], ["mRNA", "RNA", 19, 23], ["cDNA", "DNA", 29, 33], ["cytokine", "PROTEIN", 88, 96], ["cytokines", "PROTEIN", 232, 241], ["interferon-\u03b3 (IFN-\u03b3", "PROTEIN", 243, 262], ["interleukin (IL) 4, 5, 6, 10 and 12", "PROTEIN", 265, 300], ["tumor necrosis factor-\u03b1", "PROTEIN", 305, 328], ["TNF", "PROTEIN", 330, 333], ["\u03b1", "PROTEIN", 334, 335], ["the cDNA", "TEST", 25, 33], ["The TaqMan", "TEST", 143, 153], ["qPCR assay", "TEST", 167, 177], ["cytokines", "TEST", 232, 241], ["interferon", "TEST", 243, 253], ["IFN", "TEST", 257, 260], ["interleukin (IL)", "TREATMENT", 265, 281], ["tumor necrosis factor", "TEST", 305, 326], ["TNF", "TEST", 330, 333], ["tumor", "OBSERVATION_MODIFIER", 305, 310], ["necrosis", "OBSERVATION", 311, 319]]], ["The levels of transcription of the V-abl Abelson murine leukemia viral oncogene (ABL) and zeta polypeptide (YWHAZ)\u2014previously referred as best-performing housekeeping genes in feline blood due to their stable transcription [31]\u2014were employed for normalization.", [["blood", "ANATOMY", 183, 188], ["Abelson murine leukemia viral", "ORGANISM", 41, 70], ["ABL", "GENE_OR_GENE_PRODUCT", 81, 84], ["zeta polypeptide", "GENE_OR_GENE_PRODUCT", 90, 106], ["YWHAZ", "GENE_OR_GENE_PRODUCT", 108, 113], ["feline", "ORGANISM", 176, 182], ["blood", "ORGANISM_SUBSTANCE", 183, 188], ["V-abl Abelson murine leukemia viral oncogene", "DNA", 35, 79], ["ABL", "DNA", 81, 84], ["zeta polypeptide", "DNA", 90, 106], ["YWHAZ", "PROTEIN", 108, 113], ["housekeeping genes", "DNA", 154, 172], ["murine", "SPECIES", 49, 55], ["feline", "SPECIES", 176, 182], ["the V", "TEST", 31, 36], ["abl Abelson murine leukemia viral oncogene", "TREATMENT", 37, 79], ["zeta polypeptide", "TREATMENT", 90, 106], ["abl Abelson murine leukemia", "OBSERVATION", 37, 64]]], ["Briefly, to assess the transcription levels of cytokines and reference genes in the samples from this study, a standard curve was acquired using a serial 10-fold dilution of synthetic standards.", [["samples", "ANATOMY", 84, 91], ["cytokines", "PROTEIN", 47, 56], ["reference genes", "DNA", 61, 76], ["this study", "TEST", 97, 107], ["a standard curve", "TEST", 109, 125], ["a serial 10-fold dilution of synthetic standards", "TREATMENT", 145, 193]]], ["Afterwards, the transcription levels of the cytokines were normalized to the geometric means of the housekeeping genes, as described elsewhere [32].Assessment of lymphocyte subsets by flow cytometry ::: Sampling ::: Material and methodsThe isolation of feline PBMC was carried out using the commercial available density gradient ficoll-hystopaque\u2013density of 1077 g/mL (Histopaque\u2014Sigma-Aldrich, Buchs, Switzerland) as reported previously [24], up to 12 hours after blood collection.", [["lymphocyte", "ANATOMY", 162, 172], ["PBMC", "ANATOMY", 260, 264], ["blood", "ANATOMY", 465, 470], ["lymphocyte", "CELL", 162, 172], ["feline", "ORGANISM", 253, 259], ["PBMC", "CELL", 260, 264], ["blood", "ORGANISM_SUBSTANCE", 465, 470], ["cytokines", "PROTEIN", 44, 53], ["housekeeping genes", "DNA", 100, 118], ["lymphocyte subsets", "CELL_TYPE", 162, 180], ["feline PBMC", "CELL_TYPE", 253, 264], ["feline", "SPECIES", 253, 259], ["feline", "SPECIES", 253, 259], ["the transcription levels", "TEST", 12, 36], ["the cytokines", "TEST", 40, 53], ["flow cytometry", "TEST", 184, 198], ["The isolation of feline PBMC", "TREATMENT", 236, 264], ["the commercial available density gradient ficoll", "TREATMENT", 287, 335], ["blood collection", "TEST", 465, 481], ["housekeeping genes", "OBSERVATION", 100, 118], ["lymphocyte subsets", "OBSERVATION", 162, 180], ["feline PBMC", "OBSERVATION", 253, 264]]], ["The pellets were resuspended in freezing medium with 10% DMSO (Sigma-Aldrich), 50% Fetal Calf Serum (FCS, Hyclone\u2013USA), and 40% RPMI 1640 (Roswell Park Memorial Institute\u2014Sigma\u2013Aldrich) medium and stored in liquid nitrogen.Assessment of lymphocyte subsets by flow cytometry ::: Sampling ::: Material and methodsFor the flow cytometry analysis, the PBMC were quickly thawed at 37\u00b0C and then resuspended in 10 mL of complete medium (1x RPMI 1640 medium\u2014Sigma-Aldrich, Zug, Switzerland), containing 10% FCS 100 M/mL Glutamine and 1% v/v antibiotic/antimycotic (Ab/Am) (Gibco Life Technologies, Zug, Switzerland), previously warmed to 37\u00b0 C. The solution was centrifuged (560 x g, 10 minutes), the cells were washed once in 10 mL of 1x HBSS (Hank's Balanced Salt Solution, Sigma-Aldrich) and the pellet was resuspended in 1 ml of HBSS.", [["lymphocyte", "ANATOMY", 237, 247], ["PBMC", "ANATOMY", 348, 352], ["cells", "ANATOMY", 694, 699], ["DMSO", "CHEMICAL", 57, 61], ["Glutamine", "CHEMICAL", 513, 522], ["DMSO", "CHEMICAL", 57, 61], ["nitrogen", "CHEMICAL", 214, 222], ["Glutamine", "CHEMICAL", 513, 522], ["DMSO", "SIMPLE_CHEMICAL", 57, 61], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 63, 76], ["Serum", "ORGANISM_SUBSTANCE", 94, 99], ["lymphocyte", "CELL", 237, 247], ["PBMC", "CELL", 348, 352], ["C", "SIMPLE_CHEMICAL", 379, 380], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 451, 464], ["Zug", "SIMPLE_CHEMICAL", 466, 469], ["Glutamine", "SIMPLE_CHEMICAL", 513, 522], ["v/v antibiotic", "SIMPLE_CHEMICAL", 530, 544], ["antimycotic", "SIMPLE_CHEMICAL", 545, 556], ["cells", "CELL", 694, 699], ["lymphocyte subsets", "CELL_TYPE", 237, 255], ["PBMC", "CELL_TYPE", 348, 352], ["The pellets", "TREATMENT", 0, 11], ["Fetal Calf Serum", "TEST", 83, 99], ["liquid nitrogen", "TREATMENT", 207, 222], ["flow cytometry", "TEST", 259, 273], ["the flow cytometry analysis", "TEST", 315, 342], ["the PBMC", "TEST", 344, 352], ["Glutamine", "TREATMENT", 513, 522], ["v antibiotic", "TREATMENT", 532, 544], ["antimycotic", "TREATMENT", 545, 556], ["the cells", "TREATMENT", 690, 699], ["1x HBSS", "TREATMENT", 729, 736], ["Hank's Balanced Salt Solution", "TREATMENT", 738, 767], ["Sigma-Aldrich)", "TREATMENT", 769, 783], ["the pellet", "TREATMENT", 788, 798], ["HBSS", "TREATMENT", 826, 830], ["Calf", "ANATOMY", 89, 93], ["lymphocyte subsets", "OBSERVATION", 237, 255]]], ["Three aliquots of PBMC were incubated for 30 minutes, at 4\u00b0C, with 5 \u03bcl of one of the antibody/combination of antibodies, previously diluted in HBSS: 1 \u2013mouse anti-feline CD4-RPE (1:50, Vpg34, ABDserotec, D\u00fcsseldorf, Germany); 2 \u2013mouse anti-feline CD8-FITC (1:50, fCD8, Southern Biotech, Allschwil, Switzerland); 3 \u2013mouse anti-feline CD5-FITC (1:100, f43, Southern Biotech) and mouse anti-canine CD21-RPE (1:5, CA2.1D6, ABD Serotec, cross-reacting with feline CD21).", [["PBMC", "ANATOMY", 18, 22], ["RPE", "ANATOMY", 175, 178], ["anti-canine CD21-RPE", "ANATOMY", 384, 404], ["CA2.1D6", "ANATOMY", 411, 418], ["FITC", "CHEMICAL", 252, 256], ["FITC", "CHEMICAL", 338, 342], ["PBMC", "CELL", 18, 22], ["RPE", "TISSUE", 175, 178], ["CD8", "GENE_OR_GENE_PRODUCT", 248, 251], ["FITC", "GENE_OR_GENE_PRODUCT", 252, 256], ["CD5", "GENE_OR_GENE_PRODUCT", 334, 337], ["FITC", "GENE_OR_GENE_PRODUCT", 338, 342], ["mouse", "ORGANISM", 378, 383], ["CD21", "GENE_OR_GENE_PRODUCT", 396, 400], ["RPE", "TISSUE", 401, 404], ["CA2.1D6", "CELL", 411, 418], ["ABD Serotec", "GENE_OR_GENE_PRODUCT", 420, 431], ["feline", "ORGANISM", 453, 459], ["CD21", "GENE_OR_GENE_PRODUCT", 460, 464], ["PBMC", "CELL_TYPE", 18, 22], ["antibody", "PROTEIN", 86, 94], ["antibodies", "PROTEIN", 110, 120], ["CD4", "PROTEIN", 171, 174], ["CD8", "PROTEIN", 248, 251], ["FITC", "PROTEIN", 252, 256], ["fCD8", "PROTEIN", 264, 268], ["CD5", "PROTEIN", 334, 337], ["FITC", "PROTEIN", 338, 342], ["1:100", "PROTEIN", 344, 349], ["f43", "PROTEIN", 351, 354], ["Southern Biotech", "PROTEIN", 356, 372], ["mouse anti-canine CD21", "PROTEIN", 378, 400], ["RPE", "PROTEIN", 401, 404], ["1:5, CA2.1D6", "PROTEIN", 406, 418], ["ABD Serotec", "PROTEIN", 420, 431], ["feline CD21", "PROTEIN", 453, 464], ["mouse", "SPECIES", 378, 383], ["mouse", "SPECIES", 378, 383], ["PBMC", "TREATMENT", 18, 22], ["the antibody", "TREATMENT", 82, 94], ["antibodies", "PROBLEM", 110, 120], ["RPE", "TEST", 175, 178], ["Vpg34", "TEST", 186, 191], ["RPE", "TEST", 401, 404], ["CA2", "TEST", 411, 414], ["ABD Serotec", "TREATMENT", 420, 431], ["ABD", "ANATOMY", 420, 423]]], ["Unlabeled samples were employed as negative controls for non-specific binding.Assessment of lymphocyte subsets by flow cytometry ::: Sampling ::: Material and methodsAfter incubation, the cells were washed twice by centrifugation with HBSS and resuspended in 200 \u03bcL of HBSS for acquisition on the flow cytometer.", [["samples", "ANATOMY", 10, 17], ["lymphocyte", "ANATOMY", 92, 102], ["cells", "ANATOMY", 188, 193], ["samples", "CANCER", 10, 17], ["lymphocyte", "CELL", 92, 102], ["cells", "CELL", 188, 193], ["lymphocyte subsets", "CELL_TYPE", 92, 110], ["Unlabeled samples", "TEST", 0, 17], ["non-specific binding", "PROBLEM", 57, 77], ["flow cytometry", "TEST", 114, 128], ["the cells", "TREATMENT", 184, 193], ["HBSS", "TREATMENT", 235, 239], ["HBSS", "TREATMENT", 269, 273], ["the flow cytometer", "TEST", 293, 311], ["lymphocyte subsets", "OBSERVATION", 92, 110]]], ["The cytofluorimetric analysis was performed using the Guava EasyCyte 8HT flow cytometer (Millipore, Darmstadt, Germany) using the guavaSoft 2.5 software for data analysis.", [["The cytofluorimetric analysis", "TEST", 0, 29], ["the Guava", "TEST", 50, 59], ["the guavaSoft", "TEST", 126, 139], ["data analysis", "TEST", 157, 170]]], ["The population of lymphocytes was defined on the basis of their size and granularity (forward and side scatter) and a gate was set for further analysis.", [["lymphocytes", "ANATOMY", 18, 29], ["lymphocytes", "CELL", 18, 29], ["lymphocytes", "CELL_TYPE", 18, 29], ["lymphocytes", "PROBLEM", 18, 29], ["a gate", "TEST", 116, 122], ["further analysis", "TEST", 135, 151], ["population", "OBSERVATION_MODIFIER", 4, 14], ["lymphocytes", "OBSERVATION", 18, 29], ["size", "OBSERVATION_MODIFIER", 64, 68], ["granularity", "OBSERVATION", 73, 84]]], ["Data were collected from 10,000 cells and are expressed as percentages of positive cells inside the gate.Statistics ::: Sampling ::: Material and methodsData were stored in and analyzed by the Statistical Package for Social Sciences (SPSS), version 16.0.", [["cells", "ANATOMY", 32, 37], ["cells", "ANATOMY", 83, 88], ["cells", "CELL", 32, 37], ["cells", "CELL", 83, 88], ["positive cells", "CELL_TYPE", 74, 88], ["positive cells inside the gate", "PROBLEM", 74, 104], ["methodsData", "TEST", 146, 157], ["positive cells", "OBSERVATION", 74, 88]]], ["The following categorical variables were used to group the cats for further analyses: co-infection by FIV or FeLV (positive or negative), general condition (good, fair and poor) and distributions of lesions (L1, L2 and L3).", [["lesions", "ANATOMY", 199, 206], ["co-infection", "DISEASE", 86, 98], ["cats", "ORGANISM", 59, 63], ["FIV", "ORGANISM", 102, 105], ["FeLV", "ORGANISM", 109, 113], ["lesions", "PATHOLOGICAL_FORMATION", 199, 206], ["FIV", "SPECIES", 102, 105], ["the cats", "TEST", 55, 63], ["further analyses", "TEST", 68, 84], ["co-infection", "PROBLEM", 86, 98], ["FIV", "PROBLEM", 102, 105], ["FeLV", "PROBLEM", 109, 113], ["lesions (L1, L2 and L3)", "PROBLEM", 199, 222], ["lesions", "OBSERVATION", 199, 206], ["L1", "ANATOMY_MODIFIER", 208, 210], ["L2", "ANATOMY_MODIFIER", 212, 214], ["L3", "ANATOMY", 219, 221]]], ["With regards to the co-infection with FeLV, only progressively FeLV-infected cats were included in the statistical analyses and compared to cats without retrovirus infection; cats with regressive FeLV infection were excluded from these analyses.", [["co-infection", "DISEASE", 20, 32], ["FeLV-infected", "DISEASE", 63, 76], ["retrovirus infection", "DISEASE", 153, 173], ["FeLV infection", "DISEASE", 196, 210], ["FeLV", "ORGANISM", 38, 42], ["FeLV", "ORGANISM", 63, 67], ["cats", "ORGANISM", 77, 81], ["cats", "ORGANISM", 140, 144], ["retrovirus", "ORGANISM", 153, 163], ["cats", "ORGANISM", 175, 179], ["FeLV", "ORGANISM", 196, 200], ["cats", "SPECIES", 77, 81], ["cats", "SPECIES", 140, 144], ["cats", "SPECIES", 175, 179], ["FeLV", "SPECIES", 38, 42], ["FeLV", "SPECIES", 196, 200], ["the co-infection with FeLV", "PROBLEM", 16, 42], ["progressively FeLV-infected cats", "PROBLEM", 49, 81], ["the statistical analyses", "TEST", 99, 123], ["retrovirus infection", "PROBLEM", 153, 173], ["regressive FeLV infection", "PROBLEM", 185, 210], ["these analyses", "TEST", 230, 244], ["co-infection", "OBSERVATION", 20, 32], ["FeLV", "OBSERVATION", 38, 42], ["without", "UNCERTAINTY", 145, 152], ["retrovirus", "ANATOMY", 153, 163], ["infection", "OBSERVATION", 164, 173], ["regressive", "OBSERVATION_MODIFIER", 185, 195], ["FeLV infection", "OBSERVATION", 196, 210]]], ["Concerning FIV, cats were considered FIV-positive when they were confirmed to be positive by Western blot.", [["FIV", "ORGANISM", 11, 14], ["cats", "ORGANISM", 16, 20], ["FIV", "ORGANISM", 37, 40], ["cats", "SPECIES", 16, 20], ["FIV", "SPECIES", 11, 14], ["FIV", "SPECIES", 37, 40], ["FIV", "TEST", 37, 40]]], ["The Pearson\u2019s chi-square test for independence was used to determine a significant association between the categorical variables.", [["a significant association between the categorical variables", "PROBLEM", 69, 128]]], ["Fisher's exact test (pF) was applied to the comparison of variables with only two categories.", [["Fisher's exact test", "TEST", 0, 19]]], ["The Mann-Whitney U-test (pMWU) and the Kruskall-Wallis (pKW) tests were performed to test for statistical differences in cytokine transcription and percentage of each lymphocyte subset and the treatment length between two groups or among many groups, respectively.", [["lymphocyte", "ANATOMY", 167, 177], ["lymphocyte", "CELL", 167, 177], ["cytokine", "PROTEIN", 121, 129], ["lymphocyte subset", "CELL_TYPE", 167, 184], ["the Kruskall-Wallis (pKW) tests", "TEST", 35, 66], ["cytokine transcription", "TEST", 121, 143], ["each lymphocyte subset", "TREATMENT", 162, 184], ["the treatment length", "TREATMENT", 189, 209]]], ["P-values below or equal to 0.05 were considered significant.Animals ::: ResultsThirty cats with sporotrichosis were included in the study.", [["sporotrichosis", "DISEASE", 96, 110], ["cats", "ORGANISM", 86, 90], ["cats", "SPECIES", 86, 90], ["P-values", "TEST", 0, 8], ["sporotrichosis", "PROBLEM", 96, 110], ["the study", "TEST", 128, 137], ["sporotrichosis", "OBSERVATION", 96, 110]]], ["Six cats (20.0%) were included in group L1, ten (33.3%) in group L2 and fourteen (46.7%) in group L3.", [["cats", "ORGANISM", 4, 8], ["cats", "SPECIES", 4, 8], ["Six cats", "TEST", 0, 8], ["L1", "ANATOMY", 40, 42], ["L3", "ANATOMY", 98, 100]]], ["Twenty-one cats were male (70.0%).", [["cats", "ORGANISM", 11, 15], ["cats", "SPECIES", 11, 15]]], ["Twenty-four (80.0%) were in good general condition, three (10.0%) in fair general condition and three (10.0%) in poor general condition.", [["poor general condition", "PROBLEM", 113, 135]]], ["Fourteen cats (46.7%) were under 2 years old, (<2 years), six (20.0%) were between 2 and five years old (\u2265 2 \u22645 years) and seven (23.3%) were more than five years old (>5 years).", [["cats", "ORGANISM", 9, 13], ["cats", "SPECIES", 9, 13]]], ["In three (10.0%) adult cats, age class was unknown.Detection of co-infection with feline retroviruses ::: ResultsAmong the thirty cats with sporotrichosis included in this study, three were positive for FIV antibodies and six were positive for FeLV provirus (S1 Table); none of the cats was double-positive for FeLV and FIV.", [["co-infection", "DISEASE", 64, 76], ["feline retroviruses", "DISEASE", 82, 101], ["sporotrichosis", "DISEASE", 140, 154], ["FeLV provirus", "DISEASE", 244, 257], ["cats", "ORGANISM", 23, 27], ["feline", "ORGANISM", 82, 88], ["retroviruses", "ORGANISM", 89, 101], ["cats", "ORGANISM", 130, 134], ["FIV", "ORGANISM", 203, 206], ["FeLV", "ORGANISM", 244, 248], ["cats", "ORGANISM", 282, 286], ["FeLV", "ORGANISM", 311, 315], ["FIV", "ORGANISM", 320, 323], ["FIV antibodies", "PROTEIN", 203, 217], ["cats", "SPECIES", 23, 27], ["feline", "SPECIES", 82, 88], ["cats", "SPECIES", 130, 134], ["cats", "SPECIES", 282, 286], ["FIV", "SPECIES", 203, 206], ["FeLV", "SPECIES", 244, 248], ["FeLV", "SPECIES", 311, 315], ["FIV", "SPECIES", 320, 323], ["co-infection", "PROBLEM", 64, 76], ["sporotrichosis", "PROBLEM", 140, 154], ["this study", "TEST", 167, 177], ["FIV antibodies", "TEST", 203, 217], ["FeLV provirus", "PROBLEM", 244, 257], ["the cats", "TEST", 278, 286], ["FeLV", "PROBLEM", 311, 315], ["co-infection", "OBSERVATION", 64, 76], ["sporotrichosis", "OBSERVATION", 140, 154], ["FeLV provirus", "OBSERVATION", 244, 257]]], ["All cases that tested positive for FIV antibodies by ELISA tested also positive by FIV Western-blot (detecting also antibodies to FIV); moreover, all cats testing positive for FeLV antigen by ELISA tested also positive by FeLV real-time qPCR assay (detection of FeLV provirus).", [["FIV", "ORGANISM", 35, 38], ["FIV", "ORGANISM", 83, 86], ["FIV", "ORGANISM", 130, 133], ["cats", "ORGANISM", 150, 154], ["FeLV", "ORGANISM", 176, 180], ["FeLV", "ORGANISM", 222, 226], ["FeLV", "ORGANISM", 262, 266], ["FIV antibodies", "PROTEIN", 35, 49], ["antibodies", "PROTEIN", 116, 126], ["FeLV antigen", "PROTEIN", 176, 188], ["FIV", "SPECIES", 35, 38], ["FIV", "SPECIES", 83, 86], ["FIV", "SPECIES", 130, 133], ["FeLV", "SPECIES", 176, 180], ["All cases", "TEST", 0, 9], ["FIV antibodies", "TEST", 35, 49], ["ELISA", "TEST", 53, 58], ["all cats testing", "TEST", 146, 162], ["FeLV antigen", "TEST", 176, 188], ["ELISA", "TEST", 192, 197], ["qPCR assay", "TEST", 237, 247], ["FeLV provirus", "PROBLEM", 262, 275], ["FeLV provirus", "OBSERVATION", 262, 275]]], ["The use of ELISA alone resulted in one false negative case of FIV; the cat was FIV-ELISA negative but FIV Western blot positive and was regarded as FIV-infected.", [["FIV-infected", "DISEASE", 148, 160], ["FIV", "ORGANISM", 62, 65], ["cat", "ORGANISM", 71, 74], ["FIV", "ORGANISM", 79, 82], ["FIV", "ORGANISM", 102, 105], ["FIV", "ORGANISM", 148, 151], ["FIV", "SPECIES", 62, 65], ["cat", "SPECIES", 71, 74], ["FIV", "SPECIES", 79, 82], ["FIV", "SPECIES", 102, 105], ["FIV", "SPECIES", 148, 151], ["ELISA", "TREATMENT", 11, 16], ["the cat", "TEST", 67, 74], ["FIV-ELISA", "TEST", 79, 88], ["FIV Western blot", "TEST", 102, 118], ["FIV", "PROBLEM", 148, 151], ["infected", "OBSERVATION", 152, 160]]], ["One FeLV-exposed cat was provirus positive without detectable antigenemia.", [["antigenemia", "DISEASE", 62, 73], ["FeLV", "ORGANISM", 4, 8], ["cat", "ORGANISM", 17, 20], ["provirus", "ORGANISM", 25, 33], ["One FeLV", "TEST", 0, 8], ["provirus positive", "PROBLEM", 25, 42], ["detectable antigenemia", "PROBLEM", 51, 73], ["FeLV", "OBSERVATION", 4, 8], ["without", "UNCERTAINTY", 43, 50], ["detectable", "OBSERVATION_MODIFIER", 51, 61], ["antigenemia", "OBSERVATION", 62, 73]]], ["This cat was not considered in the statistical analyses concerning retrovirus infections since it was categorized as having regressive FeLV infection.Detection of co-infection with feline retroviruses ::: ResultsA poor general condition was observed in two out of three FIV positive cats and it was associated to FIV infection when compared to retrovirus-negative cats (pF < 0.01).", [["retrovirus infections", "DISEASE", 67, 88], ["FeLV infection", "DISEASE", 135, 149], ["co-infection", "DISEASE", 163, 175], ["feline retroviruses", "DISEASE", 181, 200], ["FIV infection", "DISEASE", 313, 326], ["cat", "ORGANISM", 5, 8], ["retrovirus", "ORGANISM", 67, 77], ["FeLV", "ORGANISM", 135, 139], ["feline", "ORGANISM", 181, 187], ["retroviruses", "ORGANISM", 188, 200], ["FIV", "ORGANISM", 270, 273], ["cats", "ORGANISM", 283, 287], ["FIV", "ORGANISM", 313, 316], ["retrovirus", "ORGANISM", 344, 354], ["cats", "ORGANISM", 364, 368], ["feline", "SPECIES", 181, 187], ["cats", "SPECIES", 283, 287], ["FeLV", "SPECIES", 135, 139], ["FIV", "SPECIES", 270, 273], ["FIV", "SPECIES", 313, 316], ["retrovirus infections", "PROBLEM", 67, 88], ["regressive FeLV infection", "PROBLEM", 124, 149], ["co-infection", "PROBLEM", 163, 175], ["FIV infection", "PROBLEM", 313, 326], ["retrovirus", "TEST", 344, 354], ["pF", "TEST", 370, 372], ["not considered", "UNCERTAINTY", 13, 27], ["retrovirus infections", "OBSERVATION", 67, 88], ["regressive", "OBSERVATION_MODIFIER", 124, 134], ["FeLV infection", "OBSERVATION", 135, 149], ["co-infection", "OBSERVATION", 163, 175], ["infection", "OBSERVATION", 317, 326]]], ["In cats with progressive FeLV infection, a poor general condition was observed in one out of five cats.", [["FeLV infection", "DISEASE", 25, 39], ["cats", "ORGANISM", 3, 7], ["FeLV", "ORGANISM", 25, 29], ["cats", "ORGANISM", 98, 102], ["cats", "SPECIES", 3, 7], ["cats", "SPECIES", 98, 102], ["FeLV", "SPECIES", 25, 29], ["progressive FeLV infection", "PROBLEM", 13, 39], ["a poor general condition", "PROBLEM", 41, 65], ["progressive", "OBSERVATION_MODIFIER", 13, 24], ["FeLV", "OBSERVATION_MODIFIER", 25, 29], ["infection", "OBSERVATION", 30, 39], ["poor", "OBSERVATION_MODIFIER", 43, 47]]], ["Among cats that tested negative for both retroviruses (n = 21), 95.2% were in a good general condition, 4.8% were in a fair general condition and none of them presented a poor general condition.", [["cats", "ORGANISM", 6, 10], ["retroviruses", "ORGANISM", 41, 53], ["cats", "SPECIES", 6, 10], ["Among cats", "TEST", 0, 10]]], ["Thus, all the cats that presented with poor general condition were co-infected with either FeLV (progressive infection) or FIV while none of the retrovirus-negative cats presented poor general condition (pF = 0.01).Assessment of cytokine profile ::: ResultsThe assessment of cytokine profile by means of quantitative RT-PCR was performed in all 30 animals.", [["FeLV", "DISEASE", 91, 95], ["infection", "DISEASE", 109, 118], ["cats", "ORGANISM", 14, 18], ["FeLV", "ORGANISM", 91, 95], ["FIV", "ORGANISM", 123, 126], ["retrovirus", "ORGANISM", 145, 155], ["cats", "ORGANISM", 165, 169], ["cytokine", "PROTEIN", 229, 237], ["cytokine", "PROTEIN", 275, 283], ["cats", "SPECIES", 14, 18], ["cats", "SPECIES", 165, 169], ["FIV", "SPECIES", 123, 126], ["poor general condition", "PROBLEM", 39, 61], ["FeLV (progressive infection)", "PROBLEM", 91, 119], ["FIV", "PROBLEM", 123, 126], ["the retrovirus", "TEST", 141, 155], ["pF", "TEST", 204, 206], ["The assessment of cytokine profile", "TEST", 257, 291], ["quantitative RT-PCR", "TEST", 304, 323], ["progressive", "OBSERVATION_MODIFIER", 97, 108], ["infection", "OBSERVATION", 109, 118]]], ["When comparing the 21 retrovirus-negative cats with sporotrichosis, no significant differences were found among cats in groups L1, L2 and L3 in cytokine transcription in any of the tested cytokines (S2 Table).", [["sporotrichosis", "DISEASE", 52, 66], ["retrovirus", "ORGANISM", 22, 32], ["cats", "ORGANISM", 42, 46], ["cats", "ORGANISM", 112, 116], ["cytokine", "PROTEIN", 144, 152], ["cytokines", "PROTEIN", 188, 197], ["S2", "PROTEIN", 199, 201], ["cats", "SPECIES", 42, 46], ["cats", "SPECIES", 112, 116], ["sporotrichosis", "PROBLEM", 52, 66], ["significant differences", "PROBLEM", 71, 94], ["cytokine transcription", "TREATMENT", 144, 166], ["sporotrichosis", "OBSERVATION", 52, 66], ["no", "UNCERTAINTY", 68, 70], ["significant", "OBSERVATION_MODIFIER", 71, 82], ["L1", "ANATOMY", 127, 129], ["L2", "ANATOMY", 131, 133], ["L3", "ANATOMY", 138, 140], ["cytokine transcription", "OBSERVATION", 144, 166]]], ["It was not possible to compare the cytokine levels among cats with no retrovirus co-infection according to their general condition due to the small number (n = 1) of animals in fair general condition.Assessment of cytokine profile ::: ResultsWhen analyzing the cytokine levels according to the retrovirus status, significantly higher IL-10 transcription levels were found in FIV-positive cats and in cats with progressive FeLV infection compared to retrovirus-negative cats (Fig 1).", [["retrovirus co-infection", "DISEASE", 70, 93], ["FeLV infection", "DISEASE", 422, 436], ["cats", "ORGANISM", 57, 61], ["retrovirus", "ORGANISM", 294, 304], ["IL-10", "GENE_OR_GENE_PRODUCT", 334, 339], ["FIV", "ORGANISM", 375, 378], ["cats", "ORGANISM", 388, 392], ["cats", "ORGANISM", 400, 404], ["FeLV", "ORGANISM", 422, 426], ["retrovirus", "ORGANISM", 449, 459], ["cats", "ORGANISM", 469, 473], ["cytokine", "PROTEIN", 35, 43], ["cytokine", "PROTEIN", 214, 222], ["cytokine", "PROTEIN", 261, 269], ["IL", "PROTEIN", 334, 336], ["cats", "SPECIES", 57, 61], ["cats", "SPECIES", 388, 392], ["cats", "SPECIES", 400, 404], ["cats", "SPECIES", 469, 473], ["FIV", "SPECIES", 375, 378], ["FeLV", "SPECIES", 422, 426], ["the cytokine levels", "TEST", 31, 50], ["retrovirus co-infection", "PROBLEM", 70, 93], ["the cytokine levels", "TEST", 257, 276], ["the retrovirus status", "TEST", 290, 311], ["transcription levels", "TEST", 340, 360], ["FIV", "TEST", 375, 378], ["progressive FeLV infection", "PROBLEM", 410, 436], ["retrovirus", "TEST", 449, 459], ["not possible", "UNCERTAINTY", 7, 19], ["no", "UNCERTAINTY", 67, 69], ["retrovirus co-infection", "OBSERVATION", 70, 93], ["small", "OBSERVATION_MODIFIER", 142, 147], ["positive cats", "OBSERVATION", 379, 392], ["progressive", "OBSERVATION_MODIFIER", 410, 421], ["FeLV infection", "OBSERVATION", 422, 436]]], ["Moreover, cats with progressive FeLV infection also had significantly lower IL-4 levels and FIV-infected cats had significantly lower IL-12 (Fig 1) when compared to retrovirus-negative cats.", [["FeLV infection", "DISEASE", 32, 46], ["cats", "ORGANISM", 10, 14], ["FeLV", "ORGANISM", 32, 36], ["IL-4", "GENE_OR_GENE_PRODUCT", 76, 80], ["FIV", "ORGANISM", 92, 95], ["cats", "ORGANISM", 105, 109], ["IL-12", "GENE_OR_GENE_PRODUCT", 134, 139], ["retrovirus", "ORGANISM", 165, 175], ["cats", "ORGANISM", 185, 189], ["IL", "PROTEIN", 76, 78], ["IL-12", "PROTEIN", 134, 139], ["cats", "SPECIES", 10, 14], ["cats", "SPECIES", 105, 109], ["cats", "SPECIES", 185, 189], ["FeLV", "SPECIES", 32, 36], ["FIV", "SPECIES", 92, 95], ["progressive FeLV infection", "PROBLEM", 20, 46], ["FIV", "TEST", 92, 95], ["infected cats", "PROBLEM", 96, 109], ["significantly lower IL", "PROBLEM", 114, 136], ["retrovirus", "TEST", 165, 175], ["progressive", "OBSERVATION_MODIFIER", 20, 31], ["FeLV infection", "OBSERVATION", 32, 46], ["infected", "OBSERVATION", 96, 104]]], ["No significant differences were found in IL-6, IFN-\u03b3 and TNF-\u03b1 transcription levels.Evaluation of lymphocytes subsets by flow cytometry ::: ResultsThis analysis was done in 29 out of the 30 cats in the study, since live cell recovery after thawing was too low to perform the assay in one FeLV-positive cat.", [["lymphocytes", "ANATOMY", 98, 109], ["cell", "ANATOMY", 220, 224], ["IL-6", "GENE_OR_GENE_PRODUCT", 41, 45], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 47, 52], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 57, 62], ["lymphocytes", "CELL", 98, 109], ["cats", "ORGANISM", 190, 194], ["cell", "CELL", 220, 224], ["FeLV", "ORGANISM", 288, 292], ["cat", "ORGANISM", 302, 305], ["IFN", "PROTEIN", 47, 50], ["TNF", "PROTEIN", 57, 60], ["lymphocytes subsets", "CELL_TYPE", 98, 117], ["significant differences", "PROBLEM", 3, 26], ["IL", "TEST", 41, 43], ["IFN", "TEST", 47, 50], ["TNF", "TEST", 57, 60], ["transcription levels", "TEST", 63, 83], ["Evaluation of lymphocytes subsets", "TEST", 84, 117], ["This analysis", "TEST", 147, 160], ["the study", "TEST", 198, 207], ["the assay", "TEST", 271, 280], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["lymphocytes subsets", "OBSERVATION", 98, 117]]], ["There were no significant differences in the lymphocyte subsets among the cats in groups L1, L2 and L3 (S3 Table).Evaluation of lymphocytes subsets by flow cytometry ::: ResultsWhen considering retroviral infections, FIV-positive cats with sporotrichosis had significantly lower CD4+ and higher CD8+ cells than retrovirus-negative cats with sporotrichosis (Fig 2).", [["lymphocyte", "ANATOMY", 45, 55], ["lymphocytes", "ANATOMY", 128, 139], ["CD4+", "ANATOMY", 279, 283], ["CD8+ cells", "ANATOMY", 295, 305], ["retroviral infections", "DISEASE", 194, 215], ["sporotrichosis", "DISEASE", 240, 254], ["sporotrichosis", "DISEASE", 341, 355], ["lymphocyte", "CELL", 45, 55], ["cats", "ORGANISM", 74, 78], ["lymphocytes", "CELL", 128, 139], ["retroviral", "ORGANISM", 194, 204], ["FIV", "ORGANISM", 217, 220], ["cats", "ORGANISM", 230, 234], ["CD4", "GENE_OR_GENE_PRODUCT", 279, 282], ["CD8", "GENE_OR_GENE_PRODUCT", 295, 298], ["retrovirus", "ORGANISM", 311, 321], ["cats", "ORGANISM", 331, 335], ["lymphocyte subsets", "CELL_TYPE", 45, 63], ["lymphocytes subsets", "CELL_TYPE", 128, 147], ["CD4", "PROTEIN", 279, 282], ["CD8", "PROTEIN", 295, 298], ["cats", "SPECIES", 74, 78], ["cats", "SPECIES", 230, 234], ["cats", "SPECIES", 331, 335], ["retroviral", "SPECIES", 194, 204], ["FIV", "SPECIES", 217, 220], ["significant differences", "PROBLEM", 14, 37], ["the lymphocyte subsets", "TEST", 41, 63], ["Evaluation of lymphocytes subsets", "TEST", 114, 147], ["retroviral infections", "PROBLEM", 194, 215], ["FIV", "TEST", 217, 220], ["sporotrichosis", "PROBLEM", 240, 254], ["significantly lower CD4", "PROBLEM", 259, 282], ["higher CD8+ cells", "PROBLEM", 288, 305], ["retrovirus", "TEST", 311, 321], ["sporotrichosis", "PROBLEM", 341, 355], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["differences", "OBSERVATION_MODIFIER", 26, 37], ["lymphocyte subsets", "OBSERVATION", 45, 63], ["groups", "ANATOMY_MODIFIER", 82, 88], ["L1", "ANATOMY_MODIFIER", 89, 91], ["L2", "ANATOMY_MODIFIER", 93, 95], ["L3", "ANATOMY_MODIFIER", 100, 102], ["lymphocytes subsets", "OBSERVATION", 128, 147], ["retroviral infections", "OBSERVATION", 194, 215], ["sporotrichosis", "OBSERVATION", 240, 254], ["higher CD8+ cells", "OBSERVATION", 288, 305]]], ["The inversion of CD4:CD8 ratio was present in two out of three FIV-positive cats, but was not observed in cats with progressive FeLV infection or in retrovirus-negative cats.", [["FeLV infection", "DISEASE", 128, 142], ["CD4", "GENE_OR_GENE_PRODUCT", 17, 20], ["CD8", "GENE_OR_GENE_PRODUCT", 21, 24], ["FIV", "ORGANISM", 63, 66], ["cats", "ORGANISM", 76, 80], ["cats", "ORGANISM", 106, 110], ["FeLV", "ORGANISM", 128, 132], ["retrovirus", "ORGANISM", 149, 159], ["cats", "ORGANISM", 169, 173], ["CD4", "PROTEIN", 17, 20], ["CD8", "PROTEIN", 21, 24], ["cats", "SPECIES", 106, 110], ["cats", "SPECIES", 169, 173], ["FIV", "SPECIES", 63, 66], ["FeLV", "SPECIES", 128, 132], ["CD8 ratio", "TEST", 21, 30], ["progressive FeLV infection", "PROBLEM", 116, 142], ["positive cats", "OBSERVATION", 67, 80], ["progressive", "OBSERVATION_MODIFIER", 116, 127], ["FeLV infection", "OBSERVATION", 128, 142]]], ["FIV-positive cats had significantly lower CD4:CD8 ratio compared to retrovirus-negative cats (PMWU = 0.006).", [["FIV", "ORGANISM", 0, 3], ["cats", "ORGANISM", 13, 17], ["CD4", "GENE_OR_GENE_PRODUCT", 42, 45], ["CD8", "GENE_OR_GENE_PRODUCT", 46, 49], ["retrovirus", "ORGANISM", 68, 78], ["cats", "ORGANISM", 88, 92], ["CD4", "PROTEIN", 42, 45], ["CD8", "PROTEIN", 46, 49], ["cats", "SPECIES", 13, 17], ["cats", "SPECIES", 88, 92], ["FIV", "SPECIES", 0, 3], ["FIV", "TEST", 0, 3], ["CD8 ratio", "TEST", 46, 55], ["retrovirus", "TEST", 68, 78], ["PMWU", "TEST", 94, 98]]], ["No significant differences were observed between FIV-positive and retrovirus-negative cats in CD5 (feline T cells) and CD21 (B cells).", [["CD5", "ANATOMY", 94, 97], ["T cells", "ANATOMY", 106, 113], ["CD21 (B cells", "ANATOMY", 119, 132], ["FIV", "ORGANISM", 49, 52], ["retrovirus", "ORGANISM", 66, 76], ["cats", "ORGANISM", 86, 90], ["CD5", "GENE_OR_GENE_PRODUCT", 94, 97], ["feline", "ORGANISM", 99, 105], ["T cells", "CELL", 106, 113], ["CD21", "GENE_OR_GENE_PRODUCT", 119, 123], ["B cells", "CELL", 125, 132], ["CD5 (feline T cells", "CELL_TYPE", 94, 113], ["CD21", "PROTEIN", 119, 123], ["B cells", "CELL_TYPE", 125, 132], ["significant differences", "PROBLEM", 3, 26], ["FIV", "TEST", 49, 52], ["retrovirus", "TEST", 66, 76], ["CD21", "TEST", 119, 123], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["retrovirus", "ANATOMY", 66, 76]]], ["Additionally, there was no significant difference in any of the tested lymphocytes subsets when cats with progressive FeLV infection were compared to retrovirus-negative cats.Clinical follow-up ::: ResultsBased on the data collected from the medical records, 24 cats were followed up until treatment outcome.", [["lymphocytes", "ANATOMY", 71, 82], ["FeLV infection", "DISEASE", 118, 132], ["lymphocytes", "CELL", 71, 82], ["cats", "ORGANISM", 96, 100], ["FeLV", "ORGANISM", 118, 122], ["retrovirus", "ORGANISM", 150, 160], ["cats", "ORGANISM", 170, 174], ["cats", "ORGANISM", 262, 266], ["lymphocytes subsets", "CELL_TYPE", 71, 90], ["cats", "SPECIES", 170, 174], ["FeLV", "SPECIES", 118, 122], ["significant difference", "PROBLEM", 27, 49], ["progressive FeLV infection", "PROBLEM", 106, 132], ["retrovirus", "TEST", 150, 160], ["no", "UNCERTAINTY", 24, 26], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["difference", "OBSERVATION", 39, 49], ["progressive", "OBSERVATION_MODIFIER", 106, 117], ["FeLV infection", "OBSERVATION", 118, 132]]], ["Four retrovirus-negative cats and one cat with progressive FeLV infection were lost to follow up.Clinical follow-up ::: ResultsAmong the remaining retrovirus-negative cats (n = 17), clinical cure was observed in sixteen and therapeutic failure in one cat.", [["FeLV infection", "DISEASE", 59, 73], ["retrovirus", "ORGANISM", 5, 15], ["cats", "ORGANISM", 25, 29], ["cat", "ORGANISM", 38, 41], ["FeLV", "ORGANISM", 59, 63], ["retrovirus", "ORGANISM", 147, 157], ["cats", "ORGANISM", 167, 171], ["cat", "ORGANISM", 251, 254], ["cats", "SPECIES", 25, 29], ["cat", "SPECIES", 38, 41], ["cats", "SPECIES", 167, 171], ["cat", "SPECIES", 251, 254], ["FeLV", "SPECIES", 59, 63], ["Four retrovirus", "TEST", 0, 15], ["progressive FeLV infection", "PROBLEM", 47, 73], ["therapeutic failure", "PROBLEM", 224, 243], ["retrovirus", "OBSERVATION", 5, 15], ["negative cats", "OBSERVATION", 16, 29], ["progressive", "OBSERVATION_MODIFIER", 47, 58], ["FeLV", "OBSERVATION_MODIFIER", 59, 63], ["infection", "OBSERVATION", 64, 73], ["retrovirus", "ANATOMY", 147, 157], ["therapeutic", "OBSERVATION_MODIFIER", 224, 235], ["failure", "OBSERVATION", 236, 243]]], ["Among the remaining cats with progressive FeLV infection (n = 4), three were treated with ITZ+KI and all of them were cured.", [["FeLV infection", "DISEASE", 42, 56], ["ITZ", "CHEMICAL", 90, 93], ["ITZ", "CHEMICAL", 90, 93], ["cats", "ORGANISM", 20, 24], ["FeLV", "ORGANISM", 42, 46], ["ITZ", "SIMPLE_CHEMICAL", 90, 93], ["cats", "SPECIES", 20, 24], ["progressive FeLV infection", "PROBLEM", 30, 56], ["ITZ+KI", "TREATMENT", 90, 96], ["progressive", "OBSERVATION_MODIFIER", 30, 41], ["FeLV infection", "OBSERVATION", 42, 56]]], ["All FIV-positive cats (n = 3) were treated with ITZ alone and two of them were cured.", [["ITZ", "CHEMICAL", 48, 51], ["ITZ", "CHEMICAL", 48, 51], ["FIV", "ORGANISM", 4, 7], ["cats", "ORGANISM", 17, 21], ["ITZ", "SIMPLE_CHEMICAL", 48, 51], ["cats", "SPECIES", 17, 21], ["All FIV", "TEST", 0, 7], ["ITZ", "TREATMENT", 48, 51], ["FIV", "OBSERVATION", 4, 7], ["positive cats", "OBSERVATION", 8, 21]]], ["The cure rates were not related to the treatment protocol or to the retrovirus status.", [["retrovirus", "ORGANISM", 68, 78], ["the treatment protocol", "TREATMENT", 35, 57]]], ["The S4 Table shows therapeutic aspects of the cats from this study according to their retrovirus status.Clinical follow-up ::: ResultsThe treatment length was not statistically different between the groups, regardless of therapeutic protocol or retrovirus status.", [["cats", "ORGANISM", 46, 50], ["retrovirus", "ORGANISM", 86, 96], ["retrovirus", "ORGANISM", 245, 255], ["this study", "TEST", 56, 66], ["therapeutic protocol", "TREATMENT", 221, 241], ["retrovirus status", "PROBLEM", 245, 262], ["length", "OBSERVATION_MODIFIER", 148, 154]]], ["Among cats that were clinically cured, the overall median treatment length was 12 weeks: 12 weeks in retrovirus-negative cats, 9.5 weeks in cats with progressive FeLV infection and 20.5 weeks in FIV-positive cats.", [["FeLV infection", "DISEASE", 162, 176], ["cats", "ORGANISM", 6, 10], ["retrovirus", "ORGANISM", 101, 111], ["cats", "ORGANISM", 121, 125], ["cats", "ORGANISM", 140, 144], ["FeLV", "ORGANISM", 162, 166], ["FIV", "ORGANISM", 195, 198], ["cats", "ORGANISM", 208, 212], ["cats", "SPECIES", 6, 10], ["cats", "SPECIES", 121, 125], ["cats", "SPECIES", 140, 144], ["cats", "SPECIES", 208, 212], ["FeLV", "SPECIES", 162, 166], ["FIV", "SPECIES", 195, 198], ["retrovirus", "TEST", 101, 111], ["progressive FeLV infection", "PROBLEM", 150, 176], ["progressive", "OBSERVATION_MODIFIER", 150, 161], ["FeLV infection", "OBSERVATION", 162, 176]]], ["The median treatment length in retrovirus-negative cats was higher in the therapeutic protocol using ITZ alone (median = 12 weeks) when compared to ITZ + KI (median = 9 weeks).", [["ITZ", "CHEMICAL", 101, 104], ["ITZ", "CHEMICAL", 148, 151], ["ITZ", "CHEMICAL", 101, 104], ["retrovirus", "ORGANISM", 31, 41], ["cats", "ORGANISM", 51, 55], ["ITZ", "SIMPLE_CHEMICAL", 101, 104], ["cats", "SPECIES", 51, 55], ["The median treatment length in retrovirus", "TREATMENT", 0, 41], ["ITZ", "TEST", 148, 151], ["retrovirus", "ANATOMY", 31, 41]]], ["In cats with progressive FeLV infection, the treatment length was also higher in cats treated with ITZ alone (median = 13 weeks) in comparison to those treated with ITZ+KI (median = 9 weeks).DiscussionIn this study, 30 cats with sporotrichosis were investigated for feline retrovirus co-infection and immunological aspects based on cytokine expression profiles of peripheral blood mononuclear cells.", [["peripheral blood mononuclear cells", "ANATOMY", 364, 398], ["FeLV infection", "DISEASE", 25, 39], ["ITZ", "CHEMICAL", 99, 102], ["ITZ", "CHEMICAL", 165, 168], ["sporotrichosis", "DISEASE", 229, 243], ["feline retrovirus co-infection", "DISEASE", 266, 296], ["ITZ", "CHEMICAL", 99, 102], ["ITZ", "CHEMICAL", 165, 168], ["cats", "ORGANISM", 3, 7], ["FeLV", "ORGANISM", 25, 29], ["cats", "ORGANISM", 81, 85], ["ITZ", "SIMPLE_CHEMICAL", 99, 102], ["ITZ", "SIMPLE_CHEMICAL", 165, 168], ["cats", "ORGANISM", 219, 223], ["feline retrovirus", "ORGANISM", 266, 283], ["peripheral blood mononuclear cells", "CELL", 364, 398], ["cytokine", "PROTEIN", 332, 340], ["peripheral blood mononuclear cells", "CELL_TYPE", 364, 398], ["cats", "SPECIES", 3, 7], ["cats", "SPECIES", 219, 223], ["feline", "SPECIES", 266, 272], ["FeLV", "SPECIES", 25, 29], ["feline retrovirus", "SPECIES", 266, 283], ["progressive FeLV infection", "PROBLEM", 13, 39], ["ITZ", "TREATMENT", 99, 102], ["this study", "TEST", 204, 214], ["sporotrichosis", "PROBLEM", 229, 243], ["feline retrovirus co-infection", "PROBLEM", 266, 296], ["cytokine expression", "TEST", 332, 351], ["peripheral blood mononuclear cells", "PROBLEM", 364, 398], ["progressive", "OBSERVATION_MODIFIER", 13, 24], ["FeLV infection", "OBSERVATION", 25, 39], ["peripheral", "ANATOMY_MODIFIER", 364, 374], ["blood", "ANATOMY", 375, 380], ["mononuclear cells", "OBSERVATION", 381, 398]]], ["To the best our knowledge, this is the first study to assess cytokine transcription in the blood of cats with sporotrichosis.DiscussionPrevious studies have not established a correlation between severe sporotrichosis and feline retrovirus co-infections [10,12,24] likely explained by the use of clinical and therapeutic aspects in case definitions.", [["blood", "ANATOMY", 91, 96], ["sporotrichosis", "DISEASE", 110, 124], ["sporotrichosis", "DISEASE", 202, 216], ["feline retrovirus co-infections", "DISEASE", 221, 252], ["blood", "ORGANISM_SUBSTANCE", 91, 96], ["cats", "ORGANISM", 100, 104], ["feline retrovirus", "ORGANISM", 221, 238], ["cytokine", "PROTEIN", 61, 69], ["cats", "SPECIES", 100, 104], ["the first study", "TEST", 35, 50], ["cytokine transcription", "PROBLEM", 61, 83], ["sporotrichosis", "PROBLEM", 110, 124], ["DiscussionPrevious studies", "TEST", 125, 151], ["severe sporotrichosis", "PROBLEM", 195, 216], ["feline retrovirus co-infections", "PROBLEM", 221, 252], ["sporotrichosis", "OBSERVATION", 110, 124], ["severe", "OBSERVATION_MODIFIER", 195, 201], ["sporotrichosis", "OBSERVATION", 202, 216]]], ["Recently, Miranda et al. [24] described the leukocyte profile in blood of cats with sporotrichosis, but because there were no FIV co-infected cats and the number of FeLV co-infected cats was limited, no statistical correlation with leukocyte profile could be established.", [["leukocyte", "ANATOMY", 44, 53], ["blood", "ANATOMY", 65, 70], ["leukocyte", "ANATOMY", 232, 241], ["sporotrichosis", "DISEASE", 84, 98], ["FIV co-infected", "DISEASE", 126, 141], ["FeLV co-infected", "DISEASE", 165, 181], ["leukocyte", "CELL", 44, 53], ["blood", "ORGANISM_SUBSTANCE", 65, 70], ["cats", "ORGANISM", 74, 78], ["FIV", "ORGANISM", 126, 129], ["cats", "ORGANISM", 142, 146], ["FeLV", "ORGANISM", 165, 169], ["cats", "ORGANISM", 182, 186], ["leukocyte", "CELL", 232, 241], ["cats", "SPECIES", 74, 78], ["cats", "SPECIES", 142, 146], ["cats", "SPECIES", 182, 186], ["FIV", "SPECIES", 126, 129], ["the leukocyte profile", "TEST", 40, 61], ["sporotrichosis", "PROBLEM", 84, 98], ["FIV co", "TEST", 126, 132], ["infected cats", "PROBLEM", 133, 146], ["FeLV co", "TEST", 165, 172], ["leukocyte profile", "TEST", 232, 249], ["sporotrichosis", "OBSERVATION", 84, 98]]], ["In the present study, there was also a low incidence of FeLV and FIV infected cats; this may have reduced the statistical power for detecting significant differences potentially caused by retrovirus infections.DiscussionThe low incidence of retrovirus infections in most study populations of cats and the lack of confirmation of positive test results in other studies using gold standard methods have led to an increase in the likelihood of false positive cases identified in previous reports (low positive predictive value of the screening results).DiscussionIn the current study, for diagnosing FIV status in cats, the Western blot technique, which is considered the gold standard method for detection of FIV antibodies in areas without vaccination [17], was applied.", [["FeLV and FIV infected", "DISEASE", 56, 77], ["retrovirus infections", "DISEASE", 188, 209], ["retrovirus infections", "DISEASE", 241, 262], ["FeLV", "ORGANISM", 56, 60], ["FIV", "ORGANISM", 65, 68], ["cats", "ORGANISM", 78, 82], ["retrovirus", "ORGANISM", 188, 198], ["retrovirus", "ORGANISM", 241, 251], ["cats", "ORGANISM", 292, 296], ["FIV", "ORGANISM", 597, 600], ["cats", "ORGANISM", 611, 615], ["FIV", "ORGANISM", 707, 710], ["FIV antibodies", "PROTEIN", 707, 721], ["cats", "SPECIES", 78, 82], ["cats", "SPECIES", 292, 296], ["cats", "SPECIES", 611, 615], ["FeLV", "SPECIES", 56, 60], ["FIV", "SPECIES", 65, 68], ["retrovirus", "SPECIES", 188, 198], ["FIV", "SPECIES", 597, 600], ["FIV", "SPECIES", 707, 710], ["the present study", "TEST", 3, 20], ["a low incidence of FeLV", "PROBLEM", 37, 60], ["FIV infected cats", "PROBLEM", 65, 82], ["retrovirus infections", "PROBLEM", 188, 209], ["retrovirus infections", "PROBLEM", 241, 262], ["positive test", "PROBLEM", 329, 342], ["other studies", "TEST", 354, 367], ["false positive cases", "PROBLEM", 441, 461], ["the current study", "TEST", 563, 580], ["FIV antibodies", "PROBLEM", 707, 721], ["low incidence", "OBSERVATION_MODIFIER", 39, 52], ["FeLV", "OBSERVATION", 56, 60], ["FIV", "OBSERVATION_MODIFIER", 65, 68], ["infected cats", "OBSERVATION", 69, 82], ["retrovirus infections", "OBSERVATION", 188, 209], ["low incidence", "OBSERVATION_MODIFIER", 224, 237], ["retrovirus infections", "OBSERVATION", 241, 262], ["increase", "OBSERVATION_MODIFIER", 411, 419], ["false positive cases", "OBSERVATION", 441, 461], ["FIV antibodies", "OBSERVATION", 707, 721]]], ["The occurrence of false negative cases with the use of ELISA has been previously reported in Calzolari et al. [25], when four out of 194 cats tested negative for the FIV TM ELISA and positive in the Western blot.", [["cats", "ORGANISM", 137, 141], ["FIV", "ORGANISM", 166, 169], ["FIV", "SPECIES", 166, 169], ["false negative cases", "PROBLEM", 18, 38], ["ELISA", "TEST", 55, 60], ["the FIV TM ELISA", "TEST", 162, 178], ["false negative cases", "OBSERVATION", 18, 38]]], ["As previously observed, that lack of reactivity with the recombinant TM of some FIV infected domestic cats may indeed be due to infection with a FIV distinct from that the TM antigen utilized in the ELISA [25].DiscussionReal-time PCR was employed to detected and quantify FeLV provirus in addition to FeLV p27 antigen detection by ELISA.", [["FIV infected", "DISEASE", 80, 92], ["infection", "DISEASE", 128, 137], ["TM", "GENE_OR_GENE_PRODUCT", 69, 71], ["FIV", "ORGANISM", 80, 83], ["cats", "ORGANISM", 102, 106], ["FIV", "ORGANISM", 145, 148], ["TM antigen", "GENE_OR_GENE_PRODUCT", 172, 182], ["FeLV", "ORGANISM", 272, 276], ["FeLV", "ORGANISM", 301, 305], ["p27 antigen", "GENE_OR_GENE_PRODUCT", 306, 317], ["recombinant TM", "PROTEIN", 57, 71], ["TM antigen", "PROTEIN", 172, 182], ["FeLV p27 antigen", "PROTEIN", 301, 317], ["cats", "SPECIES", 102, 106], ["FIV", "SPECIES", 80, 83], ["FIV", "SPECIES", 145, 148], ["FeLV provirus", "SPECIES", 272, 285], ["FeLV", "SPECIES", 301, 305], ["the recombinant TM", "TREATMENT", 53, 71], ["some FIV infected domestic cats", "PROBLEM", 75, 106], ["infection", "PROBLEM", 128, 137], ["a FIV", "PROBLEM", 143, 148], ["the TM antigen", "TEST", 168, 182], ["DiscussionReal-time PCR", "TEST", 210, 233], ["FeLV provirus", "PROBLEM", 272, 285], ["FeLV p27 antigen detection", "TEST", 301, 327], ["FIV", "OBSERVATION_MODIFIER", 80, 83], ["infected", "OBSERVATION", 84, 92], ["infection", "OBSERVATION", 128, 137], ["FeLV provirus", "OBSERVATION", 272, 285]]], ["PCR is a more sensitive measure for FeLV exposure than antigen detection.", [["FeLV", "ORGANISM", 36, 40], ["FeLV", "SPECIES", 36, 40], ["PCR", "TEST", 0, 3], ["FeLV exposure", "PROBLEM", 36, 49], ["antigen detection", "TEST", 55, 72]]], ["FeLV provirus-positive/antigen-negative cats have been described as having regressive FeLV infection [22].", [["FeLV infection", "DISEASE", 86, 100], ["FeLV", "ORGANISM", 0, 4], ["antigen", "GENE_OR_GENE_PRODUCT", 23, 30], ["cats", "ORGANISM", 40, 44], ["FeLV", "ORGANISM", 86, 90], ["cats", "SPECIES", 40, 44], ["FeLV provirus", "TEST", 0, 13], ["antigen", "TEST", 23, 30], ["regressive FeLV infection", "PROBLEM", 75, 100], ["regressive", "OBSERVATION_MODIFIER", 75, 85], ["FeLV infection", "OBSERVATION", 86, 100]]], ["In the current study, only one cat had a regressive FeLV-infection.", [["FeLV-infection", "DISEASE", 52, 66], ["cat", "ORGANISM", 31, 34], ["FeLV", "ORGANISM", 52, 56], ["the current study", "TEST", 3, 20], ["a regressive FeLV-infection", "PROBLEM", 39, 66], ["regressive", "OBSERVATION_MODIFIER", 41, 51], ["FeLV", "OBSERVATION", 52, 56], ["infection", "OBSERVATION", 57, 66]]], ["Because of the small number (n = 1) of FeLV regressive infection cases, this cat was not included in the statistical analysis as a separate group.", [["FeLV regressive infection", "DISEASE", 39, 64], ["FeLV", "ORGANISM", 39, 43], ["cat", "ORGANISM", 77, 80], ["the small number (n = 1) of FeLV regressive infection cases", "PROBLEM", 11, 70], ["the statistical analysis", "TEST", 101, 125], ["small", "OBSERVATION_MODIFIER", 15, 20], ["FeLV", "OBSERVATION", 39, 43], ["regressive", "OBSERVATION_MODIFIER", 44, 54], ["infection", "OBSERVATION", 55, 64]]], ["Moreover, it was also not included with the cats with progressive FeLV infection cats, since the cat was not expected to present major immunological changes at this stage.", [["FeLV infection", "DISEASE", 66, 80], ["cats", "ORGANISM", 44, 48], ["FeLV", "ORGANISM", 66, 70], ["cats", "ORGANISM", 81, 85], ["cat", "ORGANISM", 97, 100], ["cats", "SPECIES", 81, 85], ["progressive FeLV infection cats", "PROBLEM", 54, 85], ["progressive", "OBSERVATION_MODIFIER", 54, 65], ["FeLV", "OBSERVATION_MODIFIER", 66, 70], ["infection", "OBSERVATION", 71, 80]]], ["However, since this cat is latently infected, a subsequent reactivation of the viremia cannot be ruled out, especially in cases of comorbidities, immunosuppression or chronic stress [18].", [["latently infected", "DISEASE", 27, 44], ["viremia", "DISEASE", 79, 86], ["cat", "ORGANISM", 20, 23], ["cat", "SPECIES", 20, 23], ["latently infected", "PROBLEM", 27, 44], ["the viremia", "PROBLEM", 75, 86], ["comorbidities", "PROBLEM", 131, 144], ["immunosuppression", "TREATMENT", 146, 163], ["chronic stress", "PROBLEM", 167, 181], ["latently", "OBSERVATION_MODIFIER", 27, 35], ["infected", "OBSERVATION", 36, 44], ["viremia", "OBSERVATION", 79, 86], ["chronic", "OBSERVATION_MODIFIER", 167, 174]]], ["Cats with regressive FeLV infection should be further monitored for reappearance of FeLV antigen; if they become positive again, they need to be considered as potential sources of FeLV infection and will most probably show immunological changes [18].DiscussionStudies regarding immune response in human sporotrichosis are scarce; however the correlation between severe sporotrichosis and co-infection with HIV has been established [33\u201335].", [["FeLV infection", "DISEASE", 21, 35], ["FeLV infection", "DISEASE", 180, 194], ["sporotrichosis", "DISEASE", 303, 317], ["sporotrichosis", "DISEASE", 369, 383], ["co-infection", "DISEASE", 388, 400], ["HIV", "DISEASE", 406, 409], ["FeLV", "ORGANISM", 21, 25], ["FeLV", "ORGANISM", 84, 88], ["FeLV", "ORGANISM", 180, 184], ["human", "ORGANISM", 297, 302], ["sporotrichosis", "CANCER", 303, 317], ["FeLV antigen", "PROTEIN", 84, 96], ["human", "SPECIES", 297, 302], ["HIV", "SPECIES", 406, 409], ["FeLV", "SPECIES", 84, 88], ["FeLV", "SPECIES", 180, 184], ["human", "SPECIES", 297, 302], ["HIV", "SPECIES", 406, 409], ["regressive FeLV infection", "PROBLEM", 10, 35], ["FeLV antigen", "PROBLEM", 84, 96], ["positive", "PROBLEM", 113, 121], ["FeLV infection", "PROBLEM", 180, 194], ["immunological changes", "PROBLEM", 223, 244], ["immune response in human sporotrichosis", "PROBLEM", 278, 317], ["severe sporotrichosis", "PROBLEM", 362, 383], ["co-infection", "PROBLEM", 388, 400], ["HIV", "PROBLEM", 406, 409], ["regressive", "OBSERVATION_MODIFIER", 10, 20], ["FeLV infection", "OBSERVATION", 21, 35], ["FeLV infection", "OBSERVATION", 180, 194], ["severe", "OBSERVATION_MODIFIER", 362, 368], ["sporotrichosis", "OBSERVATION", 369, 383], ["co-infection", "OBSERVATION", 388, 400]]], ["The clinical and pathological presentation of sporotrichosis in HIV-positive patients [34] is often comparable to that seen in cats with sporotrichosis, whether co-infected with retrovirus or not [3,36].", [["sporotrichosis", "DISEASE", 46, 60], ["HIV-positive", "DISEASE", 64, 76], ["sporotrichosis", "DISEASE", 137, 151], ["sporotrichosis", "CANCER", 46, 60], ["HIV", "ORGANISM", 64, 67], ["patients", "ORGANISM", 77, 85], ["cats", "ORGANISM", 127, 131], ["retrovirus", "ORGANISM", 178, 188], ["HIV", "SPECIES", 64, 67], ["patients", "SPECIES", 77, 85], ["cats", "SPECIES", 127, 131], ["HIV", "SPECIES", 64, 67], ["sporotrichosis", "PROBLEM", 46, 60], ["sporotrichosis", "PROBLEM", 137, 151], ["retrovirus", "PROBLEM", 178, 188], ["sporotrichosis", "OBSERVATION", 46, 60], ["sporotrichosis", "OBSERVATION", 137, 151]]], ["This study shows a significant association between the poor general condition in cats with sporotrichosis and co-infection with FIV or with feline retroviruses in general, suggesting that retrovirus co-infections may influence the clinical presentation in cats with sporotrichosis.DiscussionThe reduced transcription levels of IL-12 in FIV co-infected cats when compared to retrovirus-negative cats in this study suggested alteration and perhaps compromise of the Th1 cellular immune response in these cats.", [["cellular", "ANATOMY", 468, 476], ["sporotrichosis", "DISEASE", 91, 105], ["co-infection", "DISEASE", 110, 122], ["feline retroviruses", "DISEASE", 140, 159], ["retrovirus co-infections", "DISEASE", 188, 212], ["sporotrichosis", "DISEASE", 266, 280], ["cats", "ORGANISM", 81, 85], ["FIV", "ORGANISM", 128, 131], ["feline retroviruses", "ORGANISM", 140, 159], ["retrovirus", "ORGANISM", 188, 198], ["cats", "ORGANISM", 256, 260], ["IL-12", "GENE_OR_GENE_PRODUCT", 327, 332], ["FIV", "ORGANISM", 336, 339], ["cats", "ORGANISM", 352, 356], ["retrovirus", "ORGANISM", 374, 384], ["cats", "ORGANISM", 394, 398], ["Th1 cellular", "CELL", 464, 476], ["cats", "ORGANISM", 502, 506], ["IL-12", "PROTEIN", 327, 332], ["cats", "SPECIES", 81, 85], ["cats", "SPECIES", 256, 260], ["cats", "SPECIES", 352, 356], ["cats", "SPECIES", 502, 506], ["FIV", "SPECIES", 128, 131], ["FIV", "SPECIES", 336, 339], ["This study", "TEST", 0, 10], ["the poor general condition", "PROBLEM", 51, 77], ["sporotrichosis", "PROBLEM", 91, 105], ["co-infection", "PROBLEM", 110, 122], ["FIV", "TREATMENT", 128, 131], ["feline retroviruses", "PROBLEM", 140, 159], ["retrovirus co-infections", "PROBLEM", 188, 212], ["sporotrichosis", "PROBLEM", 266, 280], ["IL", "TEST", 327, 329], ["FIV co", "TEST", 336, 342], ["infected cats", "PROBLEM", 343, 356], ["retrovirus", "TEST", 374, 384], ["this study", "TEST", 402, 412], ["significant", "OBSERVATION_MODIFIER", 19, 30], ["sporotrichosis", "OBSERVATION", 91, 105], ["co-infection", "OBSERVATION", 110, 122], ["retrovirus co-infections", "OBSERVATION", 188, 212], ["sporotrichosis", "OBSERVATION", 266, 280], ["Th1 cellular immune response", "OBSERVATION", 464, 492]]], ["IL-10 was significantly increased in cats with sporotrichosis co-infected with either FIV or FeLV, leading to a potential immunosuppressive condition, since this cytokine is widely involved with immunoregulatory effects [37].", [["sporotrichosis", "DISEASE", 47, 61], ["IL-10", "GENE_OR_GENE_PRODUCT", 0, 5], ["cats", "ORGANISM", 37, 41], ["FIV", "ORGANISM", 86, 89], ["FeLV", "ORGANISM", 93, 97], ["IL-10", "PROTEIN", 0, 5], ["cytokine", "PROTEIN", 162, 170], ["immunoregulatory", "PROTEIN", 195, 211], ["cats", "SPECIES", 37, 41], ["FIV", "SPECIES", 86, 89], ["FeLV", "SPECIES", 93, 97], ["IL", "TEST", 0, 2], ["sporotrichosis", "PROBLEM", 47, 61], ["FeLV", "PROBLEM", 93, 97], ["a potential immunosuppressive condition", "PROBLEM", 110, 149], ["increased", "OBSERVATION_MODIFIER", 24, 33], ["sporotrichosis", "OBSERVATION", 47, 61]]], ["IL-10 is also reported to suppress cellular immune response by inhibiting cytokine production by Th1 cells and activated macrophages [38\u201339].DiscussionFIV-positive cats are susceptible to some intracellular pathogens, including Toxoplasma gondii and Listeria monocytogenes, even in early stages of the retrovirus infection, when clinical signs are not yet observed, due to increasing levels of IL-10 and decreased levels of IL-12 [40\u201342], such as described in FIV-infected cats in the present study.", [["cellular", "ANATOMY", 35, 43], ["Th1 cells", "ANATOMY", 97, 106], ["macrophages", "ANATOMY", 121, 132], ["intracellular", "ANATOMY", 193, 206], ["Toxoplasma gondii", "DISEASE", 228, 245], ["retrovirus infection", "DISEASE", 302, 322], ["FIV-infected", "DISEASE", 460, 472], ["IL-10", "GENE_OR_GENE_PRODUCT", 0, 5], ["cellular", "CELL", 35, 43], ["Th1 cells", "CELL", 97, 106], ["macrophages", "CELL", 121, 132], ["cats", "ORGANISM", 164, 168], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 193, 206], ["Toxoplasma gondii", "ORGANISM", 228, 245], ["Listeria monocytogenes", "ORGANISM", 250, 272], ["retrovirus", "ORGANISM", 302, 312], ["IL-10", "GENE_OR_GENE_PRODUCT", 394, 399], ["IL-12", "GENE_OR_GENE_PRODUCT", 424, 429], ["FIV", "ORGANISM", 460, 463], ["cats", "ORGANISM", 473, 477], ["IL-10", "PROTEIN", 0, 5], ["cytokine", "PROTEIN", 74, 82], ["Th1 cells", "CELL_TYPE", 97, 106], ["activated macrophages", "CELL_TYPE", 111, 132], ["IL-10", "PROTEIN", 394, 399], ["IL", "PROTEIN", 424, 426], ["cats", "SPECIES", 164, 168], ["Toxoplasma gondii", "SPECIES", 228, 245], ["Listeria monocytogenes", "SPECIES", 250, 272], ["cats", "SPECIES", 473, 477], ["Toxoplasma gondii", "SPECIES", 228, 245], ["Listeria monocytogenes", "SPECIES", 250, 272], ["retrovirus", "SPECIES", 302, 312], ["FIV", "SPECIES", 460, 463], ["cytokine production", "TEST", 74, 93], ["activated macrophages", "TEST", 111, 132], ["positive cats", "PROBLEM", 155, 168], ["some intracellular pathogens", "PROBLEM", 188, 216], ["Toxoplasma gondii", "PROBLEM", 228, 245], ["Listeria monocytogenes", "PROBLEM", 250, 272], ["the retrovirus infection", "PROBLEM", 298, 322], ["clinical signs", "TEST", 329, 343], ["increasing levels of IL", "PROBLEM", 373, 396], ["IL", "TEST", 424, 426], ["the present study", "TEST", 481, 498], ["pathogens", "OBSERVATION", 207, 216], ["Listeria monocytogenes", "OBSERVATION", 250, 272], ["early stages", "OBSERVATION_MODIFIER", 282, 294], ["retrovirus infection", "OBSERVATION", 302, 322], ["infected", "OBSERVATION", 464, 472]]], ["The balance between the anti-inflammatory IL-10 and pro-inflammatory cytokines, such as IL-12, seems to be a key factor for an adequate inflammation in fungal infection, since IL-10 might be required for limiting high levels of inflammation and the consequent host damage [43].", [["inflammation", "DISEASE", 136, 148], ["fungal infection", "DISEASE", 152, 168], ["inflammation", "DISEASE", 228, 240], ["IL-10", "GENE_OR_GENE_PRODUCT", 42, 47], ["IL-12", "GENE_OR_GENE_PRODUCT", 88, 93], ["IL-10", "GENE_OR_GENE_PRODUCT", 176, 181], ["anti-inflammatory IL-10", "PROTEIN", 24, 47], ["pro-inflammatory cytokines", "PROTEIN", 52, 78], ["IL-12", "PROTEIN", 88, 93], ["IL", "PROTEIN", 176, 178], ["the anti-inflammatory IL", "TREATMENT", 20, 44], ["pro-inflammatory cytokines", "TREATMENT", 52, 78], ["an adequate inflammation", "PROBLEM", 124, 148], ["fungal infection", "PROBLEM", 152, 168], ["IL", "TREATMENT", 176, 178], ["inflammation", "PROBLEM", 228, 240], ["the consequent host damage", "PROBLEM", 245, 271], ["balance", "OBSERVATION", 4, 11], ["adequate", "OBSERVATION_MODIFIER", 127, 135], ["inflammation", "OBSERVATION", 136, 148], ["fungal", "OBSERVATION_MODIFIER", 152, 158], ["infection", "OBSERVATION", 159, 168], ["inflammation", "OBSERVATION", 228, 240]]], ["In experimental murine sporotrichosis, IL-10 is involved with impairment of fungicidal activity of macrophage, as well as with unresponsiveness of T-cells [44].", [["macrophage", "ANATOMY", 99, 109], ["T-cells", "ANATOMY", 147, 154], ["sporotrichosis", "DISEASE", 23, 37], ["murine", "ORGANISM", 16, 22], ["IL-10", "GENE_OR_GENE_PRODUCT", 39, 44], ["macrophage", "CELL", 99, 109], ["T-cells", "CELL", 147, 154], ["IL-10", "PROTEIN", 39, 44], ["macrophage", "CELL_TYPE", 99, 109], ["T-cells", "CELL_TYPE", 147, 154], ["murine", "SPECIES", 16, 22], ["experimental murine sporotrichosis", "PROBLEM", 3, 37], ["fungicidal activity of macrophage", "PROBLEM", 76, 109], ["unresponsiveness of T-cells", "PROBLEM", 127, 154], ["murine", "OBSERVATION_MODIFIER", 16, 22], ["sporotrichosis", "OBSERVATION", 23, 37], ["fungicidal activity", "OBSERVATION", 76, 95]]], ["In humans, high levels of IL-10 production in response to some viral infections plays a role in viral persistence, by suppressing immune functions [45\u201347].", [["viral infections", "DISEASE", 63, 79], ["humans", "ORGANISM", 3, 9], ["IL-10", "GENE_OR_GENE_PRODUCT", 26, 31], ["IL", "PROTEIN", 26, 28], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["some viral infections", "PROBLEM", 58, 79], ["high levels", "OBSERVATION_MODIFIER", 11, 22], ["infections", "OBSERVATION", 69, 79]]], ["The high levels of IL-10 in FIV-positive cats in this study may be related to a high percentage of regulatory T (Treg) cells, since these cells can be directly activated by FIV and are normally increased in infected animals [48].", [["regulatory T (Treg) cells", "ANATOMY", 99, 124], ["cells", "ANATOMY", 138, 143], ["IL-10", "GENE_OR_GENE_PRODUCT", 19, 24], ["FIV", "ORGANISM", 28, 31], ["cats", "ORGANISM", 41, 45], ["regulatory T (Treg) cells", "CELL", 99, 124], ["cells", "CELL", 138, 143], ["FIV", "ORGANISM", 173, 176], ["IL-10", "PROTEIN", 19, 24], ["regulatory T (Treg) cells", "CELL_TYPE", 99, 124], ["FIV", "SPECIES", 28, 31], ["FIV", "SPECIES", 173, 176], ["IL", "TEST", 19, 21], ["this study", "TEST", 49, 59], ["these cells", "PROBLEM", 132, 143], ["high", "OBSERVATION_MODIFIER", 4, 8], ["normally", "OBSERVATION_MODIFIER", 185, 193], ["increased", "OBSERVATION_MODIFIER", 194, 203], ["infected", "OBSERVATION_MODIFIER", 207, 215]]], ["Regulatory T cells were not measured in this study.DiscussionFerreira et al. [49] have recently shown that Th17 immunity is required for the optimal fungal clearance in the murine model of systemic sporotrichosis.", [["T cells", "ANATOMY", 11, 18], ["sporotrichosis", "DISEASE", 198, 212], ["T cells", "CELL", 11, 18], ["Th17", "GENE_OR_GENE_PRODUCT", 107, 111], ["murine", "ORGANISM", 173, 179], ["Regulatory T cells", "CELL_TYPE", 0, 18], ["murine", "SPECIES", 173, 179], ["Regulatory T cells", "TEST", 0, 18], ["this study", "TEST", 40, 50], ["Th17 immunity", "TREATMENT", 107, 120], ["the optimal fungal clearance", "TEST", 137, 165], ["systemic sporotrichosis", "PROBLEM", 189, 212], ["T cells", "OBSERVATION", 11, 18], ["systemic", "OBSERVATION_MODIFIER", 189, 197], ["sporotrichosis", "OBSERVATION", 198, 212]]], ["Although the role of Th17 arm is still unknown in feline sporotrichosis, the levels of IL-6, a cytokine which induces the development of Th17 cells, did not differ among the cats from this study.", [["Th17 arm", "ANATOMY", 21, 29], ["Th17 cells", "ANATOMY", 137, 147], ["sporotrichosis", "DISEASE", 57, 71], ["Th17", "GENE_OR_GENE_PRODUCT", 21, 25], ["feline", "ORGANISM", 50, 56], ["sporotrichosis", "CANCER", 57, 71], ["IL-6", "GENE_OR_GENE_PRODUCT", 87, 91], ["Th17 cells", "CELL", 137, 147], ["cats", "ORGANISM", 174, 178], ["IL-6", "PROTEIN", 87, 91], ["cytokine", "PROTEIN", 95, 103], ["Th17 cells", "CELL_TYPE", 137, 147], ["feline", "SPECIES", 50, 56], ["feline sporotrichosis", "PROBLEM", 50, 71], ["IL", "TEST", 87, 89], ["Th17 cells", "PROBLEM", 137, 147], ["this study", "TEST", 184, 194], ["feline", "OBSERVATION_MODIFIER", 50, 56], ["sporotrichosis", "OBSERVATION", 57, 71], ["Th17 cells", "OBSERVATION", 137, 147]]], ["This suggests that the retrovirus co-infection and the upregulation of IL-10, with a potential polarization to a Treg cell profile, did not impair Th17 immunity.", [["Treg cell", "ANATOMY", 113, 122], ["retrovirus co-infection", "DISEASE", 23, 46], ["retrovirus", "ORGANISM", 23, 33], ["IL-10", "GENE_OR_GENE_PRODUCT", 71, 76], ["Treg cell", "CELL", 113, 122], ["Th17", "CELL", 147, 151], ["IL-10", "PROTEIN", 71, 76], ["the retrovirus co-infection", "PROBLEM", 19, 46], ["the upregulation of IL", "TREATMENT", 51, 73], ["a Treg cell profile", "TEST", 111, 130], ["retrovirus co-infection", "OBSERVATION", 23, 46], ["Treg cell profile", "OBSERVATION", 113, 130]]], ["This is relevant because despite having opposite functions, Th17 and Treg cells develop from CD4+ cell precursors through the same pathway, but depending upon the presence of different cytokines [50].", [["Th17", "ANATOMY", 60, 64], ["Treg cells", "ANATOMY", 69, 79], ["CD4+ cell", "ANATOMY", 93, 102], ["Th17", "CELL", 60, 64], ["Treg cells", "CELL", 69, 79], ["CD4", "GENE_OR_GENE_PRODUCT", 93, 96], ["Th17 and Treg cells", "CELL_TYPE", 60, 79], ["CD4", "PROTEIN", 93, 96], ["cytokines", "PROTEIN", 185, 194], ["Th17 and Treg cells", "PROBLEM", 60, 79], ["CD4+ cell precursors", "PROBLEM", 93, 113], ["Treg cells", "OBSERVATION", 69, 79], ["cell precursors", "OBSERVATION", 98, 113]]], ["Despite the very low levels of IL-6 detected in the cats from this study, it is not possible to suggest that Th17 profile is depressed in favor of Tregs increase in retrovirus co-infection, due to the small number of FIV-positive cats.", [["Tregs", "ANATOMY", 147, 152], ["depressed", "DISEASE", 125, 134], ["retrovirus co-infection", "DISEASE", 165, 188], ["IL-6", "GENE_OR_GENE_PRODUCT", 31, 35], ["cats", "ORGANISM", 52, 56], ["Tregs", "CELL", 147, 152], ["retrovirus", "ORGANISM", 165, 175], ["FIV", "ORGANISM", 217, 220], ["cats", "ORGANISM", 230, 234], ["IL-6", "PROTEIN", 31, 35], ["Tregs", "CELL_TYPE", 147, 152], ["cats", "SPECIES", 230, 234], ["FIV", "SPECIES", 217, 220], ["this study", "TEST", 62, 72], ["Th17 profile", "PROBLEM", 109, 121], ["depressed", "PROBLEM", 125, 134], ["Tregs increase", "PROBLEM", 147, 161], ["retrovirus co-infection", "PROBLEM", 165, 188], ["very", "OBSERVATION_MODIFIER", 12, 16], ["low", "OBSERVATION_MODIFIER", 17, 20], ["not possible", "UNCERTAINTY", 80, 92], ["Th17", "OBSERVATION", 109, 113], ["retrovirus co-infection", "OBSERVATION", 165, 188], ["small", "OBSERVATION_MODIFIER", 201, 206], ["FIV", "OBSERVATION", 217, 220], ["positive cats", "OBSERVATION", 221, 234]]], ["Another limitation of this study was the absence of a control group of healthy cats, so that it cannot be confirmed whether IL-6 levels are altered in cats with sporotrichosis, co-infected with retrovirus infections or not, in comparison to healthy cats.DiscussionAlthough the first steps of fungus-host interactions are considered determinant for further adaptive response in the murine model [51\u201354], the scarcity of information on innate immunity in feline sporotrichosis remains a concern.", [["sporotrichosis", "DISEASE", 161, 175], ["retrovirus infections", "DISEASE", 194, 215], ["sporotrichosis", "DISEASE", 460, 474], ["cats", "ORGANISM", 79, 83], ["IL-6", "GENE_OR_GENE_PRODUCT", 124, 128], ["cats", "ORGANISM", 151, 155], ["retrovirus", "ORGANISM", 194, 204], ["cats", "ORGANISM", 249, 253], ["murine", "ORGANISM", 381, 387], ["feline", "ORGANISM", 453, 459], ["IL-6", "PROTEIN", 124, 128], ["cats", "SPECIES", 79, 83], ["cats", "SPECIES", 151, 155], ["cats", "SPECIES", 249, 253], ["murine", "SPECIES", 381, 387], ["feline", "SPECIES", 453, 459], ["retrovirus", "SPECIES", 194, 204], ["this study", "TEST", 22, 32], ["IL", "TEST", 124, 126], ["sporotrichosis", "PROBLEM", 161, 175], ["retrovirus infections", "PROBLEM", 194, 215], ["fungus", "PROBLEM", 292, 298], ["feline sporotrichosis", "PROBLEM", 453, 474], ["sporotrichosis", "OBSERVATION", 161, 175], ["retrovirus infections", "OBSERVATION", 194, 215], ["sporotrichosis", "OBSERVATION", 460, 474]]], ["A detrimental role of nitric oxide (NO) in the murine immune response to S. schenckii was reported and related to T-cell suppression and fungal dissemination, which was attributed to increased apoptosis and significant elevations of IL-10 and TNF-\u03b1 [44,54].", [["T-cell", "ANATOMY", 114, 120], ["nitric oxide", "CHEMICAL", 22, 34], ["NO", "CHEMICAL", 36, 38], ["nitric oxide", "CHEMICAL", 22, 34], ["NO", "CHEMICAL", 36, 38], ["nitric oxide", "SIMPLE_CHEMICAL", 22, 34], ["NO", "SIMPLE_CHEMICAL", 36, 38], ["murine", "ORGANISM", 47, 53], ["S. schenckii", "ORGANISM", 73, 85], ["T-cell", "CELL", 114, 120], ["IL-10", "GENE_OR_GENE_PRODUCT", 233, 238], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 243, 248], ["IL-10", "PROTEIN", 233, 238], ["TNF", "PROTEIN", 243, 246], ["murine", "SPECIES", 47, 53], ["S. schenckii", "SPECIES", 73, 85], ["S. schenckii", "SPECIES", 73, 85], ["nitric oxide", "TREATMENT", 22, 34], ["S. schenckii", "PROBLEM", 73, 85], ["T-cell suppression", "PROBLEM", 114, 132], ["fungal dissemination", "PROBLEM", 137, 157], ["increased apoptosis", "PROBLEM", 183, 202], ["significant elevations of IL", "PROBLEM", 207, 235], ["TNF", "TEST", 243, 246], ["fungal dissemination", "OBSERVATION", 137, 157], ["increased", "OBSERVATION_MODIFIER", 183, 192], ["apoptosis", "OBSERVATION", 193, 202], ["significant", "OBSERVATION_MODIFIER", 207, 218], ["elevations", "OBSERVATION_MODIFIER", 219, 229]]], ["Interestingly, FIV co-infected cats from this study presented higher levels of IL-10 (PMWU = 0.05).", [["FIV", "ORGANISM", 15, 18], ["cats", "ORGANISM", 31, 35], ["IL-10", "GENE_OR_GENE_PRODUCT", 79, 84], ["IL", "PROTEIN", 79, 81], ["cats", "SPECIES", 31, 35], ["FIV", "SPECIES", 15, 18], ["this study", "TEST", 41, 51], ["IL", "TEST", 79, 81], ["PMWU", "TEST", 86, 90], ["FIV", "OBSERVATION_MODIFIER", 15, 18], ["co-infected", "OBSERVATION", 19, 30]]], ["In addition, it has been shown that PD-1, the programmed cell death protein 1, is upregulated in FIV-infected lymphocytes and may correlate with dysfunction or exhaustion of T cells and with immunosuppression in infected cats [55].", [["cell", "ANATOMY", 57, 61], ["lymphocytes", "ANATOMY", 110, 121], ["T cells", "ANATOMY", 174, 181], ["FIV-infected lymphocytes", "DISEASE", 97, 121], ["PD-1", "GENE_OR_GENE_PRODUCT", 36, 40], ["programmed cell death protein 1", "GENE_OR_GENE_PRODUCT", 46, 77], ["FIV", "ORGANISM", 97, 100], ["lymphocytes", "CELL", 110, 121], ["T cells", "CELL", 174, 181], ["cats", "ORGANISM", 221, 225], ["programmed cell death protein 1", "PROTEIN", 46, 77], ["FIV-infected lymphocytes", "CELL_TYPE", 97, 121], ["T cells", "CELL_TYPE", 174, 181], ["cats", "SPECIES", 221, 225], ["FIV", "SPECIES", 97, 100], ["PD", "TEST", 36, 38], ["the programmed cell death protein", "TEST", 42, 75], ["infected lymphocytes", "PROBLEM", 101, 121], ["dysfunction", "PROBLEM", 145, 156], ["exhaustion of T cells", "PROBLEM", 160, 181], ["immunosuppression", "TREATMENT", 191, 208], ["infected lymphocytes", "OBSERVATION", 101, 121], ["may correlate with", "UNCERTAINTY", 126, 144]]], ["It could be speculated that the cytokine changes in cats with sporotrichosis coinfected with FIV may be at some level linked to the large number of yeast commonly found in cutaneous lesions of feline sporotrichosis.", [["cutaneous lesions", "ANATOMY", 172, 189], ["sporotrichosis", "DISEASE", 62, 76], ["FIV", "DISEASE", 93, 96], ["sporotrichosis", "DISEASE", 200, 214], ["cats", "ORGANISM", 52, 56], ["FIV", "ORGANISM", 93, 96], ["cutaneous lesions", "PATHOLOGICAL_FORMATION", 172, 189], ["feline", "ORGANISM", 193, 199], ["cytokine", "PROTEIN", 32, 40], ["cats", "SPECIES", 52, 56], ["yeast", "SPECIES", 148, 153], ["feline", "SPECIES", 193, 199], ["FIV", "SPECIES", 93, 96], ["yeast", "SPECIES", 148, 153], ["the cytokine changes in cats", "PROBLEM", 28, 56], ["sporotrichosis", "PROBLEM", 62, 76], ["FIV", "TREATMENT", 93, 96], ["yeast", "PROBLEM", 148, 153], ["cutaneous lesions of feline sporotrichosis", "PROBLEM", 172, 214], ["cytokine", "OBSERVATION", 32, 40], ["sporotrichosis", "OBSERVATION", 62, 76], ["large", "OBSERVATION_MODIFIER", 132, 137], ["number", "OBSERVATION_MODIFIER", 138, 144], ["yeast commonly", "OBSERVATION", 148, 162], ["cutaneous", "ANATOMY", 172, 181], ["lesions", "OBSERVATION", 182, 189], ["feline sporotrichosis", "OBSERVATION", 193, 214]]], ["However, further work is required to address these issues properly.DiscussionThe evaluation of lymphocyte subsets by flow cytometry showed a lower percentage of CD4+ cells and a higher percentage of CD8+ cells, as well as a lower CD4:CD8 ratio in FIV-positive cats, when compared to retrovirus-negative cats.", [["lymphocyte", "ANATOMY", 95, 105], ["CD4+ cells", "ANATOMY", 161, 171], ["CD8+ cells", "ANATOMY", 199, 209], ["lymphocyte", "CELL", 95, 105], ["CD4", "GENE_OR_GENE_PRODUCT", 161, 164], ["CD8", "GENE_OR_GENE_PRODUCT", 199, 202], ["CD4", "GENE_OR_GENE_PRODUCT", 230, 233], ["CD8", "GENE_OR_GENE_PRODUCT", 234, 237], ["FIV", "ORGANISM", 247, 250], ["cats", "ORGANISM", 260, 264], ["retrovirus", "ORGANISM", 283, 293], ["cats", "ORGANISM", 303, 307], ["lymphocyte subsets", "CELL_TYPE", 95, 113], ["CD4", "PROTEIN", 161, 164], ["CD8+ cells", "CELL_TYPE", 199, 209], ["CD4", "PROTEIN", 230, 233], ["CD8", "PROTEIN", 234, 237], ["cats", "SPECIES", 303, 307], ["FIV", "SPECIES", 247, 250], ["The evaluation", "TEST", 77, 91], ["lymphocyte subsets", "TEST", 95, 113], ["flow cytometry", "TEST", 117, 131], ["CD4+ cells", "PROBLEM", 161, 171], ["CD8+ cells", "PROBLEM", 199, 209], ["CD8 ratio", "TEST", 234, 243], ["FIV", "TEST", 247, 250], ["positive cats", "PROBLEM", 251, 264], ["retrovirus", "TEST", 283, 293], ["lower percentage", "OBSERVATION_MODIFIER", 141, 157], ["CD4+ cells", "OBSERVATION", 161, 171], ["CD8+ cells", "OBSERVATION", 199, 209], ["positive cats", "OBSERVATION", 251, 264]]], ["This finding is consistent with what has been reported for FIV infection, in which the inversion of CD4:CD8 ratio is commonly detected, along with decreasing CD4+ levels and increasing CD8+ levels [56].", [["FIV infection", "DISEASE", 59, 72], ["FIV", "ORGANISM", 59, 62], ["CD4", "GENE_OR_GENE_PRODUCT", 100, 103], ["CD8", "GENE_OR_GENE_PRODUCT", 104, 107], ["CD4", "GENE_OR_GENE_PRODUCT", 158, 161], ["CD8", "GENE_OR_GENE_PRODUCT", 185, 188], ["CD4", "PROTEIN", 100, 103], ["CD8", "PROTEIN", 104, 107], ["CD4", "PROTEIN", 158, 161], ["CD8", "PROTEIN", 185, 188], ["FIV", "SPECIES", 59, 62], ["FIV infection", "PROBLEM", 59, 72], ["CD8 ratio", "TEST", 104, 113], ["decreasing CD4+ levels", "PROBLEM", 147, 169], ["increasing CD8+ levels", "PROBLEM", 174, 196], ["consistent with", "UNCERTAINTY", 16, 31], ["infection", "OBSERVATION", 63, 72], ["decreasing", "OBSERVATION_MODIFIER", 147, 157], ["CD4", "OBSERVATION", 158, 161], ["increasing", "OBSERVATION_MODIFIER", 174, 184]]], ["This might be linked to the low concentration of IL-12 in FIV-positive cats described in this study, as well as to their poor general condition.DiscussionCellular immunity was recently referred to as crucial for controlling feline sporotrichosis [24], presumably through Th1-driven mechanisms, with increased percentages of CD4+ cells in cats with good general condition, localized lesions, a well-organized granulomatous inflammatory response and a low fungal burden.", [["Cellular", "ANATOMY", 154, 162], ["CD4+ cells", "ANATOMY", 324, 334], ["lesions", "ANATOMY", 382, 389], ["granulomatous", "ANATOMY", 408, 421], ["sporotrichosis", "DISEASE", 231, 245], ["IL-12", "GENE_OR_GENE_PRODUCT", 49, 54], ["FIV", "ORGANISM", 58, 61], ["cats", "ORGANISM", 71, 75], ["feline", "ORGANISM", 224, 230], ["Th1", "GENE_OR_GENE_PRODUCT", 271, 274], ["CD4", "GENE_OR_GENE_PRODUCT", 324, 327], ["cats", "ORGANISM", 338, 342], ["lesions", "PATHOLOGICAL_FORMATION", 382, 389], ["IL-12", "PROTEIN", 49, 54], ["CD4", "PROTEIN", 324, 327], ["feline", "SPECIES", 224, 230], ["cats", "SPECIES", 338, 342], ["FIV", "SPECIES", 58, 61], ["the low concentration of IL", "TREATMENT", 24, 51], ["this study", "TEST", 89, 99], ["controlling feline sporotrichosis", "PROBLEM", 212, 245], ["CD4+ cells in cats", "PROBLEM", 324, 342], ["localized lesions", "PROBLEM", 372, 389], ["a well-organized granulomatous inflammatory response", "PROBLEM", 391, 443], ["a low fungal burden", "PROBLEM", 448, 467], ["positive cats", "OBSERVATION_MODIFIER", 62, 75], ["increased", "OBSERVATION_MODIFIER", 299, 308], ["CD4+ cells", "OBSERVATION", 324, 334], ["good", "OBSERVATION_MODIFIER", 348, 352], ["localized", "OBSERVATION_MODIFIER", 372, 381], ["lesions", "OBSERVATION", 382, 389], ["well-organized", "OBSERVATION_MODIFIER", 393, 407], ["granulomatous", "OBSERVATION_MODIFIER", 408, 421], ["inflammatory response", "OBSERVATION", 422, 443], ["low", "OBSERVATION_MODIFIER", 450, 453], ["fungal burden", "OBSERVATION", 454, 467]]], ["In humans, the decrease in CD4+ cell counts also correlated with disseminated sporotrichosis [57].", [["CD4+ cell", "ANATOMY", 27, 36], ["sporotrichosis", "DISEASE", 78, 92], ["humans", "ORGANISM", 3, 9], ["CD4", "GENE_OR_GENE_PRODUCT", 27, 30], ["CD4", "PROTEIN", 27, 30], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["CD4+ cell counts", "TEST", 27, 43], ["disseminated sporotrichosis", "PROBLEM", 65, 92], ["decrease", "OBSERVATION_MODIFIER", 15, 23], ["cell counts", "OBSERVATION", 32, 43], ["disseminated", "OBSERVATION_MODIFIER", 65, 77], ["sporotrichosis", "OBSERVATION", 78, 92]]], ["The poor general condition and the disseminated lesions with high fungal burden in cats with sporotrichosis were related to higher CD8low+ cells percentage, which is suggested to be elicited by a Th2 immunity background [58].", [["lesions", "ANATOMY", 48, 55], ["CD8low+ cells", "ANATOMY", 131, 144], ["sporotrichosis", "DISEASE", 93, 107], ["disseminated lesions", "PATHOLOGICAL_FORMATION", 35, 55], ["cats", "ORGANISM", 83, 87], ["CD8low+ cells", "CELL", 131, 144], ["CD8low", "PROTEIN", 131, 137], ["cats", "SPECIES", 83, 87], ["The poor general condition", "PROBLEM", 0, 26], ["the disseminated lesions", "PROBLEM", 31, 55], ["high fungal burden in cats", "PROBLEM", 61, 87], ["sporotrichosis", "PROBLEM", 93, 107], ["higher CD8low+ cells percentage", "PROBLEM", 124, 155], ["poor", "OBSERVATION_MODIFIER", 4, 8], ["disseminated", "OBSERVATION_MODIFIER", 35, 47], ["lesions", "OBSERVATION", 48, 55], ["high", "OBSERVATION_MODIFIER", 61, 65], ["fungal", "OBSERVATION_MODIFIER", 66, 72], ["burden", "OBSERVATION_MODIFIER", 73, 79], ["sporotrichosis", "OBSERVATION", 93, 107], ["cells percentage", "OBSERVATION", 139, 155]]], ["In coronavirus infection, cats that did not develop Feline Infectious Peritonitis (FIP), a fatal granulomatous disease, had higher tissue levels of IL-10, which probably prevented excessive macrophage activation and the development of FIP [59].", [["granulomatous", "ANATOMY", 97, 110], ["tissue", "ANATOMY", 131, 137], ["macrophage", "ANATOMY", 190, 200], ["coronavirus infection", "DISEASE", 3, 24], ["Feline", "DISEASE", 52, 58], ["Infectious Peritonitis", "DISEASE", 59, 81], ["FIP", "DISEASE", 83, 86], ["granulomatous disease", "DISEASE", 97, 118], ["FIP", "DISEASE", 235, 238], ["coronavirus", "ORGANISM", 3, 14], ["cats", "ORGANISM", 26, 30], ["Feline", "ORGANISM", 52, 58], ["tissue", "TISSUE", 131, 137], ["IL-10", "GENE_OR_GENE_PRODUCT", 148, 153], ["macrophage", "CELL", 190, 200], ["IL", "PROTEIN", 148, 150], ["coronavirus", "SPECIES", 3, 14], ["cats", "SPECIES", 26, 30], ["coronavirus infection", "PROBLEM", 3, 24], ["Feline Infectious Peritonitis", "PROBLEM", 52, 81], ["a fatal granulomatous disease", "PROBLEM", 89, 118], ["higher tissue levels of IL", "PROBLEM", 124, 150], ["excessive macrophage activation", "PROBLEM", 180, 211], ["coronavirus", "OBSERVATION_MODIFIER", 3, 14], ["infection", "OBSERVATION", 15, 24], ["Infectious", "OBSERVATION_MODIFIER", 59, 69], ["Peritonitis", "OBSERVATION", 70, 81], ["fatal", "OBSERVATION_MODIFIER", 91, 96], ["granulomatous", "OBSERVATION", 97, 110], ["higher tissue", "OBSERVATION_MODIFIER", 124, 137], ["probably prevented", "UNCERTAINTY", 161, 179], ["excessive", "OBSERVATION_MODIFIER", 180, 189], ["macrophage activation", "OBSERVATION", 190, 211], ["FIP", "OBSERVATION", 235, 238]]], ["Although further studies are still necessary to determine the mechanisms driving ineffective granulomas in feline sporotrichosis, it could be considered that, as described in coronavirus-infected cats, the retrovirus co-infection with upregulation of IL-10 is possibly involved with the impairment of granuloma formation and increasing fungal load in lesions of feline sporotrichosis.DiscussionCats with severe sporotrichosis clearly outnumbered retrovirus co-infected cats.", [["granulomas", "ANATOMY", 93, 103], ["granuloma", "ANATOMY", 301, 310], ["lesions", "ANATOMY", 351, 358], ["granulomas", "DISEASE", 93, 103], ["feline sporotrichosis", "DISEASE", 107, 128], ["coronavirus-infected", "DISEASE", 175, 195], ["granuloma", "DISEASE", 301, 310], ["sporotrichosis", "DISEASE", 369, 383], ["sporotrichosis", "DISEASE", 411, 425], ["granulomas", "PATHOLOGICAL_FORMATION", 93, 103], ["feline", "ORGANISM", 107, 113], ["coronavirus", "ORGANISM", 175, 186], ["cats", "ORGANISM", 196, 200], ["retrovirus", "ORGANISM", 206, 216], ["IL-10", "GENE_OR_GENE_PRODUCT", 251, 256], ["granuloma", "PATHOLOGICAL_FORMATION", 301, 310], ["lesions", "PATHOLOGICAL_FORMATION", 351, 358], ["feline", "ORGANISM", 362, 368], ["retrovirus", "ORGANISM", 446, 456], ["cats", "ORGANISM", 469, 473], ["IL-10", "PROTEIN", 251, 256], ["feline", "SPECIES", 107, 113], ["cats", "SPECIES", 196, 200], ["feline", "SPECIES", 362, 368], ["cats", "SPECIES", 469, 473], ["further studies", "TEST", 9, 24], ["ineffective granulomas in feline sporotrichosis", "PROBLEM", 81, 128], ["coronavirus", "PROBLEM", 175, 186], ["infected cats", "PROBLEM", 187, 200], ["the retrovirus co-infection", "PROBLEM", 202, 229], ["upregulation of IL", "TREATMENT", 235, 253], ["granuloma formation", "PROBLEM", 301, 320], ["increasing fungal load in lesions of feline sporotrichosis", "PROBLEM", 325, 383], ["severe sporotrichosis", "PROBLEM", 404, 425], ["ineffective", "OBSERVATION_MODIFIER", 81, 92], ["granulomas", "OBSERVATION", 93, 103], ["feline sporotrichosis", "OBSERVATION", 107, 128], ["retrovirus co-infection", "OBSERVATION", 206, 229], ["possibly involved", "UNCERTAINTY", 260, 277], ["granuloma", "OBSERVATION", 301, 310], ["increasing", "OBSERVATION_MODIFIER", 325, 335], ["fungal load", "OBSERVATION", 336, 347], ["lesions", "OBSERVATION", 351, 358], ["feline sporotrichosis", "OBSERVATION", 362, 383], ["severe", "OBSERVATION_MODIFIER", 404, 410], ["sporotrichosis", "OBSERVATION", 411, 425]]], ["Thus, whether cats with severe sporotrichosis and negative for FIV and FeLV are truly free of other comorbidities or immunosuppressive conditions remains unknown.", [["sporotrichosis", "DISEASE", 31, 45], ["cats", "ORGANISM", 14, 18], ["FIV", "ORGANISM", 63, 66], ["FeLV", "ORGANISM", 71, 75], ["cats", "SPECIES", 14, 18], ["FIV", "SPECIES", 63, 66], ["FeLV", "SPECIES", 71, 75], ["severe sporotrichosis", "PROBLEM", 24, 45], ["FIV", "PROBLEM", 63, 66], ["FeLV", "PROBLEM", 71, 75], ["other comorbidities", "PROBLEM", 94, 113], ["immunosuppressive conditions", "PROBLEM", 117, 145], ["severe", "OBSERVATION_MODIFIER", 24, 30], ["sporotrichosis", "OBSERVATION", 31, 45]]], ["Since most of the areas in which sporotrichosis occurs in Rio de Janeiro have low educational and socioeconomic status and poor health assistance [5,60\u201361], infectious diseases other than sporotrichosis can spread.", [["sporotrichosis", "DISEASE", 33, 47], ["infectious diseases", "DISEASE", 157, 176], ["sporotrichosis", "DISEASE", 188, 202], ["infectious diseases", "PROBLEM", 157, 176], ["sporotrichosis", "PROBLEM", 188, 202], ["sporotrichosis", "OBSERVATION", 33, 47]]], ["In addition, the vaccination and prophylactic deworming status in the population of cats with sporotrichosis have yet to be determined [62].DiscussionCertainly, helminth infections typically lead to an increased production of IL-10 and Th2 cytokines, such as IL-4 [63\u201364], and to the down-regulation of Th1 cytokines [63].", [["sporotrichosis", "DISEASE", 94, 108], ["helminth infections", "DISEASE", 161, 180], ["cats", "ORGANISM", 84, 88], ["IL-10", "GENE_OR_GENE_PRODUCT", 226, 231], ["Th2", "GENE_OR_GENE_PRODUCT", 236, 239], ["IL-4", "GENE_OR_GENE_PRODUCT", 259, 263], ["Th1", "GENE_OR_GENE_PRODUCT", 303, 306], ["IL-10", "PROTEIN", 226, 231], ["Th2 cytokines", "PROTEIN", 236, 249], ["Th1 cytokines", "PROTEIN", 303, 316], ["cats", "SPECIES", 84, 88], ["the vaccination", "TREATMENT", 13, 28], ["prophylactic deworming", "TREATMENT", 33, 55], ["sporotrichosis", "PROBLEM", 94, 108], ["helminth infections", "PROBLEM", 161, 180], ["an increased production of IL", "PROBLEM", 199, 228], ["Th2 cytokines", "TEST", 236, 249], ["IL", "TEST", 259, 261], ["increased", "OBSERVATION_MODIFIER", 202, 211]]], ["An experimental study in rats with sporotrichosis showed that different profiles of cytokines are driven depending on the coinfection with Taenia taeniaeformis [65].", [["sporotrichosis", "DISEASE", 35, 49], ["Taenia taeniaeformis", "DISEASE", 139, 159], ["rats", "ORGANISM", 25, 29], ["Taenia taeniaeformis", "ORGANISM", 139, 159], ["cytokines", "PROTEIN", 84, 93], ["rats", "SPECIES", 25, 29], ["Taenia taeniaeformis", "SPECIES", 139, 159], ["Taenia taeniaeformis", "SPECIES", 139, 159], ["An experimental study", "TEST", 0, 21], ["sporotrichosis", "PROBLEM", 35, 49], ["cytokines", "PROBLEM", 84, 93], ["Taenia taeniaeformis", "PROBLEM", 139, 159]]], ["The authors demonstrated that IL-10 was increased in rats co-infected with the worm.", [["IL-10", "GENE_OR_GENE_PRODUCT", 30, 35], ["rats", "ORGANISM", 53, 57], ["IL-10", "PROTEIN", 30, 35], ["rats", "SPECIES", 53, 57]]], ["These animals showed a less organized inflammatory infiltrate, and a higher fungal burden.", [["a less organized inflammatory infiltrate", "PROBLEM", 21, 61], ["a higher fungal burden", "PROBLEM", 67, 89], ["less", "OBSERVATION_MODIFIER", 23, 27], ["organized", "OBSERVATION_MODIFIER", 28, 37], ["inflammatory", "OBSERVATION_MODIFIER", 38, 50], ["infiltrate", "OBSERVATION", 51, 61], ["higher", "OBSERVATION_MODIFIER", 69, 75], ["fungal", "OBSERVATION_MODIFIER", 76, 82], ["burden", "OBSERVATION", 83, 89]]], ["As previously speculated for FIV, the Sporothrix/helminths co-infection could lead to the imbalance of cytokines, resulting in impaired response to Sporothrix and in the lack of control over the fungal infection in cats.DiscussionTherefore, other comorbidities should be considered as potential challenges and the presence of immunosuppressive conditions during the course of sporotrichosis in cats could explain the occurrence of relapses, the worsening on clinical condition after the beginning of the treatment and therapeutic failure.DiscussionIn this study, the immunological changes related to retrovirus co-infection in cats with sporotrichosis were not associated with a difference in the clinical outcome or duration of treatment.", [["helminths co-infection", "DISEASE", 49, 71], ["Sporothrix", "DISEASE", 148, 158], ["fungal infection", "DISEASE", 195, 211], ["sporotrichosis", "DISEASE", 376, 390], ["retrovirus co-infection", "DISEASE", 600, 623], ["sporotrichosis", "DISEASE", 637, 651], ["FIV", "ORGANISM", 29, 32], ["Sporothrix/helminths", "ORGANISM", 38, 58], ["cats", "ORGANISM", 215, 219], ["cats", "ORGANISM", 394, 398], ["retrovirus", "ORGANISM", 600, 610], ["cats", "ORGANISM", 627, 631], ["cytokines", "PROTEIN", 103, 112], ["cats", "SPECIES", 215, 219], ["cats", "SPECIES", 394, 398], ["cats", "SPECIES", 627, 631], ["FIV", "SPECIES", 29, 32], ["FIV", "TREATMENT", 29, 32], ["the Sporothrix/helminths co-infection", "PROBLEM", 34, 71], ["the imbalance of cytokines", "PROBLEM", 86, 112], ["impaired response to Sporothrix", "PROBLEM", 127, 158], ["the fungal infection in cats", "PROBLEM", 191, 219], ["immunosuppressive conditions", "TREATMENT", 326, 354], ["sporotrichosis", "PROBLEM", 376, 390], ["relapses", "PROBLEM", 431, 439], ["the worsening on clinical condition", "PROBLEM", 441, 476], ["the treatment", "TREATMENT", 500, 513], ["therapeutic failure", "PROBLEM", 518, 537], ["this study", "TEST", 551, 561], ["the immunological changes", "PROBLEM", 563, 588], ["retrovirus co-infection in cats", "PROBLEM", 600, 631], ["sporotrichosis", "PROBLEM", 637, 651], ["treatment", "TREATMENT", 729, 738], ["impaired", "OBSERVATION_MODIFIER", 127, 135], ["response to Sporothrix", "OBSERVATION", 136, 158], ["fungal", "OBSERVATION_MODIFIER", 195, 201], ["infection", "OBSERVATION", 202, 211], ["sporotrichosis", "OBSERVATION", 376, 390], ["relapses", "OBSERVATION", 431, 439], ["worsening", "OBSERVATION_MODIFIER", 445, 454], ["therapeutic", "OBSERVATION_MODIFIER", 518, 529], ["failure", "OBSERVATION", 530, 537], ["retrovirus co-infection", "OBSERVATION", 600, 623], ["sporotrichosis", "OBSERVATION", 637, 651]]], ["Still, the combination of ITZ and KI in the treatment of cats decreased the median treatment length in cats in this study.", [["ITZ", "CHEMICAL", 26, 29], ["KI", "CHEMICAL", 34, 36], ["ITZ", "CHEMICAL", 26, 29], ["ITZ", "SIMPLE_CHEMICAL", 26, 29], ["KI", "SIMPLE_CHEMICAL", 34, 36], ["cats", "ORGANISM", 57, 61], ["cats", "ORGANISM", 103, 107], ["ITZ", "TREATMENT", 26, 29], ["the treatment of cats", "TREATMENT", 40, 61], ["the median treatment length", "TREATMENT", 72, 99], ["this study", "TEST", 111, 121], ["median treatment", "OBSERVATION_MODIFIER", 76, 92], ["length", "OBSERVATION_MODIFIER", 93, 99]]], ["Even though this reduction was not statistically significant, it is important to state that the combination of these drugs had previously shown promising results in the treatment of feline sporotrichosis [11].", [["sporotrichosis", "DISEASE", 189, 203], ["feline", "ORGANISM", 182, 188], ["these drugs", "TREATMENT", 111, 122], ["feline sporotrichosis", "PROBLEM", 182, 203], ["sporotrichosis", "OBSERVATION", 189, 203]]], ["While the effectiveness of KI is not proved to be due to the direct action on fungi [66], the mechanism through which its use is successful remains obscure.", [["KI", "CHEMICAL", 27, 29]]], ["Although this issue still needs to be addressed, a potential immunomodulation is suggested [67\u201369] and could have contributed to the shorter treatment length in cats treated with KI in this study, especially on FeLV co-infection.", [["KI", "CHEMICAL", 179, 181], ["FeLV co-infection", "DISEASE", 211, 228], ["cats", "ORGANISM", 161, 165], ["FeLV", "ORGANISM", 211, 215], ["this study", "TEST", 185, 195], ["FeLV co-infection", "PROBLEM", 211, 228], ["FeLV co-infection", "OBSERVATION", 211, 228]]], ["However, this study had a retrospective design, with retrospective evaluation of medical records.", [["this study", "TEST", 9, 19], ["retrospective evaluation", "TEST", 53, 77]]], ["Prospective double blinded controlled studies should be performed to properly assess effectiveness of the different therapeutic regimes.DiscussionDespite the efforts towards the better understanding of interactions between Sporothrix spp. and feline immune system, much of the progress that has been performed in vitro and in vivo experimental models is still to be explored in cats.", [["immune system", "ANATOMY", 250, 263], ["Sporothrix spp", "ORGANISM", 223, 237], ["feline", "ORGANISM", 243, 249], ["immune system", "ANATOMICAL_SYSTEM", 250, 263], ["cats", "ORGANISM", 378, 382], ["feline", "SPECIES", 243, 249], ["Prospective double blinded controlled studies", "TEST", 0, 45], ["the different therapeutic regimes", "TREATMENT", 102, 135], ["Sporothrix spp", "PROBLEM", 223, 237]]], ["Retrovirus/Sporothrix co-infection in cats from this study led to important changes in immunological balance, leaning towards an immunosuppressive profile with higher levels of IL-10, which could prevent the activation of a Th1 response that would be favourable against sporotrichosis.", [["sporotrichosis", "DISEASE", 270, 284], ["Retrovirus/Sporothrix", "ORGANISM", 0, 21], ["cats", "ORGANISM", 38, 42], ["IL-10", "GENE_OR_GENE_PRODUCT", 177, 182], ["IL", "PROTEIN", 177, 179], ["cats", "SPECIES", 38, 42], ["Retrovirus/Sporothrix co-infection", "PROBLEM", 0, 34], ["this study", "TEST", 48, 58], ["important changes in immunological balance", "PROBLEM", 66, 108], ["an immunosuppressive profile", "TEST", 126, 154], ["sporotrichosis", "PROBLEM", 270, 284], ["Sporothrix co-infection", "OBSERVATION", 11, 34]]], ["The consequent imbalance in host-pathogen interactions may potentially result in higher availability of Sporothrix in skin lesions and increased transmission from cats to humans.", [["skin lesions", "ANATOMY", 118, 130], ["skin lesions", "DISEASE", 118, 130], ["skin lesions", "PATHOLOGICAL_FORMATION", 118, 130], ["cats", "ORGANISM", 163, 167], ["humans", "ORGANISM", 171, 177], ["cats", "SPECIES", 163, 167], ["humans", "SPECIES", 171, 177], ["humans", "SPECIES", 171, 177], ["The consequent imbalance", "PROBLEM", 0, 24], ["Sporothrix", "PROBLEM", 104, 114], ["skin lesions", "PROBLEM", 118, 130], ["imbalance", "OBSERVATION", 15, 24], ["Sporothrix", "OBSERVATION", 104, 114], ["skin", "ANATOMY", 118, 122], ["lesions", "OBSERVATION", 123, 130], ["increased", "OBSERVATION_MODIFIER", 135, 144]]], ["Indeed, all cats that had the most severe clinical presentation and poor general condition were co-infected with FeLV or FIV.", [["cats", "ORGANISM", 12, 16], ["FeLV", "ORGANISM", 113, 117], ["FIV", "ORGANISM", 121, 124], ["cats", "SPECIES", 12, 16], ["FeLV", "SPECIES", 113, 117], ["FIV", "SPECIES", 121, 124], ["poor general condition", "PROBLEM", 68, 90]]], ["Therefore, these results encourage the development of prospective longitudinal studies that address the impact of immunological changes in the outcome of cats with sporotrichosis.", [["sporotrichosis", "DISEASE", 164, 178], ["cats", "ORGANISM", 154, 158], ["cats", "SPECIES", 154, 158], ["prospective longitudinal studies", "TEST", 54, 86], ["immunological changes", "PROBLEM", 114, 135], ["sporotrichosis", "PROBLEM", 164, 178], ["sporotrichosis", "OBSERVATION", 164, 178]]], ["This would be the key to better understand prognostic determinants of feline sporotrichosis and to developing new therapy strategies to control disease spread.", [["sporotrichosis", "DISEASE", 77, 91], ["feline", "ORGANISM", 70, 76], ["feline sporotrichosis", "PROBLEM", 70, 91], ["new therapy strategies", "TREATMENT", 110, 132], ["disease spread", "PROBLEM", 144, 158]]]], "PMC7273055": [["FundingSCI is supported by a Future Leader Fellowship, Heart Foundation of Australia.Funding", [["Heart", "ANATOMY", 55, 60]]]], "PMC7101942": [["1.1 The Nature of the Sickle Mutation ::: 1.", [["Sickle", "DISEASE", 22, 28], ["Sickle Mutation", "OBSERVATION", 22, 37]]], ["PathogenesisSickle cell anaemia is a hereditary disorder of haemoglobin (Hb) where the sickle gene is inherited, homozygously, from both parents.", [["PathogenesisSickle cell", "ANATOMY", 0, 23], ["PathogenesisSickle cell anaemia", "DISEASE", 0, 31], ["hereditary disorder", "DISEASE", 37, 56], ["PathogenesisSickle cell", "CELL", 0, 23], ["haemoglobin", "GENE_OR_GENE_PRODUCT", 60, 71], ["Hb", "GENE_OR_GENE_PRODUCT", 73, 75], ["Hb", "PROTEIN", 73, 75], ["sickle gene", "DNA", 87, 98], ["PathogenesisSickle cell anaemia", "PROBLEM", 0, 31], ["a hereditary disorder of haemoglobin (Hb", "PROBLEM", 35, 75], ["cell anaemia", "OBSERVATION", 19, 31], ["hereditary", "OBSERVATION_MODIFIER", 37, 47]]], ["The sickle mutation is the result of a single base change (GAT \u2192 GTT) in the sixth codon of exon 1 of the \u03b2-globin gene responsible for the synthesis of the \u03b2-globin polypeptide of the Hb molecule (\u03b12\u03b22).", [["sickle mutation", "DISEASE", 4, 19], ["\u03b2-globin", "GENE_OR_GENE_PRODUCT", 106, 114], ["Hb molecule", "GENE_OR_GENE_PRODUCT", 185, 196], ["\u03b12\u03b22", "GENE_OR_GENE_PRODUCT", 198, 202], ["sixth codon", "DNA", 77, 88], ["exon 1", "DNA", 92, 98], ["\u03b2-globin gene", "DNA", 106, 119], ["\u03b2-globin polypeptide", "PROTEIN", 157, 177], ["Hb molecule", "PROTEIN", 185, 196], ["\u03b12\u03b22", "PROTEIN", 198, 202], ["The sickle mutation", "PROBLEM", 0, 19], ["a single base change", "TREATMENT", 37, 57], ["GAT \u2192 GTT", "TREATMENT", 59, 68], ["sickle mutation", "OBSERVATION", 4, 19], ["Hb", "ANATOMY", 185, 187]]], ["This change, in turn, results in replacement of the normal glutamic acid with valine at position 6 of the \u03b2-globin chain and the formation of sickle Hb.[6,7] In a sense, the mutation is akin to a typographical error where a change of one letter of a keyword of a manuscript (\u2018punctuation mutation\u2019) corrupts the meaning of the intended message.", [["glutamic acid", "CHEMICAL", 59, 72], ["valine", "CHEMICAL", 78, 84], ["glutamic acid", "CHEMICAL", 59, 72], ["valine", "CHEMICAL", 78, 84], ["glutamic acid", "AMINO_ACID", 59, 72], ["valine", "AMINO_ACID", 78, 84], ["\u03b2-globin chain", "GENE_OR_GENE_PRODUCT", 106, 120], ["position 6", "PROTEIN", 88, 98], ["\u03b2-globin chain", "PROTEIN", 106, 120], ["replacement", "TREATMENT", 33, 44], ["valine at position", "TREATMENT", 78, 96], ["the \u03b2-globin chain", "TREATMENT", 102, 120], ["sickle Hb.", "PROBLEM", 142, 152]]], ["Typographical errors in articles, however, are episodic and have a transient effect that is effaced with time.", [["Typographical errors in articles", "PROBLEM", 0, 32], ["episodic", "PROBLEM", 47, 55], ["a transient effect", "PROBLEM", 65, 83], ["transient effect", "OBSERVATION", 67, 83], ["effaced", "OBSERVATION", 92, 99]]], ["The sickle mutation, on the hand, is permanent and often afflicts a life with pain, disability and morbid existence.1.2.1 Vascular Occlusion ::: 1.2 Consequences of the Sickle Mutation ::: 1.", [["hand", "ANATOMY", 28, 32], ["Vascular", "ANATOMY", 122, 130], ["sickle mutation", "DISEASE", 4, 19], ["pain", "DISEASE", 78, 82], ["disability", "DISEASE", 84, 94], ["Sickle", "DISEASE", 169, 175], ["Vascular", "MULTI-TISSUE_STRUCTURE", 122, 130], ["The sickle mutation", "PROBLEM", 0, 19], ["pain", "PROBLEM", 78, 82], ["morbid existence", "PROBLEM", 99, 115], ["Vascular Occlusion", "TEST", 122, 140], ["sickle mutation", "OBSERVATION", 4, 19], ["permanent", "OBSERVATION", 37, 46], ["Vascular", "ANATOMY", 122, 130], ["Occlusion", "OBSERVATION", 131, 140], ["1.2 Consequences", "OBSERVATION_MODIFIER", 145, 161], ["Sickle Mutation", "OBSERVATION", 169, 184]]], ["PathogenesisThe most important pathophysiological event in sickle cell anaemia that explains most of its clinical manifestations is vascular occlusion which may involve both the micro- and macro-vasculature.[8\u201311] Factors that culminate in vascular occlusion are listed in table II.[9,11\u201314] The primary process that leads to vascular occlusion is the polymerisation of sickle Hb upon deoxygenation which, in turn, results in distortion of the shape of red blood cells (RBCs), cellular dehydration, and decreased deformability and stickiness of RBC that promotes their adhesion to vascular endothelium.", [["sickle cell", "ANATOMY", 59, 70], ["vascular", "ANATOMY", 132, 140], ["macro-vasculature", "ANATOMY", 189, 206], ["vascular", "ANATOMY", 240, 248], ["vascular", "ANATOMY", 326, 334], ["red blood cells", "ANATOMY", 453, 468], ["RBCs", "ANATOMY", 470, 474], ["cellular", "ANATOMY", 477, 485], ["RBC", "ANATOMY", 545, 548], ["vascular endothelium", "ANATOMY", 581, 601], ["sickle cell anaemia", "DISEASE", 59, 78], ["vascular occlusion", "DISEASE", 132, 150], ["vascular occlusion", "DISEASE", 240, 258], ["vascular occlusion", "DISEASE", 326, 344], ["sickle", "DISEASE", 370, 376], ["dehydration", "DISEASE", 486, 497], ["sickle", "CHEMICAL", 370, 376], ["sickle cell", "CELL", 59, 70], ["vascular", "MULTI-TISSUE_STRUCTURE", 132, 140], ["vascular", "MULTI-TISSUE_STRUCTURE", 240, 248], ["vascular", "MULTI-TISSUE_STRUCTURE", 326, 334], ["Hb", "GENE_OR_GENE_PRODUCT", 377, 379], ["red blood cells", "CELL", 453, 468], ["RBCs", "CELL", 470, 474], ["cellular", "CELL", 477, 485], ["RBC", "CELL", 545, 548], ["vascular endothelium", "TISSUE", 581, 601], ["Hb", "PROTEIN", 377, 379], ["red blood cells", "CELL_TYPE", 453, 468], ["RBCs", "CELL_TYPE", 470, 474], ["RBC", "CELL_TYPE", 545, 548], ["Pathogenesis", "PROBLEM", 0, 12], ["sickle cell anaemia", "PROBLEM", 59, 78], ["vascular occlusion", "PROBLEM", 132, 150], ["vascular occlusion", "TREATMENT", 240, 258], ["vascular occlusion", "PROBLEM", 326, 344], ["sickle", "PROBLEM", 370, 376], ["Hb upon deoxygenation", "PROBLEM", 377, 398], ["red blood cells", "TEST", 453, 468], ["RBCs", "TEST", 470, 474], ["cellular dehydration", "PROBLEM", 477, 497], ["decreased deformability", "PROBLEM", 503, 526], ["stickiness of RBC", "PROBLEM", 531, 548], ["most important", "OBSERVATION_MODIFIER", 16, 30], ["sickle cell anaemia", "OBSERVATION", 59, 78], ["vascular", "ANATOMY", 132, 140], ["occlusion", "OBSERVATION", 141, 150], ["micro", "OBSERVATION_MODIFIER", 178, 183], ["macro-vasculature", "ANATOMY", 189, 206], ["vascular", "ANATOMY", 240, 248], ["occlusion", "OBSERVATION", 249, 258], ["vascular", "ANATOMY", 326, 334], ["occlusion", "OBSERVATION", 335, 344], ["sickle", "OBSERVATION_MODIFIER", 370, 376], ["deoxygenation", "OBSERVATION_MODIFIER", 385, 398], ["blood cells", "ANATOMY", 457, 468], ["cellular dehydration", "OBSERVATION", 477, 497], ["decreased deformability", "OBSERVATION", 503, 526], ["stickiness", "OBSERVATION_MODIFIER", 531, 541], ["RBC", "OBSERVATION", 545, 548], ["adhesion", "OBSERVATION_MODIFIER", 569, 577], ["vascular endothelium", "ANATOMY", 581, 601]]], ["Progress in the pathogenesis of vascular occlusion pertains to cellular dehydration and adhesion to endothelial cells described in sections 1.2.2 and 1.2.3, respectively.", [["vascular", "ANATOMY", 32, 40], ["cellular", "ANATOMY", 63, 71], ["endothelial cells", "ANATOMY", 100, 117], ["sections", "ANATOMY", 131, 139], ["vascular occlusion", "DISEASE", 32, 50], ["dehydration", "DISEASE", 72, 83], ["vascular", "MULTI-TISSUE_STRUCTURE", 32, 40], ["cellular", "CELL", 63, 71], ["endothelial cells", "CELL", 100, 117], ["endothelial cells", "CELL_TYPE", 100, 117], ["vascular occlusion", "PROBLEM", 32, 50], ["cellular dehydration", "PROBLEM", 63, 83], ["adhesion to endothelial cells", "PROBLEM", 88, 117], ["vascular", "ANATOMY", 32, 40], ["occlusion", "OBSERVATION", 41, 50], ["cellular", "OBSERVATION_MODIFIER", 63, 71], ["dehydration", "OBSERVATION", 72, 83], ["adhesion", "OBSERVATION_MODIFIER", 88, 96], ["endothelial cells", "OBSERVATION", 100, 117]]]], "PMC7336100": [["Introduction (John Reader and Petar Jandri\u0107)For the biggest part of human history, science and philosophy have always been dialectically intertwined with religion.", [["human", "ORGANISM", 68, 73], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73]]], ["While it is only reasonable to protect modern-day Galileos from various \u2018inquisitions\u2019, and while it would be meaningless to try and understand the Book of Genesis using scientific methods such as radiocarbon dating, our current divisions between science and religion arrive at a high cost.", [["scientific methods", "TREATMENT", 170, 188]]], ["Along the way, unfortunately, we also lose their historicity, their shared wisdom, and opportunities for productive collaboration.Introduction (John Reader and Petar Jandri\u0107)Religion works on the basis of an enchanted world (spirits; myths; magical or providential events; external interventions; etc.).", [["external interventions", "TREATMENT", 273, 295]]], ["In our \u2018hard to define; messy; unpredictable; digital and analog; technological and non-technological; biological and informational\u2019 postdigital reality (Jandri\u0107 et al. 2018: 895), philosophies such as New Materialism can now enter the fray as vehicles of re-enchantment.", [["New Materialism", "PROBLEM", 202, 217], ["New", "OBSERVATION_MODIFIER", 202, 205], ["Materialism", "OBSERVATION", 206, 217]]], ["To address this challenge, John Reader and Petar Jandri\u0107 reached out to people of various religious denominations (including atheists and agnostics) with the following question:Introduction (John Reader and Petar Jandri\u0107)", [["people", "ORGANISM", 72, 78], ["people", "SPECIES", 72, 78]]]]}